{"data": [{"entities": {"mentions": [{"start": 0, "end": 11, "username": "kordeneha1", "id": "792165987273601024"}, {"start": 23, "end": 39, "username": "MalinHultcrantz", "id": "212681144"}, {"start": 42, "end": 56, "username": "TBSsteharding", "id": "1975260703"}, {"start": 59, "end": 73, "username": "IreneGhobrial", "id": "452461489"}, {"start": 78, "end": 92, "username": "DrOlaLandgren", "id": "2257190339"}]}, "text": "@kordeneha1 I remember @MalinHultcrantz , @TBSsteharding , @IreneGhobrial and @DrOlaLandgren were there. Who else?!", "referenced_tweets": [{"type": "replied_to", "id": "1600959733535748096"}], "source": "Twitter for Android", "author_id": "3078258341", "conversation_id": "1600940905732902913", "in_reply_to_user_id": "792165987273601024", "created_at": "2022-12-08T22:09:26.000Z", "edit_history_tweet_ids": ["1600975868389490688"], "id": "1600975868389490688", "lang": "en"}, {"entities": {"mentions": [{"start": 3, "end": 17, "username": "profghjackson", "id": "1014890726818238465"}, {"start": 79, "end": 87, "username": "iStopMM", "id": "844232399319941122"}, {"start": 121, "end": 135, "username": "sykristinsson", "id": "3078258341"}], "hashtags": [{"start": 19, "end": 25, "tag": "ASH22"}], "annotations": [{"start": 20, "end": 24, "probability": 0.5711, "type": "Other", "normalized_text": "ASH22"}]}, "text": "RT @profghjackson: #ASH22 a fabulous collection of abstracts and data from the @iStopMM team with practice changing data @sykristinsson #mm\u2026", "referenced_tweets": [{"type": "retweeted", "id": "1600763735995736064"}], "source": "Twitter Web App", "author_id": "3078258341", "conversation_id": "1600967894669852673", "created_at": "2022-12-08T21:37:45.000Z", "edit_history_tweet_ids": ["1600967894669852673"], "id": "1600967894669852673", "lang": "en"}, {"entities": {"mentions": [{"start": 0, "end": 11, "username": "kordeneha1", "id": "792165987273601024"}], "annotations": [{"start": 17, "end": 25, "probability": 0.7523, "type": "Other", "normalized_text": "The Beach"}]}, "text": "@kordeneha1 Ahhh The Beach! Am I right?", "referenced_tweets": [{"type": "replied_to", "id": "1600956081253253120"}], "source": "Twitter for Android", "author_id": "3078258341", "conversation_id": "1600940905732902913", "in_reply_to_user_id": "792165987273601024", "created_at": "2022-12-08T20:55:25.000Z", "edit_history_tweet_ids": ["1600957243465535488"], "id": "1600957243465535488", "lang": "en"}, {"text": "Arrived to New Orleans yesterday.  \n\nFirst challenge of #ASH22 was pulling the hotel sheets from where they are tucked :)\n\nLooking forward to the challenge of choosing sessions, balancing meetings, listening to jazz, and watching the world cup! \n\nAnd I love it!\n\n#ASH22 https://t.co/Eo87wQJKkU", "source": "Twitter for Android", "author_id": "3078258341", "entities": {"hashtags": [{"start": 56, "end": 62, "tag": "ASH22"}, {"start": 263, "end": 269, "tag": "ASH22"}], "annotations": [{"start": 11, "end": 21, "probability": 0.9932, "type": "Place", "normalized_text": "New Orleans"}, {"start": 57, "end": 61, "probability": 0.7101, "type": "Other", "normalized_text": "ASH22"}, {"start": 264, "end": 268, "probability": 0.4413, "type": "Other", "normalized_text": "ASH22"}], "urls": [{"start": 270, "end": 293, "url": "https://t.co/Eo87wQJKkU", "expanded_url": "https://twitter.com/sykristinsson/status/1600940905732902913/photo/1", "display_url": "pic.twitter.com/Eo87wQJKkU", "media_key": "3_1600940902654025737"}]}, "conversation_id": "1600940905732902913", "created_at": "2022-12-08T19:50:30.000Z", "edit_history_tweet_ids": ["1600940905732902913"], "id": "1600940905732902913", "lang": "en"}, {"entities": {"mentions": [{"start": 3, "end": 14, "username": "Daw6Jessie", "id": "1455299166511538176"}], "hashtags": [{"start": 31, "end": 37, "tag": "ASH22"}, {"start": 124, "end": 133, "tag": "IMFASH22"}], "annotations": [{"start": 32, "end": 36, "probability": 0.6781, "type": "Other", "normalized_text": "ASH22"}, {"start": 125, "end": 132, "probability": 0.626, "type": "Other", "normalized_text": "IMFASH22"}]}, "text": "RT @Daw6Jessie: Gearing up for #ASH22, looking forward to many scientific presentations, and also this educational program: #IMFASH22 @IMFm\u2026", "referenced_tweets": [{"type": "retweeted", "id": "1600630491115552768"}], "source": "Twitter for Android", "author_id": "3078258341", "conversation_id": "1600682932846620672", "created_at": "2022-12-08T02:45:25.000Z", "edit_history_tweet_ids": ["1600682932846620672"], "id": "1600682932846620672", "lang": "en"}, {"entities": {"mentions": [{"start": 3, "end": 17, "username": "profghjackson", "id": "1014890726818238465"}, {"start": 80, "end": 88, "username": "iStopMM", "id": "844232399319941122"}, {"start": 89, "end": 103, "username": "sykristinsson", "id": "3078258341"}], "hashtags": [{"start": 107, "end": 115, "tag": "Ash2022"}, {"start": 116, "end": 121, "tag": "mmsm"}], "annotations": [{"start": 108, "end": 114, "probability": 0.4278, "type": "Other", "normalized_text": "Ash2022"}]}, "text": "RT @profghjackson: Looking forward to more outstanding outputs from the amazing @iStopMM @sykristinsson at #Ash2022 #mmsm", "referenced_tweets": [{"type": "retweeted", "id": "1600372667277668352"}], "source": "Twitter for Android", "author_id": "3078258341", "conversation_id": "1600591592263499777", "created_at": "2022-12-07T20:42:27.000Z", "edit_history_tweet_ids": ["1600591592263499777"], "id": "1600591592263499777", "lang": "en"}, {"entities": {"mentions": [{"start": 0, "end": 9, "username": "ManniMD1", "id": "1269642863924609025"}, {"start": 10, "end": 25, "username": "AaronGoodman33", "id": "854692626015993857"}, {"start": 26, "end": 34, "username": "iStopMM", "id": "844232399319941122"}, {"start": 68, "end": 81, "username": "ingigerdursv", "id": "740181058210107392"}], "annotations": [{"start": 85, "end": 91, "probability": 0.6196, "type": "Other", "normalized_text": "thunder"}]}, "text": "@ManniMD1 @AaronGoodman33 @iStopMM Sounds great! Please don't steal @ingigerdursv \u00b4s thunder :)", "referenced_tweets": [{"type": "replied_to", "id": "1600546555081027584"}], "source": "Twitter Web App", "author_id": "3078258341", "conversation_id": "1600545405540126720", "in_reply_to_user_id": "1269642863924609025", "created_at": "2022-12-07T17:47:00.000Z", "edit_history_tweet_ids": ["1600547436505743365"], "id": "1600547436505743365", "lang": "en"}, {"entities": {"mentions": [{"start": 0, "end": 9, "username": "ManniMD1", "id": "1269642863924609025"}, {"start": 10, "end": 18, "username": "iStopMM", "id": "844232399319941122"}]}, "text": "@ManniMD1 @iStopMM Yes! Love it!", "referenced_tweets": [{"type": "replied_to", "id": "1600545405540126720"}], "source": "Twitter Web App", "author_id": "3078258341", "conversation_id": "1600545405540126720", "in_reply_to_user_id": "1269642863924609025", "created_at": "2022-12-07T17:40:54.000Z", "edit_history_tweet_ids": ["1600545902980202496"], "id": "1600545902980202496", "lang": "en"}, {"entities": {"mentions": [{"start": 40, "end": 48, "username": "iStopMM", "id": "844232399319941122"}], "urls": [{"start": 56, "end": 79, "url": "https://t.co/nhswuksEfL", "expanded_url": "https://twitter.com/sykristinsson/status/1589629504422805506?s=20&t=g_0BgnWQYjXFx96LRgJKJg", "display_url": "twitter.com/sykristinsson/\u2026"}]}, "text": "And here are all the abstracts from the @iStopMM study: https://t.co/nhswuksEfL", "referenced_tweets": [{"type": "quoted", "id": "1589629504422805506"}, {"type": "replied_to", "id": "1600544434160275457"}], "source": "Twitter Web App", "author_id": "3078258341", "conversation_id": "1600544417827504144", "in_reply_to_user_id": "3078258341", "created_at": "2022-12-07T17:35:04.000Z", "edit_history_tweet_ids": ["1600544435825438720"], "id": "1600544435825438720", "lang": "en"}, {"entities": {"mentions": [{"start": 29, "end": 40, "username": "UrviShahMD", "id": "905435513879973892"}], "annotations": [{"start": 107, "end": 113, "probability": 0.369, "type": "Other", "normalized_text": "Placebo"}, {"start": 118, "end": 121, "probability": 0.4052, "type": "Organization", "normalized_text": "MGUS"}, {"start": 123, "end": 125, "probability": 0.4939, "type": "Other", "normalized_text": "SMM"}], "urls": [{"start": 5, "end": 28, "url": "https://t.co/TH5rAuCksy", "expanded_url": "https://ash.confex.com/ash/2022/webprogram/Paper159794.html", "display_url": "ash.confex.com/ash/2022/webpr\u2026", "status": 200, "title": "Paper: A Randomized Placebo Controlled Study of a Plant-Based Dietary Versus Supplement Versus Placebo Intervention in Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Multiple Myeloma (SMM) - the Nutrition Prevention (NUTRIVENTION-3) Study", "description": "Program: Oral and Poster Abstracts Session: 902. Health Services and Quality\u2014Lymphoid Malignancies: Poster I Hematology Disease Topics & Pathways: clinical trials, adult, Research, Clinical Research, Plasma Cell Disorders, Diseases, metabolism, Lymphoid Malignancies, Biological Processes, microbiome, Study Population, Human Urvi A Shah, MD 1, Francesca Castro, MS 2 *, Aishwarya Anuraj, MBBS 3 *, Eliana Schach, BA 4,5 *, Andriy Derkach, PhD 6 *, Nisha S. Joseph, MD 7, Peter A. Adintori, MS, RD, CSO, CDN,", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Paper159794.html"}]}, "text": "2213 https://t.co/TH5rAuCksy\n@UrviShahMD Yes! A randomized study of a Plant-Based Dietary vs Supplement vs Placebo in MGUS/SMM. Although no results are in abstracts, this is supercool!", "referenced_tweets": [{"type": "replied_to", "id": "1600544431962480640"}], "source": "Twitter Web App", "author_id": "3078258341", "conversation_id": "1600544417827504144", "in_reply_to_user_id": "3078258341", "created_at": "2022-12-07T17:35:04.000Z", "edit_history_tweet_ids": ["1600544434160275457"], "id": "1600544434160275457", "lang": "en"}, {"entities": {"mentions": [{"start": 30, "end": 42, "username": "DrGerLobato", "id": "3689670976"}], "annotations": [{"start": 106, "end": 109, "probability": 0.5177, "type": "Other", "normalized_text": "MGUS"}, {"start": 115, "end": 117, "probability": 0.7062, "type": "Other", "normalized_text": "SMM"}], "urls": [{"start": 6, "end": 29, "url": "https://t.co/fgV6EeXHO1", "expanded_url": "https://ash.confex.com/ash/2022/webprogram/Paper165371.html", "display_url": "ash.confex.com/ash/2022/webpr\u2026", "status": 200, "title": "Paper: Evolving Pattern Improves the IMWG 2/20/20 Classification for Patients with Smoldering Multiple Myeloma", "description": "Program: Oral and Poster Abstracts Session: 652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster I Hematology Disease Topics & Pathways: Research, epidemiology, Clinical Research, Plasma Cell Disorders, Diseases, real-world evidence, Lymphoid Malignancies, survivorship Luis Gerardo Rodr\u00edguez-Lobato, MD, PhD *, Anna de Daniel i Bisbe, MD *, Natalia Tovar, MD, PhD *, Raquel Jim\u00e9nez-Segura, MD *, M. Teresa Cibeira, MD, PhD *, David F. Moreno, MD *, Aina Oliver-Caldes, MD *,", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Paper165371.html"}, {"start": 137, "end": 160, "url": "https://t.co/6s1n7JNZ4S", "expanded_url": "https://twitter.com/sykristinsson/status/1600544431962480640/photo/1", "display_url": "pic.twitter.com/6s1n7JNZ4S", "media_key": "3_1600543535308193794"}]}, "text": "#1892 https://t.co/fgV6EeXHO1\n@DrGerLobato A much-needed way of thinking when it comes to risk models for MGUS and SMM = Dynamic models! https://t.co/6s1n7JNZ4S", "referenced_tweets": [{"type": "replied_to", "id": "1600544427709169664"}], "source": "Twitter Web App", "author_id": "3078258341", "conversation_id": "1600544417827504144", "in_reply_to_user_id": "3078258341", "created_at": "2022-12-07T17:35:03.000Z", "edit_history_tweet_ids": ["1600544431962480640"], "id": "1600544431962480640", "lang": "en"}, {"entities": {"mentions": [{"start": 29, "end": 45, "username": "eliaseythorsson", "id": "133109181"}], "annotations": [{"start": 156, "end": 159, "probability": 0.5186, "type": "Place", "normalized_text": "MGUS"}], "urls": [{"start": 5, "end": 28, "url": "https://t.co/ZGqXHCm3Tv", "expanded_url": "https://ash.confex.com/ash/2022/webprogram/Paper170166.html", "display_url": "ash.confex.com/ash/2022/webpr\u2026", "status": 200, "title": "Paper: Predicting the Need for Upfront Bone Marrow Sampling in Individuals with MGUS: Derivation of a Multivariable Prediction Model Using the Prospective Population-Based Istopmm Cohort", "description": "Program: Oral and Poster Abstracts Type: Oral Session: 652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Precursor States: MGUS and Smoldering Myeloma Hematology Disease Topics & Pathways: adult, Research, Clinical Research, real-world evidence, Human, Study Population Elias Eythorsson, MD, PhD 1 *, S\u00e6mundur R\u00f6gnvaldsson, MD 1,2 *, Sigr\u00fan Thorsteinsd\u00f3ttir, MD, PhD 3,4, Elin Ruth Reed 3 *, Gudr\u00fan \u00c1sta Sigurdard\u00f3ttir 3 *, Brynjar Vidarsson, MD 1, P\u00e1ll Torfi Onundarson, MD 1,", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Paper170166.html"}]}, "text": "#107 https://t.co/ZGqXHCm3Tv\n@eliaseythorsson  Yes, I shamelessly picked one of my own abstracts :) Predicting the need for upfront bone marrow sampling in MGUS. We will present a risk model online during the presentation on Saturday!", "referenced_tweets": [{"type": "replied_to", "id": "1600544426300145664"}], "source": "Twitter Web App", "author_id": "3078258341", "conversation_id": "1600544417827504144", "in_reply_to_user_id": "3078258341", "created_at": "2022-12-07T17:35:02.000Z", "edit_history_tweet_ids": ["1600544427709169664"], "id": "1600544427709169664", "lang": "en"}, {"text": "#106 https://t.co/wC0NxMOlgL\nA gene score based upon twelve highly differentiating genes showed excellent accuracy in predicting 10-year MM progression from MGUS. Biology and clinical features will better define MGUS risk.", "referenced_tweets": [{"type": "replied_to", "id": "1600544424450211840"}], "source": "Twitter Web App", "author_id": "3078258341", "conversation_id": "1600544417827504144", "entities": {"annotations": [{"start": 157, "end": 160, "probability": 0.5628, "type": "Organization", "normalized_text": "MGUS"}, {"start": 212, "end": 215, "probability": 0.4646, "type": "Other", "normalized_text": "MGUS"}], "urls": [{"start": 5, "end": 28, "url": "https://t.co/wC0NxMOlgL", "expanded_url": "https://ash.confex.com/ash/2022/webprogram/Paper163654.html", "display_url": "ash.confex.com/ash/2022/webpr\u2026", "status": 200, "title": "Paper: A 12 Gene Signature Accurately Predicts Multiple Myeloma Progression from Monoclonal Gammopathy of Undetermined Significance", "description": "Program: Oral and Poster Abstracts Type: Oral Session: 652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Precursor States: MGUS and Smoldering Myeloma Hematology Disease Topics & Pathways: Research, Translational Research, epidemiology, Clinical Research Fumou Sun 1 *, Jun Ying 2 *, Yan Cheng 1 *, David Mery 1 *, Visanu Wanchai 1,3 *, Eric R. Siegel 2 *, Hongwei Xu 1 *, Dongzheng Gai 1 *, Jiahao Xu 4 *, Timothy Cody Ashby 3 *, Clyde Bailey 5 *, Samer Al Hadidi, MD, MSc 1,", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Paper163654.html"}]}, "in_reply_to_user_id": "3078258341", "created_at": "2022-12-07T17:35:02.000Z", "edit_history_tweet_ids": ["1600544426300145664"], "id": "1600544426300145664", "lang": "en"}, {"entities": {"mentions": [{"start": 29, "end": 45, "username": "FrancescoMaura4", "id": "1158556316576751617"}, {"start": 241, "end": 255, "username": "DrOlaLandgren", "id": "2257190339"}], "annotations": [{"start": 94, "end": 97, "probability": 0.6309, "type": "Other", "normalized_text": "NDMM"}, {"start": 235, "end": 238, "probability": 0.5077, "type": "Other", "normalized_text": "NDMM"}], "urls": [{"start": 5, "end": 28, "url": "https://t.co/zz69h8v4xU", "expanded_url": "https://ash.confex.com/ash/2022/webprogram/Paper160215.html", "display_url": "ash.confex.com/ash/2022/webpr\u2026", "status": 200, "title": "Paper: Individualized Treatment-Adjusted Risk Stratification in Newly Diagnosed Multiple Myeloma", "description": "Program: Oral and Poster Abstracts Type: Oral Session: 652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Prognostic Markers in Multiple Myeloma Hematology Disease Topics & Pathways: Research, artificial intelligence (AI), Translational Research, Clinical Research, Combination therapy, genomics, Plasma Cell Disorders, bioinformatics, patient-reported outcomes, Diseases, Therapies, Lymphoid Malignancies, computational biology, Biological Processes, Technology and Procedures,", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Paper160215.html"}]}, "text": "#646 https://t.co/zz69h8v4xU\n@FrancescoMaura4  A comprehensive model utilizing data from 1840 NDMM patients, that captures the interaction of genomic, clinical and therapy factors, enabling personally-tailored therapeutic decisions in NDMM. @DrOlaLandgren", "referenced_tweets": [{"type": "replied_to", "id": "1600544422852456448"}], "source": "Twitter Web App", "author_id": "3078258341", "conversation_id": "1600544417827504144", "in_reply_to_user_id": "3078258341", "created_at": "2022-12-07T17:35:02.000Z", "edit_history_tweet_ids": ["1600544424450211840"], "id": "1600544424450211840", "lang": "en"}, {"entities": {"mentions": [{"start": 29, "end": 39, "username": "myelomaMD", "id": "301568235"}, {"start": 189, "end": 202, "username": "BrianDurieMD", "id": "339306345"}], "annotations": [{"start": 78, "end": 80, "probability": 0.4828, "type": "Other", "normalized_text": "SMM"}, {"start": 124, "end": 126, "probability": 0.5338, "type": "Other", "normalized_text": "MRD"}], "urls": [{"start": 5, "end": 28, "url": "https://t.co/jrHlkNAN2G", "expanded_url": "https://ash.confex.com/ash/2022/webprogram/Paper168930.html", "display_url": "ash.confex.com/ash/2022/webpr\u2026", "status": 200, "title": "Paper: Fixed Duration Therapy with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone for High Risk Smoldering Multiple Myeloma-Results of the Ascent Trial", "description": "Program: Oral and Poster Abstracts Type: Oral Session: 653. Myeloma and Plasma Cell Dyscrasias: Prospective Therapeutic Trials: Risk-adapted Treatment Strategies in Myeloma and Related Conditions Hematology Disease Topics & Pathways: Research, clinical trials, Biological therapies, Antibody Therapy, Clinical Research, Plasma Cell Disorders, Combination therapy, Diseases, Therapies, Lymphoid Malignancies, Human, Minimal Residual Disease Shaji K Kumar, MD 1, Melissa Alsina, MD** 2, Betsy Laplant, MS 3 *,", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Paper168930.html"}]}, "text": "#757 https://t.co/jrHlkNAN2G\n@myelomaMD  The Ascent trial, treating high-risk SMM with dara-KRd and looking at response and MRD, and importantly toxicity in these asymptomatic individuals. @BrianDurieMD", "referenced_tweets": [{"type": "replied_to", "id": "1600544420968878080"}], "source": "Twitter Web App", "author_id": "3078258341", "conversation_id": "1600544417827504144", "in_reply_to_user_id": "3078258341", "created_at": "2022-12-07T17:35:01.000Z", "edit_history_tweet_ids": ["1600544422852456448"], "id": "1600544422852456448", "lang": "en"}, {"entities": {"mentions": [{"start": 29, "end": 38, "username": "mvmateos", "id": "2239926566"}, {"start": 198, "end": 214, "username": "BrunoPaiva_UNAV", "id": "1335161063382376448"}], "annotations": [{"start": 45, "end": 47, "probability": 0.3793, "type": "Other", "normalized_text": "GEM"}, {"start": 49, "end": 53, "probability": 0.3491, "type": "Person", "normalized_text": "Cesar"}, {"start": 115, "end": 117, "probability": 0.3979, "type": "Other", "normalized_text": "KRd"}], "urls": [{"start": 5, "end": 28, "url": "https://t.co/V845ob33DR", "expanded_url": "https://ash.confex.com/ash/2022/webprogram/Paper159606.html", "display_url": "ash.confex.com/ash/2022/webpr\u2026", "status": 200, "title": "Paper: Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Post-Hoc Analysis of Sustained Undetectable Measurable Residual Disease (MRD)", "description": "Program: Oral and Poster Abstracts Type: Oral Session: 731. Autologous Transplantation: Clinical and Epidemiological: Multiple Myeloma and CHIP Hematology Disease Topics & Pathways: Clinical Practice (Health Services and Quality), Plasma Cell Disorders, Diseases, Therapies, therapy sequence, Lymphoid Malignancies, Minimal Residual Disease Maria-Victoria Mateos, MD 1, Joaqu\u00edn Mart\u00ednez-L\u00f3pez, MD, PhD 2 *, Paula Rodr\u00edguez-Otero, MD, PhD 3 *, Jes\u00fas San-Miguel, MD, PhD 4, Veronica Gonzalez-Calle, MD, PhD 1 *,", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Paper159606.html"}]}, "text": "#118 https://t.co/V845ob33DR\n@mvmateos   The GEM-Cesar trial for high-risk SMM. An aggressive approach to SMM with KRd, high-dose melphalan, KRd and len-maintenance. 23% MRD neg 4 years after ASCT. @BrunoPaiva_UNAV", "referenced_tweets": [{"type": "replied_to", "id": "1600544419299704833"}], "source": "Twitter Web App", "author_id": "3078258341", "conversation_id": "1600544417827504144", "in_reply_to_user_id": "3078258341", "created_at": "2022-12-07T17:35:01.000Z", "edit_history_tweet_ids": ["1600544420968878080"], "id": "1600544420968878080", "lang": "en"}, {"entities": {"mentions": [{"start": 29, "end": 39, "username": "JBomsztyk", "id": "2686017822"}], "annotations": [{"start": 62, "end": 72, "probability": 0.673, "type": "Other", "normalized_text": "amyloidosis"}, {"start": 95, "end": 97, "probability": 0.3971, "type": "Other", "normalized_text": "FLC"}, {"start": 140, "end": 146, "probability": 0.5748, "type": "Other", "normalized_text": "amyloid"}, {"start": 202, "end": 204, "probability": 0.5421, "type": "Other", "normalized_text": "FLC"}, {"start": 244, "end": 246, "probability": 0.5221, "type": "Other", "normalized_text": "FLC"}], "urls": [{"start": 5, "end": 28, "url": "https://t.co/c1sF5fOUXn", "expanded_url": "https://ash.confex.com/ash/2022/webprogram/Paper160018.html", "display_url": "ash.confex.com/ash/2022/webpr\u2026", "status": 200, "title": "Paper: Use of Matrix-Assisted Laser Desorption/Ionisation Time-of-Flight Mass Spectrometry (MALDI-TOF MS) Free Light Chain Assessment for the Diagnosis and Monitoring of Systemic Immunoglobulin Light Chain (AL) Amyloidosis", "description": "Program: Oral and Poster Abstracts Type: Oral Session: 652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Disease Monitoring Hematology Disease Topics & Pathways: Plasma Cell Disorders, Diseases, Lymphoid Malignancies, emerging technologies, Technology and Procedures, Minimal Residual Disease Joshua Bomsztyk 1 *, Sriram Ravichandran, MBBS, MRCP, FRCPath 2 *, Hannah Victoria Giles, FRCPath, MRCP 3 *, Oscar Berlanga, PhD 4 *, Stephen Harding, PhD 5, Jahanzaib Khwaja 6 *, Shameem", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Paper160018.html"}]}, "text": "#972 https://t.co/c1sF5fOUXn\n@JBomsztyk Mass spec abstract in amyloidosis! Detection of clonal FLC by mass spec shows 100% concordance with amyloid fibril typing from tissue biopsies and can identify a FLC clone in pts presenting with a normal FLC ratio.", "referenced_tweets": [{"type": "replied_to", "id": "1600544417827504144"}], "source": "Twitter Web App", "author_id": "3078258341", "conversation_id": "1600544417827504144", "in_reply_to_user_id": "3078258341", "created_at": "2022-12-07T17:35:00.000Z", "edit_history_tweet_ids": ["1600544419299704833"], "id": "1600544419299704833", "lang": "en"}, {"entities": {"mentions": [{"start": 235, "end": 243, "username": "mtmdphd", "id": "190337035"}], "hashtags": [{"start": 98, "end": 104, "tag": "ASH22"}], "annotations": [{"start": 35, "end": 41, "probability": 0.5641, "type": "Other", "normalized_text": "myeloma"}, {"start": 73, "end": 76, "probability": 0.711, "type": "Other", "normalized_text": "MGUS"}, {"start": 99, "end": 103, "probability": 0.6266, "type": "Other", "normalized_text": "ASH22"}]}, "text": "Here is my top list of interesting myeloma abstracts, mostly focusing on MGUS and smoldering, for #ASH22. I have included a mixture of things, including treatment trials, mass spectrometry, risk models, genetics, amyloidosis and more. @mtmdphd", "source": "Twitter Web App", "author_id": "3078258341", "conversation_id": "1600544417827504144", "created_at": "2022-12-07T17:35:00.000Z", "edit_history_tweet_ids": ["1600544417827504144"], "id": "1600544417827504144", "lang": "en"}, {"entities": {"mentions": [{"start": 0, "end": 8, "username": "mtmdphd", "id": "190337035"}, {"start": 9, "end": 21, "username": "DrGerLobato", "id": "3689670976"}, {"start": 22, "end": 36, "username": "SagarLonialMD", "id": "2289851689"}, {"start": 37, "end": 49, "username": "nsc_natalie", "id": "462524995"}, {"start": 50, "end": 62, "username": "MayoMyeloma", "id": "30386069"}, {"start": 63, "end": 75, "username": "mweissmdphd", "id": "1475230458"}, {"start": 76, "end": 91, "username": "SJ_OncBiostats", "id": "103409025"}, {"start": 92, "end": 101, "username": "scmedlin", "id": "2922392948"}], "annotations": [{"start": 132, "end": 138, "probability": 0.7642, "type": "Other", "normalized_text": "myeloma"}]}, "text": "@mtmdphd @DrGerLobato @SagarLonialMD @nsc_natalie @MayoMyeloma @mweissmdphd @SJ_OncBiostats @scmedlin This one is on my top list of myeloma abstract. Congrats to the authors. Evolving pattern is the key!", "referenced_tweets": [{"type": "replied_to", "id": "1600123245784485888"}], "source": "Twitter Web App", "author_id": "3078258341", "conversation_id": "1600123245784485888", "in_reply_to_user_id": "190337035", "created_at": "2022-12-06T13:51:52.000Z", "edit_history_tweet_ids": ["1600125875445329921"], "id": "1600125875445329921", "lang": "en"}, {"entities": {"mentions": [{"start": 0, "end": 8, "username": "mtmdphd", "id": "190337035"}, {"start": 9, "end": 25, "username": "FrancescoMaura4", "id": "1158556316576751617"}, {"start": 26, "end": 40, "username": "DrOlaLandgren", "id": "2257190339"}, {"start": 41, "end": 50, "username": "scmedlin", "id": "2922392948"}, {"start": 51, "end": 62, "username": "TempusLabs", "id": "3909851415"}, {"start": 63, "end": 72, "username": "KanevaMD", "id": "1900965823"}, {"start": 73, "end": 83, "username": "garyigrad", "id": "577013399"}]}, "text": "@mtmdphd @FrancescoMaura4 @DrOlaLandgren @scmedlin @TempusLabs @KanevaMD @garyigrad On my top list of abstracts. Congratulations!", "referenced_tweets": [{"type": "replied_to", "id": "1600120907858518018"}], "source": "Twitter Web App", "author_id": "3078258341", "conversation_id": "1600120907858518018", "in_reply_to_user_id": "190337035", "created_at": "2022-12-06T13:43:13.000Z", "edit_history_tweet_ids": ["1600123699687878656"], "id": "1600123699687878656", "lang": "en"}, {"entities": {"mentions": [{"start": 4, "end": 12, "username": "iStopMM", "id": "844232399319941122"}], "hashtags": [{"start": 61, "end": 67, "tag": "ASH22"}], "annotations": [{"start": 62, "end": 66, "probability": 0.7091, "type": "Other", "normalized_text": "ASH22"}, {"start": 223, "end": 233, "probability": 0.986, "type": "Place", "normalized_text": "New Orleans"}], "urls": [{"start": 236, "end": 259, "url": "https://t.co/UdAS2UvU8m", "expanded_url": "https://twitter.com/sykristinsson/status/1600123462827184128/photo/1", "display_url": "pic.twitter.com/UdAS2UvU8m", "media_key": "3_1600122050370277376"}]}, "text": "The @iStopMM team is very excited to present our findings at #ASH22\n\nPresentations from the study are, like before, primarily performed by medical student, PhD students, and postdocs. I am so proud of the team!\n\nSee you in New Orleans! https://t.co/UdAS2UvU8m", "source": "Twitter Web App", "author_id": "3078258341", "conversation_id": "1600123462827184128", "created_at": "2022-12-06T13:42:17.000Z", "edit_history_tweet_ids": ["1600123462827184128"], "id": "1600123462827184128", "lang": "en"}, {"entities": {"mentions": [{"start": 3, "end": 11, "username": "mtmdphd", "id": "190337035"}], "annotations": [{"start": 50, "end": 64, "probability": 0.4746, "type": "Other", "normalized_text": "Marrow Sampling"}, {"start": 86, "end": 89, "probability": 0.5454, "type": "Organization", "normalized_text": "MGUS"}]}, "text": "RT @mtmdphd: Predicting the Need for Upfront Bone Marrow Sampling in Individuals with MGUS: Derivation of a Multivariable Prediction Model\u2026", "referenced_tweets": [{"type": "retweeted", "id": "1599092878080606208"}], "source": "Twitter for Android", "author_id": "3078258341", "conversation_id": "1599103486184284160", "created_at": "2022-12-03T18:09:15.000Z", "edit_history_tweet_ids": ["1599103486184284160"], "id": "1599103486184284160", "lang": "en"}, {"entities": {"mentions": [{"start": 3, "end": 13, "username": "VincentRK", "id": "24261916"}], "annotations": [{"start": 36, "end": 39, "probability": 0.4867, "type": "Other", "normalized_text": "MGUS"}, {"start": 88, "end": 94, "probability": 0.863, "type": "Other", "normalized_text": "iStopMM"}]}, "text": "RT @VincentRK: #5 Not everyone with MGUS diagnosis needs a marrow. Choosing wisely. The iStopMM trial provides a model that limits unnecess\u2026", "referenced_tweets": [{"type": "retweeted", "id": "1599075821737500673"}], "source": "Twitter for Android", "author_id": "3078258341", "conversation_id": "1599103210932752385", "created_at": "2022-12-03T18:08:10.000Z", "edit_history_tweet_ids": ["1599103210932752385"], "id": "1599103210932752385", "lang": "en"}, {"entities": {"mentions": [{"start": 3, "end": 16, "username": "Abdallah81MD", "id": "1026947037080772610"}], "annotations": [{"start": 121, "end": 138, "probability": 0.661, "type": "Other", "normalized_text": "autoimmune disease"}]}, "text": "RT @Abdallah81MD: This large, prospective screening study negates the previously reported biological correlation between autoimmune disease\u2026", "referenced_tweets": [{"type": "retweeted", "id": "1595845251604049920"}], "source": "Twitter for Android", "author_id": "3078258341", "conversation_id": "1597316570455617536", "created_at": "2022-11-28T19:48:41.000Z", "edit_history_tweet_ids": ["1597316570455617536"], "id": "1597316570455617536", "lang": "en"}, {"entities": {"mentions": [{"start": 3, "end": 12, "username": "ManniMD1", "id": "1269642863924609025"}], "hashtags": [{"start": 115, "end": 121, "tag": "ASH22"}], "annotations": [{"start": 116, "end": 120, "probability": 0.7276, "type": "Other", "normalized_text": "ASH22"}]}, "text": "RT @ManniMD1: Although this study is only a poster (worthy of oral!), it is one of the most impactful abstracts at #ASH22, with impacts far\u2026", "referenced_tweets": [{"type": "retweeted", "id": "1592885241953554432"}], "source": "Twitter for Android", "author_id": "3078258341", "conversation_id": "1592911233518534656", "created_at": "2022-11-16T16:03:27.000Z", "edit_history_tweet_ids": ["1592911233518534656"], "id": "1592911233518534656", "lang": "en"}, {"text": "Six years since the launch of the iStopMM study today!\n\nOn 11/15 2016, we invited all Icelanders &gt;40 years to participate in a clinical trial.\nTo our surprise, &gt;50,000 participants in &lt;30 days!\nIn 2018 a world record of 80,759 had signed informed consent (54% of the population). https://t.co/Xx9jsDDKGx", "source": "Twitter Web App", "author_id": "3078258341", "conversation_id": "1592604400178331648", "entities": {"annotations": [{"start": 34, "end": 40, "probability": 0.7199, "type": "Other", "normalized_text": "iStopMM"}, {"start": 86, "end": 95, "probability": 0.3779, "type": "Other", "normalized_text": "Icelanders"}], "urls": [{"start": 289, "end": 312, "url": "https://t.co/Xx9jsDDKGx", "expanded_url": "https://twitter.com/sykristinsson/status/1592604400178331648/photo/1", "display_url": "pic.twitter.com/Xx9jsDDKGx", "media_key": "3_1592601628858793984"}]}, "created_at": "2022-11-15T19:44:12.000Z", "edit_history_tweet_ids": ["1592604400178331648"], "id": "1592604400178331648", "lang": "en"}, {"entities": {"mentions": [{"start": 3, "end": 15, "username": "Crowther_MJ", "id": "187922446"}, {"start": 42, "end": 56, "username": "RDAnalyticsAB", "id": "1461992557999792129"}], "hashtags": [{"start": 114, "end": 130, "tag": "multiplemyeloma"}], "annotations": [{"start": 115, "end": 129, "probability": 0.4888, "type": "Other", "normalized_text": "multiplemyeloma"}]}, "text": "RT @Crowther_MJ: Such a privilege for the @RDAnalyticsAB team to contribute to some of this inspirational work in #multiplemyeloma, led by\u2026", "referenced_tweets": [{"type": "retweeted", "id": "1592087263571501057"}], "source": "Twitter Web App", "author_id": "3078258341", "conversation_id": "1592515535182483457", "created_at": "2022-11-15T13:51:05.000Z", "edit_history_tweet_ids": ["1592515535182483457"], "id": "1592515535182483457", "lang": "en"}, {"entities": {"mentions": [{"start": 53, "end": 61, "username": "iStopMM", "id": "844232399319941122"}, {"start": 68, "end": 77, "username": "ManniMD1", "id": "1269642863924609025"}, {"start": 80, "end": 96, "username": "eliaseythorsson", "id": "133109181"}], "urls": [{"start": 253, "end": 276, "url": "https://t.co/gKQu3Bphcg", "expanded_url": "https://twitter.com/ManniMD1/status/1590440079591624705", "display_url": "twitter.com/ManniMD1/statu\u2026"}]}, "text": "Thank you so much for choosing our abstract from the @iStopMM study @ManniMD1 !\n@eliaseythorsson has done a fantastic job with our data which I am confident will provide evidence for physicians to omit bone marrow biopsy in individuals with M-proteins. https://t.co/gKQu3Bphcg", "referenced_tweets": [{"type": "quoted", "id": "1590440079591624705"}], "source": "Twitter Web App", "author_id": "3078258341", "conversation_id": "1591899435725987840", "created_at": "2022-11-13T21:02:56.000Z", "edit_history_tweet_ids": ["1591899435725987840"], "id": "1591899435725987840", "lang": "en"}, {"entities": {"mentions": [{"start": 3, "end": 19, "username": "Myeloma_Society", "id": "841751045034369025"}, {"start": 61, "end": 77, "username": "Myeloma_Society", "id": "841751045034369025"}], "annotations": [{"start": 102, "end": 104, "probability": 0.9396, "type": "Organization", "normalized_text": "FDA"}]}, "text": "RT @Myeloma_Society: There is still time to register for the @Myeloma_Society joint workshop with the FDA on November 8-9. This two day mee\u2026", "referenced_tweets": [{"type": "retweeted", "id": "1588501796082929664"}], "source": "Twitter Web App", "author_id": "3078258341", "conversation_id": "1589990361921130496", "created_at": "2022-11-08T14:36:57.000Z", "edit_history_tweet_ids": ["1589990361921130496"], "id": "1589990361921130496", "lang": "en"}, {"entities": {"mentions": [{"start": 8, "end": 22, "username": "RDAnalyticsAB", "id": "1461992557999792129"}, {"start": 23, "end": 39, "username": "MalinHultcrantz", "id": "212681144"}, {"start": 40, "end": 49, "username": "runolfpa", "id": "258483907"}, {"start": 50, "end": 63, "username": "andriclausen", "id": "4501760296"}, {"start": 64, "end": 76, "username": "Crowther_MJ", "id": "187922446"}, {"start": 78, "end": 86, "username": "mtmdphd", "id": "190337035"}, {"start": 87, "end": 103, "username": "Myeloma_Society", "id": "841751045034369025"}, {"start": 105, "end": 112, "username": "LLSusa", "id": "14323846"}, {"start": 114, "end": 127, "username": "KjartanGauti", "id": "1204778211265130498"}, {"start": 128, "end": 140, "username": "asdisrosa78", "id": "3050942903"}, {"start": 141, "end": 150, "username": "Gastasig", "id": "1500042922879762434"}, {"start": 151, "end": 167, "username": "brynjarkarlsson", "id": "1052660277316075530"}, {"start": 168, "end": 178, "username": "dimma1968", "id": "3179349334"}, {"start": 179, "end": 192, "username": "thoraspelund", "id": "91133380"}]}, "text": "... and @RDAnalyticsAB @MalinHultcrantz @runolfpa @andriclausen @Crowther_MJ  @mtmdphd @Myeloma_Society  @LLSusa  @KjartanGauti @asdisrosa78 @gastasig @brynjarkarlsson @dimma1968 @thoraspelund", "referenced_tweets": [{"type": "replied_to", "id": "1589630676047126528"}], "source": "Twitter Web App", "author_id": "3078258341", "conversation_id": "1589629504422805506", "in_reply_to_user_id": "3078258341", "created_at": "2022-11-08T13:18:56.000Z", "edit_history_tweet_ids": ["1589970726458884097"], "id": "1589970726458884097", "lang": "und"}, {"entities": {"mentions": [{"start": 0, "end": 15, "username": "siddharthkunte", "id": "209212922"}, {"start": 16, "end": 24, "username": "iStopMM", "id": "844232399319941122"}]}, "text": "@siddharthkunte @iStopMM Thanks a lot!", "referenced_tweets": [{"type": "replied_to", "id": "1589763561492221952"}], "source": "Twitter Web App", "author_id": "3078258341", "conversation_id": "1589763561492221952", "in_reply_to_user_id": "209212922", "created_at": "2022-11-08T08:56:22.000Z", "edit_history_tweet_ids": ["1589904649657933826"], "id": "1589904649657933826", "lang": "en"}, {"entities": {"mentions": [{"start": 0, "end": 12, "username": "End_myeloma", "id": "2538011298"}, {"start": 13, "end": 21, "username": "iStopMM", "id": "844232399319941122"}]}, "text": "@End_myeloma @iStopMM hahahaha thanks!", "referenced_tweets": [{"type": "replied_to", "id": "1589786911354556417"}], "source": "Twitter Web App", "author_id": "3078258341", "conversation_id": "1589629504422805506", "in_reply_to_user_id": "2538011298", "created_at": "2022-11-08T08:56:00.000Z", "edit_history_tweet_ids": ["1589904560369201155"], "id": "1589904560369201155", "lang": "tl"}, {"entities": {"mentions": [{"start": 0, "end": 13, "username": "NZ_HenryChan", "id": "1109824907393798144"}, {"start": 14, "end": 22, "username": "iStopMM", "id": "844232399319941122"}, {"start": 23, "end": 34, "username": "IMFmyeloma", "id": "34340707"}, {"start": 35, "end": 50, "username": "TheBindingSite", "id": "321436678"}, {"start": 51, "end": 63, "username": "uni_iceland", "id": "2769866904"}, {"start": 64, "end": 80, "username": "Haskoli_Islands", "id": "90458157"}, {"start": 81, "end": 95, "username": "RannisIceland", "id": "3095353150"}, {"start": 96, "end": 109, "username": "ERC_Research", "id": "467551928"}, {"start": 110, "end": 122, "username": "Landspitali", "id": "436581473"}, {"start": 123, "end": 137, "username": "TBSsteharding", "id": "1975260703"}, {"start": 138, "end": 153, "username": "ASH_hematology", "id": "84072624"}, {"start": 154, "end": 167, "username": "BrianDurieMD", "id": "339306345"}, {"start": 168, "end": 182, "username": "DrOlaLandgren", "id": "2257190339"}]}, "text": "@NZ_HenryChan @iStopMM @IMFmyeloma @TheBindingSite @uni_iceland @Haskoli_Islands @RannisIceland @ERC_Research @Landspitali @TBSsteharding @ASH_hematology @BrianDurieMD @DrOlaLandgren Thank you so much!", "referenced_tweets": [{"type": "replied_to", "id": "1589817303541387264"}], "source": "Twitter Web App", "author_id": "3078258341", "conversation_id": "1589629504422805506", "in_reply_to_user_id": "1109824907393798144", "created_at": "2022-11-08T08:55:38.000Z", "edit_history_tweet_ids": ["1589904465792225284"], "id": "1589904465792225284", "lang": "en"}, {"entities": {"mentions": [{"start": 0, "end": 11, "username": "Mohty_EBMT", "id": "2626263112"}, {"start": 12, "end": 20, "username": "iStopMM", "id": "844232399319941122"}]}, "text": "@Mohty_EBMT @iStopMM Thank you so much! You too!", "referenced_tweets": [{"type": "replied_to", "id": "1589890786765975552"}], "source": "Twitter Web App", "author_id": "3078258341", "conversation_id": "1589629504422805506", "in_reply_to_user_id": "2626263112", "created_at": "2022-11-08T08:55:19.000Z", "edit_history_tweet_ids": ["1589904385878167553"], "id": "1589904385878167553", "lang": "en"}, {"entities": {"mentions": [{"start": 0, "end": 9, "username": "szusmani", "id": "83911786"}, {"start": 10, "end": 18, "username": "iStopMM", "id": "844232399319941122"}]}, "text": "@szusmani @iStopMM Thanks a lot my friend!", "referenced_tweets": [{"type": "replied_to", "id": "1589701596531003393"}], "source": "Twitter for Android", "author_id": "3078258341", "conversation_id": "1589629504422805506", "in_reply_to_user_id": "83911786", "created_at": "2022-11-07T19:31:51.000Z", "edit_history_tweet_ids": ["1589702189307437056"], "id": "1589702189307437056", "lang": "en"}, {"entities": {"mentions": [{"start": 0, "end": 10, "username": "VincentRK", "id": "24261916"}, {"start": 11, "end": 19, "username": "iStopMM", "id": "844232399319941122"}]}, "text": "@VincentRK @iStopMM Hahahahah thanks!", "referenced_tweets": [{"type": "replied_to", "id": "1589699878753431552"}], "source": "Twitter for Android", "author_id": "3078258341", "conversation_id": "1589629504422805506", "in_reply_to_user_id": "24261916", "created_at": "2022-11-07T19:27:59.000Z", "edit_history_tweet_ids": ["1589701213922430976"], "id": "1589701213922430976", "lang": "en"}, {"entities": {"mentions": [{"start": 3, "end": 13, "username": "VincentRK", "id": "24261916"}, {"start": 15, "end": 29, "username": "sykristinsson", "id": "3078258341"}, {"start": 30, "end": 38, "username": "iStopMM", "id": "844232399319941122"}]}, "text": "RT @VincentRK: @sykristinsson @iStopMM You are ridiculously productive with a ridiculously productive trial. Congrats to you and your team\u2026", "referenced_tweets": [{"type": "retweeted", "id": "1589699878753431552"}], "source": "Twitter for Android", "author_id": "3078258341", "conversation_id": "1589701160281452545", "created_at": "2022-11-07T19:27:46.000Z", "edit_history_tweet_ids": ["1589701160281452545"], "id": "1589701160281452545", "lang": "en"}, {"entities": {"mentions": [{"start": 0, "end": 10, "username": "HiraSMian", "id": "419595308"}]}, "text": "@HiraSMian Thanks a lot!", "referenced_tweets": [{"type": "replied_to", "id": "1589638006876827648"}], "source": "Twitter Web App", "author_id": "3078258341", "conversation_id": "1589638006876827648", "in_reply_to_user_id": "419595308", "created_at": "2022-11-07T15:20:19.000Z", "edit_history_tweet_ids": ["1589638888083320833"], "id": "1589638888083320833", "lang": "en"}, {"entities": {"mentions": [{"start": 38, "end": 46, "username": "iStopMM", "id": "844232399319941122"}, {"start": 56, "end": 67, "username": "IMFmyeloma", "id": "34340707"}, {"start": 68, "end": 83, "username": "TheBindingSite", "id": "321436678"}, {"start": 85, "end": 97, "username": "uni_iceland", "id": "2769866904"}, {"start": 98, "end": 114, "username": "Haskoli_Islands", "id": "90458157"}, {"start": 115, "end": 129, "username": "RannisIceland", "id": "3095353150"}, {"start": 130, "end": 143, "username": "ERC_Research", "id": "467551928"}, {"start": 144, "end": 156, "username": "Landspitali", "id": "436581473"}, {"start": 158, "end": 172, "username": "TBSsteharding", "id": "1975260703"}, {"start": 173, "end": 188, "username": "ASH_hematology", "id": "84072624"}, {"start": 190, "end": 203, "username": "BrianDurieMD", "id": "339306345"}, {"start": 204, "end": 218, "username": "DrOlaLandgren", "id": "2257190339"}], "annotations": [{"start": 28, "end": 36, "probability": 0.6029, "type": "Other", "normalized_text": "Icelandic"}]}, "text": "Many thanks to to the whole Icelandic @iStopMM team and @IMFmyeloma @TheBindingSite  @uni_iceland @Haskoli_Islands @RannisIceland @ERC_Research @Landspitali  @TBSsteharding @ASH_hematology  @BrianDurieMD @DrOlaLandgren and many more!", "referenced_tweets": [{"type": "replied_to", "id": "1589629572265697282"}], "source": "Twitter Web App", "author_id": "3078258341", "conversation_id": "1589629504422805506", "in_reply_to_user_id": "3078258341", "created_at": "2022-11-07T14:47:41.000Z", "edit_history_tweet_ids": ["1589630676047126528"], "id": "1589630676047126528", "lang": "en"}, {"entities": {"mentions": [{"start": 93, "end": 104, "username": "thorirlong", "id": "3009607268"}], "annotations": [{"start": 72, "end": 78, "probability": 0.5166, "type": "Other", "normalized_text": "disease"}, {"start": 222, "end": 225, "probability": 0.4068, "type": "Organization", "normalized_text": "MGUS"}, {"start": 231, "end": 233, "probability": 0.5256, "type": "Organization", "normalized_text": "CKD"}], "urls": [{"start": 0, "end": 23, "url": "https://t.co/kNKC6qvvu0", "expanded_url": "https://ash.confex.com/ash/2022/webprogram/Paper170623.html", "display_url": "ash.confex.com/ash/2022/webpr\u2026", "status": 200, "title": "Paper: Monoclonal Gammopathy of Undetermined Significance and Risk of Chronic Kidney Disease: Results of the Population-Based Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) Study", "description": "Program: Oral and Poster Abstracts Session: 652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster III Hematology Disease Topics & Pathways: Research, epidemiology, Clinical Research, Plasma Cell Disorders, Diseases, Lymphoid Malignancies Thorir Einarsson Long, MD, PhD 1,2,3 *, Elias Eythorsson, MD, PhD 4 *, S\u00e6mundur R\u00f6gnvaldsson, MD 5,6 *, Olafur Indridason, MD, MHS 7 *, Runolfur Palsson, MD 6,8 *, Sigr\u00fan Thorsteinsd\u00f3ttir, MD, PhD 8,9, Ingigerdur S Sverrisdottir, MD 6,8,10", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Paper170623.html"}, {"start": 236, "end": 259, "url": "https://t.co/oY6kxaloiC", "expanded_url": "https://twitter.com/sykristinsson/status/1589629572265697282/photo/1", "display_url": "pic.twitter.com/oY6kxaloiC", "media_key": "3_1589628420073439232"}]}, "text": "https://t.co/kNKC6qvvu0\n\nLooking for M-proteins in everyone with kidney disease? \nPresenter: @thorirlong \nProspective population-based screening study of nearly 70,000 individuals\n\n\u2026 wait for it\u2026..\n\nNo association between MGUS and CKD! https://t.co/oY6kxaloiC", "referenced_tweets": [{"type": "replied_to", "id": "1589629566414655488"}], "source": "Twitter Web App", "author_id": "3078258341", "conversation_id": "1589629504422805506", "in_reply_to_user_id": "3078258341", "created_at": "2022-11-07T14:43:18.000Z", "edit_history_tweet_ids": ["1589629572265697282"], "id": "1589629572265697282", "lang": "en"}, {"entities": {"mentions": [{"start": 88, "end": 96, "username": "iStopMM", "id": "844232399319941122"}, {"start": 259, "end": 271, "username": "SaemundurMD", "id": "1054784756704010241"}], "annotations": [{"start": 187, "end": 189, "probability": 0.5616, "type": "Other", "normalized_text": "IgM"}], "urls": [{"start": 0, "end": 23, "url": "https://t.co/D7SwrDKhEu", "expanded_url": "https://ash.confex.com/ash/2022/webprogram/Paper168070.html", "display_url": "ash.confex.com/ash/2022/webpr\u2026", "status": 200, "title": "Paper: Monoclonal Gammopathy of Undetermined Significance (MGUS) with Multiple Paraproteins: Results from the Population-Based Istopmm Screening Study", "description": "Program: Oral and Poster Abstracts Session: 652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster III Hematology Disease Topics & Pathways: Research, epidemiology, Plasma Cell Disorders, Clinical Research, Diseases, Lymphoid Malignancies S\u00e6mundur R\u00f6gnvaldsson, MD 1,2 *, Jon \u00de\u00f3rir Oskarsson, MSc 3 *, Sigrun Thorsteinsdottir, MD, PhD 4,5, Elin Ruth Reed 4 *, Gudrun Asta Sigurdardottir 4 *, Brynjar Vidarsson, MD 2, Pall Torfi Onundarson, MD 2, Margret Sigurdardottir, MD 2 *,", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Paper168070.html"}, {"start": 272, "end": 295, "url": "https://t.co/CRjFIfClZO", "expanded_url": "https://twitter.com/sykristinsson/status/1589629566414655488/photo/1", "display_url": "pic.twitter.com/CRjFIfClZO", "media_key": "3_1589628011770511366"}]}, "text": "https://t.co/D7SwrDKhEu\nYou sometimes find &gt;1 M-spikes?\n\nWe screened 75422 people in @iStopMM  and found almost 10% have more than one M-proteins. Associated with older age, male, and IgM. Many disappear, none have progressed. Immune response? \nPresenter: @SaemundurMD https://t.co/CRjFIfClZO", "referenced_tweets": [{"type": "replied_to", "id": "1589629560056082432"}], "source": "Twitter Web App", "author_id": "3078258341", "conversation_id": "1589629504422805506", "in_reply_to_user_id": "3078258341", "created_at": "2022-11-07T14:43:17.000Z", "edit_history_tweet_ids": ["1589629566414655488"], "id": "1589629566414655488", "lang": "en"}, {"entities": {"mentions": [{"start": 251, "end": 263, "username": "astrunhelga", "id": "2758432772"}], "annotations": [{"start": 35, "end": 38, "probability": 0.3599, "type": "Other", "normalized_text": "CRAB"}, {"start": 106, "end": 109, "probability": 0.5122, "type": "Other", "normalized_text": "MGUS"}, {"start": 179, "end": 182, "probability": 0.4052, "type": "Other", "normalized_text": "MGUS"}], "urls": [{"start": 0, "end": 23, "url": "https://t.co/8jfMTQluaf", "expanded_url": "https://ash.confex.com/ash/2022/webprogram/Paper168822.html", "display_url": "ash.confex.com/ash/2022/webpr\u2026", "status": 200, "title": "Paper: Hypercalcemia in Individuals with Monoclonal Gammopathy of Undetermined Significance: Results from the Istopmm Study", "description": "Program: Oral and Poster Abstracts Session: 652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster III Hematology Disease Topics & Pathways: Research, adult, Clinical Practice (Health Services and Quality), elderly, Plasma Cell Disorders, Diseases, Lymphoid Malignancies, Study Population, Human \u00c1str\u00fan Helga J\u00f3nsd\u00f3ttir 1 *, S\u00e6mundur R\u00f6gnvaldsson, MD 1,2 *, Helga \u00c1g\u00fasta Sigurj\u00f3nsd\u00f3ttir 2,3 *, Sigr\u00fan Thorsteinsd\u00f3ttir, MD, PhD 3,4, Brynjar Vidarsson, MD 2, P\u00e1ll Torfi Onundarson,", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Paper168822.html"}, {"start": 264, "end": 287, "url": "https://t.co/tLQPbK4DBr", "expanded_url": "https://twitter.com/sykristinsson/status/1589629560056082432/photo/1", "display_url": "pic.twitter.com/tLQPbK4DBr", "media_key": "3_1589627613412265984"}]}, "text": "https://t.co/8jfMTQluaf\nThe \u201cC\u201c in CRAB does not walk alone!\n\nChecking s-calcium in 2546 individuals with MGUS: \n\n7.5% had hyperCa. Underlying causes similar as in &gt;70,000 non-MGUS. If associated with MM then other CRAB criteria present.\nPresenter @astrunhelga https://t.co/tLQPbK4DBr", "referenced_tweets": [{"type": "replied_to", "id": "1589629553001259008"}], "source": "Twitter Web App", "author_id": "3078258341", "conversation_id": "1589629504422805506", "in_reply_to_user_id": "3078258341", "created_at": "2022-11-07T14:43:15.000Z", "edit_history_tweet_ids": ["1589629560056082432"], "id": "1589629560056082432", "lang": "en"}, {"entities": {"mentions": [{"start": 122, "end": 130, "username": "iStopMM", "id": "844232399319941122"}, {"start": 215, "end": 231, "username": "SigrunThorstei1", "id": "1198917648630919168"}], "annotations": [{"start": 57, "end": 60, "probability": 0.5008, "type": "Other", "normalized_text": "CTPC"}, {"start": 102, "end": 104, "probability": 0.5918, "type": "Other", "normalized_text": "SMM"}, {"start": 114, "end": 117, "probability": 0.6341, "type": "Other", "normalized_text": "CTPC"}, {"start": 167, "end": 170, "probability": 0.5653, "type": "Other", "normalized_text": "MGUS"}, {"start": 172, "end": 174, "probability": 0.5205, "type": "Other", "normalized_text": "SMM"}, {"start": 176, "end": 177, "probability": 0.4613, "type": "Other", "normalized_text": "MM"}, {"start": 186, "end": 188, "probability": 0.5369, "type": "Other", "normalized_text": "SMM"}], "urls": [{"start": 0, "end": 23, "url": "https://t.co/RI350Lk9IL", "expanded_url": "https://ash.confex.com/ash/2022/webprogram/Paper168690.html", "display_url": "ash.confex.com/ash/2022/webpr\u2026", "status": 200, "title": "Paper: Circulating Tumor Plasma Cells in the Screened Istopmm Smoldering Multiple Myeloma Cohort", "description": "Program: Oral and Poster Abstracts Session: 651. Multiple Myelom a and Plasma Cell Dyscrasias: Basic and Translational: Poster III Hematology Disease Topics & Pathways: Research, Translational Research, Plasma Cell Disorders, Diseases, Lymphoid Malignancies Sigr\u00fan Thorsteinsd\u00f3ttir, MD, PhD 1,2, Jon \u00de\u00f3rir Oskarsson, MSc 3 *, S\u00e6mundur R\u00f6gnvaldsson, MD 4,5 *, Gauti G\u00edslason 1 *, Thor Aspelund, PhD 1 *, Gudr\u00fan \u00c1sta Sigurdard\u00f3ttir 1 *, \u00c1sdis R\u00f3sa Th\u00f3rdardottir 1 *, Brynjar Vidarsson, MD 5, P\u00e1ll Torfi Onundarson,", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Paper168690.html"}, {"start": 272, "end": 295, "url": "https://t.co/HDAUZMHgnP", "expanded_url": "https://twitter.com/sykristinsson/status/1589629553001259008/photo/1", "display_url": "pic.twitter.com/HDAUZMHgnP", "media_key": "3_1589626767215566851"}]}, "text": "https://t.co/RI350Lk9IL\n\nCirculating tumor plasma cells (CTPC) in an exciting topic!\n\nWe found 69% of SMM to have CTPC in @iStopMM. Detection and number increase from MGUS-SMM-MM and by SMM risk scores. \nPresenter: @SigrunThorstei1 \n\nMight be used instead of bone marrow? https://t.co/HDAUZMHgnP", "referenced_tweets": [{"type": "replied_to", "id": "1589629545870929920"}], "source": "Twitter Web App", "author_id": "3078258341", "conversation_id": "1589629504422805506", "in_reply_to_user_id": "3078258341", "created_at": "2022-11-07T14:43:13.000Z", "edit_history_tweet_ids": ["1589629553001259008"], "id": "1589629553001259008", "lang": "en"}, {"entities": {"mentions": [{"start": 110, "end": 123, "username": "ingigerdursv", "id": "740181058210107392"}, {"start": 151, "end": 159, "username": "iStopMM", "id": "844232399319941122"}], "annotations": [{"start": 73, "end": 76, "probability": 0.3936, "type": "Other", "normalized_text": "MGUS"}, {"start": 278, "end": 281, "probability": 0.4579, "type": "Other", "normalized_text": "MGUS"}], "urls": [{"start": 0, "end": 23, "url": "https://t.co/ydzq9PihCJ", "expanded_url": "https://ash.confex.com/ash/2022/webprogram/Paper169393.html", "display_url": "ash.confex.com/ash/2022/webpr\u2026", "status": 200, "title": "Paper: Autoimmune Diseases Are Not Associated with Monoclonal Gammopathy of Undetermined Significance: Results of the Prospective Population-Based Istopmm Study", "description": "Program: Oral and Poster Abstracts Session: 652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster III Hematology Disease Topics & Pathways: adult, Research, epidemiology, Plasma Cell Disorders, Clinical Research, Diseases, Lymphoid Malignancies, Human, Study Population Ingigerdur S Sverrisdottir, MD 1,2 *, Sigr\u00fan Thorsteinsd\u00f3ttir, MD, PhD 2,3, S\u00e6mundur R\u00f6gnvaldsson, MD 4 *, Thor Aspelund, PhD 2 *, Brynjar Vidarsson, MD 5, P\u00e1ll Torfi \u00d6nundarson, MD 5 *, Bjarni Agnarsson, MD", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Paper169393.html"}, {"start": 284, "end": 307, "url": "https://t.co/Fq3CvtLe8n", "expanded_url": "https://twitter.com/sykristinsson/status/1589629545870929920/photo/1", "display_url": "pic.twitter.com/Fq3CvtLe8n", "media_key": "3_1589625928606515206"}]}, "text": "https://t.co/ydzq9PihCJ\nAutoimmunity is well established risk factor for MGUS an MM. Think again! \nPresenter: @ingigerdursv: In a prospective screened @iStopMM , &gt;75000 individuals+ complete data on all diagnosis in the country: \n\nAutoimmune disease is not a risk factor for MGUS! https://t.co/Fq3CvtLe8n", "referenced_tweets": [{"type": "replied_to", "id": "1589629540409954305"}], "source": "Twitter Web App", "author_id": "3078258341", "conversation_id": "1589629504422805506", "in_reply_to_user_id": "3078258341", "created_at": "2022-11-07T14:43:12.000Z", "edit_history_tweet_ids": ["1589629545870929920"], "id": "1589629545870929920", "lang": "en"}, {"entities": {"mentions": [{"start": 80, "end": 88, "username": "iStopMM", "id": "844232399319941122"}, {"start": 171, "end": 179, "username": "jthorir", "id": "247118539"}], "annotations": [{"start": 24, "end": 26, "probability": 0.5592, "type": "Other", "normalized_text": "MRD"}, {"start": 92, "end": 94, "probability": 0.3759, "type": "Other", "normalized_text": "NGF"}], "urls": [{"start": 0, "end": 23, "url": "https://t.co/vWsOPXEfZa", "expanded_url": "https://ash.confex.com/ash/2022/webprogram/Paper168741.html", "display_url": "ash.confex.com/ash/2022/webpr\u2026", "status": 200, "title": "Paper: Determining Hemodilution in Diagnostic Bone Marrow Samples in Multiple Myeloma and Its Precursors By Next-Generation Flow Cytometry: Data from the Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) Study", "description": "Program: Oral and Poster Abstracts Session: 652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster II Hematology Disease Topics & Pathways: assays, Technology and Procedures, Minimal Residual Disease Jon \u00de\u00f3rir Oskarsson, MSc 1 *, S\u00e6mundur R\u00f6gnvaldsson, MD 2,3 *, Sigr\u00fan Thorsteinsd\u00f3ttir, MD, PhD 1,4, Hrafnhildur Una \u00de\u00f3r\u00f0ard\u00f3ttir 1 *, Gudlaug Katrin Hakonardottir 1 *, Steinar Bragi Gunnarsson 1 *, Gudr\u00fan \u00c1sta Sigurdard\u00f3ttir 1 *, \u00c1sdis R\u00f3sa Th\u00f3rdardottir 1 *, Gauti G\u00edslason 1", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Paper168741.html"}, {"start": 273, "end": 296, "url": "https://t.co/v5Ru54vLcM", "expanded_url": "https://twitter.com/sykristinsson/status/1589629540409954305/photo/1", "display_url": "pic.twitter.com/v5Ru54vLcM", "media_key": "3_1589625408626036739"}]}, "text": "https://t.co/vWsOPXEfZa\nMRD in MM can be false negative b/c of hemodilution. In @iStopMM by NGF we show a large difference in the # of PCs in 1st vs 2nd pull. \nPresenter: @jthorir\n\nSuggest hemodilution score model to evaluate quality and whether useful for diagnostic use. https://t.co/v5Ru54vLcM", "referenced_tweets": [{"type": "replied_to", "id": "1589629535292882945"}], "source": "Twitter Web App", "author_id": "3078258341", "conversation_id": "1589629504422805506", "in_reply_to_user_id": "3078258341", "created_at": "2022-11-07T14:43:10.000Z", "edit_history_tweet_ids": ["1589629540409954305"], "id": "1589629540409954305", "lang": "en"}, {"entities": {"mentions": [{"start": 102, "end": 118, "username": "SigrunThorstei1", "id": "1198917648630919168"}], "annotations": [{"start": 62, "end": 84, "probability": 0.4404, "type": "Person", "normalized_text": "Sigrun Thorsteinsdottir"}, {"start": 174, "end": 181, "probability": 0.5037, "type": "Other", "normalized_text": "\u2019s Guide"}], "urls": [{"start": 0, "end": 23, "url": "https://t.co/5SRZGKzaid", "expanded_url": "https://ash.confex.com/ash/2022/webprogram/Paper155386.html", "display_url": "ash.confex.com/ash/2022/webpr\u2026", "status": 200, "title": "Paper: The Consultant\u2019s Guide to Smoldering Multiple Myeloma", "description": "Program: Education Program Session: Treatment Approaches for the Multiple Myeloma Patient in 2022 Hematology Disease Topics & Pathways: Clinical Trials, Workforce, Plasma Cell Disorders, Diseases, Real World Evidence, Lymphoid Malignancies Sigrun Thorsteinsdottir, MD, PhD Department of Hematology, Rigshospitalet, K\u00f8benhavn, Copenhagen, Denmark Disclosures: No relevant conflicts of interest to", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Paper155386.html"}]}, "text": "https://t.co/5SRZGKzaid\nThe rising star of smoldering myeloma Sigrun Thorsteinsdottir, MD, PhD a.k.a. @SigrunThorstei1  gives an Educational Program talk on: \n\nThe Consultant\u2019s Guide to Smoldering Multiple Myeloma\n\nShe knows what she is talking about!", "referenced_tweets": [{"type": "replied_to", "id": "1589629531933282307"}], "source": "Twitter Web App", "author_id": "3078258341", "conversation_id": "1589629504422805506", "in_reply_to_user_id": "3078258341", "created_at": "2022-11-07T14:43:09.000Z", "edit_history_tweet_ids": ["1589629535292882945"], "id": "1589629535292882945", "lang": "en"}, {"entities": {"mentions": [{"start": 45, "end": 60, "username": "PalmasonRobert", "id": "1291096121733939202"}], "annotations": [{"start": 179, "end": 184, "probability": 0.6024, "type": "Other", "normalized_text": "cancer"}, {"start": 187, "end": 203, "probability": 0.7007, "type": "Other", "normalized_text": "pulmonary disease"}], "urls": [{"start": 0, "end": 23, "url": "https://t.co/LnThC0Q7yO", "expanded_url": "https://ash.confex.com/ash/2022/webprogram/Paper164758.html", "display_url": "ash.confex.com/ash/2022/webpr\u2026", "status": 200, "title": "Paper: Transient M-Proteins: Epidemiology, Causes, and the Impact of Mass Spectrometry: The Istopmm Study", "description": "Program: Oral and Poster Abstracts Type: Oral Session: 652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Disease Monitoring Hematology Disease Topics & Pathways: Plasma Cell Disorders, Diseases, Lymphoid Malignancies Robert Palmason 1,2,3 *, Oscar Berlanga, PhD 4 *, Jon Kristinn Sigurdsson 1 *, S\u00e6mundur R\u00f6gnvaldsson, MD 5,6 *, Sigrun Thorsteinsdottir, MD, PhD 1,7, Sara Ekberg, PhD 8 *, Michael Crowther, PhD 8 *, Marina Levy 1 *, Elin Ruth Reed 1 *, Jon \u00de\u00f3rir Oskarsson, MSc 9", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Paper164758.html"}, {"start": 281, "end": 304, "url": "https://t.co/VM1LyC0Weg", "expanded_url": "https://twitter.com/sykristinsson/status/1589629531933282307/photo/1", "display_url": "pic.twitter.com/VM1LyC0Weg", "media_key": "3_1589624444024197122"}]}, "text": "https://t.co/LnThC0Q7yO\nOral presentation by @PalmasonRobert : Can M-protein disappear? \nYes. Almost 10% by using standard approach. Underlying factors: infections, autoimmunity, cancer, pulmonary disease and drugs.\n\nBut by using mass spec (\u2b06\ufe0fsensitive) only 2.6% are really gone! https://t.co/VM1LyC0Weg", "referenced_tweets": [{"type": "replied_to", "id": "1589629524886446082"}], "source": "Twitter Web App", "author_id": "3078258341", "conversation_id": "1589629504422805506", "in_reply_to_user_id": "3078258341", "created_at": "2022-11-07T14:43:08.000Z", "edit_history_tweet_ids": ["1589629531933282307"], "id": "1589629531933282307", "lang": "en"}, {"entities": {"mentions": [{"start": 45, "end": 57, "username": "ThorvardurL", "id": "1199342830180651009"}, {"start": 111, "end": 119, "username": "iStopMM", "id": "844232399319941122"}], "annotations": [{"start": 74, "end": 77, "probability": 0.4052, "type": "Other", "normalized_text": "MGUS"}, {"start": 184, "end": 186, "probability": 0.6012, "type": "Other", "normalized_text": "IgA"}, {"start": 233, "end": 236, "probability": 0.466, "type": "Other", "normalized_text": "MGUS"}], "urls": [{"start": 0, "end": 23, "url": "https://t.co/fS149kE6mn", "expanded_url": "https://ash.confex.com/ash/2022/webprogram/Paper163169.html", "display_url": "ash.confex.com/ash/2022/webpr\u2026", "status": 200, "title": "Paper: Prevalence of MGUS Is High in the Istopmm Study but the Prevalence of IgA MGUS Does Not Increase with Age in the Way Other Immunoglobulin Subtypes Do", "description": "Program: Oral and Poster Abstracts Type: Oral Session: 652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Precursor States: MGUS and Smoldering Myeloma Hematology Disease Topics & Pathways: Research, clinical trials, epidemiology, Clinical Research, real-world evidence Thorvardur Jon Love, MD, PhD 1,2 *, S\u00e6mundur R\u00f6gnvaldsson, MD 3 *, Sigrun Thorsteinsdottir, MD, PhD 1,4, Thor Aspelund, PhD 1 *, Elin Ruth Reed 1 *, Brynjar Vidarsson, MD 2, Pall Torfi Onundarson, MD 2, Bjarni", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Paper163169.html"}, {"start": 273, "end": 296, "url": "https://t.co/ct1G8O4i0M", "expanded_url": "https://twitter.com/sykristinsson/status/1589629524886446082/photo/1", "display_url": "pic.twitter.com/ct1G8O4i0M", "media_key": "3_1589623815709102083"}]}, "text": "https://t.co/fS149kE6mn\nOral presentation by @ThorvardurL : How common is MGUS after screening 75422 people in @iStopMM? \n\nPrevalence is 3.9% in 40+ and 5% in 50+. All isotypes except IgA increasing with age. Most (43%) are low-risk MGUS. \nShould we screen? We for OS data https://t.co/ct1G8O4i0M", "referenced_tweets": [{"type": "replied_to", "id": "1589629516858953729"}], "source": "Twitter Web App", "author_id": "3078258341", "conversation_id": "1589629504422805506", "in_reply_to_user_id": "3078258341", "created_at": "2022-11-07T14:43:07.000Z", "edit_history_tweet_ids": ["1589629524886446082"], "id": "1589629524886446082", "lang": "en"}, {"entities": {"mentions": [{"start": 42, "end": 58, "username": "eliaseythorsson", "id": "133109181"}, {"start": 186, "end": 194, "username": "iStopMM", "id": "844232399319941122"}], "annotations": [{"start": 162, "end": 165, "probability": 0.5585, "type": "Other", "normalized_text": "BMPC"}, {"start": 237, "end": 240, "probability": 0.5048, "type": "Other", "normalized_text": "MGUS"}, {"start": 250, "end": 251, "probability": 0.5638, "type": "Other", "normalized_text": "BM"}], "urls": [{"start": 0, "end": 23, "url": "https://t.co/ZGqXHCmBJ3", "expanded_url": "https://ash.confex.com/ash/2022/webprogram/Paper170166.html", "display_url": "ash.confex.com/ash/2022/webpr\u2026", "status": 200, "title": "Paper: Predicting the Need for Upfront Bone Marrow Sampling in Individuals with MGUS: Derivation of a Multivariable Prediction Model Using the Prospective Population-Based Istopmm Cohort", "description": "Program: Oral and Poster Abstracts Type: Oral Session: 652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Precursor States: MGUS and Smoldering Myeloma Hematology Disease Topics & Pathways: adult, Research, Clinical Research, real-world evidence, Human, Study Population Elias Eythorsson, MD, PhD 1 *, S\u00e6mundur R\u00f6gnvaldsson, MD 1,2 *, Sigr\u00fan Thorsteinsd\u00f3ttir, MD, PhD 3,4, Elin Ruth Reed 3 *, Gudr\u00fan \u00c1sta Sigurdard\u00f3ttir 3 *, Brynjar Vidarsson, MD 1, P\u00e1ll Torfi Onundarson, MD 1,", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Paper170166.html"}, {"start": 279, "end": 302, "url": "https://t.co/5pjgkDzNDO", "expanded_url": "https://twitter.com/sykristinsson/status/1589629516858953729/photo/1", "display_url": "pic.twitter.com/5pjgkDzNDO", "media_key": "3_1589622746450903040"}]}, "text": "https://t.co/ZGqXHCmBJ3\nOral presentation @eliaseythorsson : Bone marrow in individual with M-protein? \nWe made a multivariable model to predict the risk of \u226510% BMPC in the prospective @iStopMM. Provides evidence to select persons with MGUS in whom BM sampling may be deferred. https://t.co/5pjgkDzNDO", "referenced_tweets": [{"type": "replied_to", "id": "1589629509418242048"}], "source": "Twitter Web App", "author_id": "3078258341", "conversation_id": "1589629504422805506", "in_reply_to_user_id": "3078258341", "created_at": "2022-11-07T14:43:05.000Z", "edit_history_tweet_ids": ["1589629516858953729"], "id": "1589629516858953729", "lang": "en"}, {"entities": {"mentions": [{"start": 42, "end": 57, "username": "PalmasonRobert", "id": "1291096121733939202"}, {"start": 122, "end": 130, "username": "iStopMM", "id": "844232399319941122"}], "annotations": [{"start": 159, "end": 163, "probability": 0.9421, "type": "Other", "normalized_text": "Covid"}, {"start": 176, "end": 179, "probability": 0.3526, "type": "Other", "normalized_text": "MGUS"}, {"start": 246, "end": 249, "probability": 0.4675, "type": "Other", "normalized_text": "MGUS"}, {"start": 269, "end": 273, "probability": 0.9078, "type": "Other", "normalized_text": "covid"}], "urls": [{"start": 0, "end": 23, "url": "https://t.co/SVUC9PkSjC", "expanded_url": "https://ash.confex.com/ash/2022/webprogram/Paper157138.html", "display_url": "ash.confex.com/ash/2022/webpr\u2026", "status": 200, "title": "Paper: Sars-Cov-2 Vaccinations Do Not Lead to Progression of Monoclonal Gammopathy of Undetermined Significance: Results from the Population-Based Istopmm Screening Study", "description": "Program: Oral and Poster Abstracts Type: Oral Session: 652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Precursor States: MGUS and Smoldering Myeloma Hematology Disease Topics & Pathways: Plasma Cell Disorders, Diseases, Lymphoid Malignancies Robert Palmason 1,2,3 *, Elias Eythorsson, MD, PhD 1 *, S\u00e6mundur R\u00f6gnvaldsson, MD 1,4 *, Sigrun Thorsteinsdottir, MD, PhD 3,5, Sara Ekberg, PhD 6 *, Michael Crowther, PhD 6 *, Elin Ruth Reed 3 *, Jon \u00de\u00f3rir Oskarsson, MSc 7 *, Gudrun", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Paper157138.html"}, {"start": 288, "end": 311, "url": "https://t.co/Iw8eT5en58", "expanded_url": "https://twitter.com/sykristinsson/status/1589629509418242048/photo/1", "display_url": "pic.twitter.com/Iw8eT5en58", "media_key": "3_1589621421390663680"}]}, "text": "https://t.co/SVUC9PkSjC\nOral presentation @PalmasonRobert: Do vaccinations trigger antibody-producing plasma cell clones? @iStopMM prospectively followed 1814 Covid vaccinated MGUS individuals. &gt;6000 tests pre&amp;post vacc: \n\nNo evidence for MGUS progression after covid vaccination. https://t.co/Iw8eT5en58", "referenced_tweets": [{"type": "replied_to", "id": "1589629504422805506"}], "source": "Twitter Web App", "author_id": "3078258341", "conversation_id": "1589629504422805506", "in_reply_to_user_id": "3078258341", "created_at": "2022-11-07T14:43:03.000Z", "edit_history_tweet_ids": ["1589629509418242048"], "id": "1589629509418242048", "lang": "en"}, {"entities": {"mentions": [{"start": 87, "end": 95, "username": "iStopMM", "id": "844232399319941122"}], "hashtags": [{"start": 71, "end": 77, "tag": "ASH22"}, {"start": 254, "end": 259, "tag": "mmsm"}], "annotations": [{"start": 72, "end": 76, "probability": 0.6339, "type": "Other", "normalized_text": "ASH22"}, {"start": 221, "end": 224, "probability": 0.4122, "type": "Organization", "normalized_text": "MGUS"}]}, "text": "4 orals, 6 posters, 1 educational and 2 Abstract achievement awards at #ASH22 from the @iStopMM study (w/9 different presenters)!\nWe are ridiculously excited to share our results after screening &gt;75,000 Icelanders for MGUS.\nAnd we are just beginning!\n#mmsm \ud83e\uddf5Abstracts:", "source": "Twitter Web App", "author_id": "3078258341", "conversation_id": "1589629504422805506", "created_at": "2022-11-07T14:43:02.000Z", "edit_history_tweet_ids": ["1589629504422805506"], "id": "1589629504422805506", "lang": "en"}, {"entities": {"mentions": [{"start": 3, "end": 14, "username": "GMyelomaAN", "id": "3083937603"}, {"start": 85, "end": 99, "username": "sykristinsson", "id": "3078258341"}, {"start": 123, "end": 134, "username": "IMFmyeloma", "id": "34340707"}], "hashtags": [{"start": 101, "end": 109, "tag": "myeloma"}, {"start": 110, "end": 122, "tag": "knowmyeloma"}], "annotations": [{"start": 43, "end": 49, "probability": 0.5205, "type": "Other", "normalized_text": "Iceland"}]}, "text": "RT @GMyelomaAN: We are starting our hybrid Iceland Patient &amp; Family Seminar with @sykristinsson \n#myeloma #knowmyeloma @IMFmyeloma https://\u2026", "referenced_tweets": [{"type": "retweeted", "id": "1587388080817831936"}], "source": "Twitter for Android", "author_id": "3078258341", "conversation_id": "1587571086639747073", "created_at": "2022-11-01T22:23:37.000Z", "edit_history_tweet_ids": ["1587571086639747073"], "id": "1587571086639747073", "lang": "en"}, {"entities": {"mentions": [{"start": 3, "end": 18, "username": "TheBindingSite", "id": "321436678"}], "annotations": [{"start": 24, "end": 30, "probability": 0.5741, "type": "Other", "normalized_text": "iStopMM"}, {"start": 104, "end": 122, "probability": 0.8761, "type": "Person", "normalized_text": "Jon Porir Oskarsson"}]}, "text": "RT @TheBindingSite: The iStopMM study has been running since 2016 and continues to produce vital data.\n\nJon Porir Oskarsson - PhD candidate\u2026", "referenced_tweets": [{"type": "retweeted", "id": "1584439548511064064"}], "source": "Twitter Web App", "author_id": "3078258341", "conversation_id": "1584472360597716992", "created_at": "2022-10-24T09:10:23.000Z", "edit_history_tweet_ids": ["1584472360597716992"], "id": "1584472360597716992", "lang": "en"}, {"entities": {"mentions": [{"start": 16, "end": 28, "username": "SaemundurMD", "id": "1054784756704010241"}, {"start": 29, "end": 37, "username": "iStopMM", "id": "844232399319941122"}], "annotations": [{"start": 61, "end": 65, "probability": 0.5904, "type": "Other", "normalized_text": "Gimli"}]}, "text": "@ArleighMccurdy @SaemundurMD @iStopMM We can always count on Gimli!", "referenced_tweets": [{"type": "replied_to", "id": "1582918513022205952"}], "source": "Twitter for Android", "author_id": "3078258341", "conversation_id": "1582879446490841088", "in_reply_to_user_id": "1334650653403197440", "created_at": "2022-10-20T02:21:10.000Z", "edit_history_tweet_ids": ["1582919828171464704"], "id": "1582919828171464704", "lang": "en"}, {"entities": {"mentions": [{"start": 3, "end": 15, "username": "SaemundurMD", "id": "1054784756704010241"}], "annotations": [{"start": 55, "end": 64, "probability": 0.4781, "type": "Other", "normalized_text": "Monoclonal"}]}, "text": "RT @SaemundurMD: Last week I defended my PhD thesis: \n\u201cMonoclonal gammopathy of what significance?\u201d \n\nI\u2019m so proud of this work and so grat\u2026", "referenced_tweets": [{"type": "retweeted", "id": "1582879446490841088"}], "source": "Twitter for Android", "author_id": "3078258341", "conversation_id": "1582884320808554496", "created_at": "2022-10-20T00:00:05.000Z", "edit_history_tweet_ids": ["1582884320808554496"], "id": "1582884320808554496", "lang": "en"}, {"entities": {"mentions": [{"start": 3, "end": 15, "username": "bjornsson_s", "id": "1126600712086069250"}, {"start": 33, "end": 47, "username": "sykristinsson", "id": "3078258341"}], "annotations": [{"start": 17, "end": 30, "probability": 0.7897, "type": "Person", "normalized_text": "Sigurdur Yngvi"}, {"start": 126, "end": 132, "probability": 0.9579, "type": "Place", "normalized_text": "Iceland"}]}, "text": "RT @bjornsson_s: Sigurdur Yngvi, @sykristinsson, is an International star in clinical haematology. We in academic Medicine in Iceland are v\u2026", "referenced_tweets": [{"type": "retweeted", "id": "1581267263625125892"}], "source": "Twitter for Android", "author_id": "3078258341", "conversation_id": "1581346754553053184", "created_at": "2022-10-15T18:10:20.000Z", "edit_history_tweet_ids": ["1581346754553053184"], "id": "1581346754553053184", "lang": "en"}, {"entities": {"mentions": [{"start": 3, "end": 13, "username": "VincentRK", "id": "24261916"}, {"start": 62, "end": 76, "username": "sykristinsson", "id": "3078258341"}], "annotations": [{"start": 54, "end": 57, "probability": 0.4892, "type": "Organization", "normalized_text": "MGUS"}, {"start": 84, "end": 86, "probability": 0.434, "type": "Other", "normalized_text": "AMN"}, {"start": 101, "end": 111, "probability": 0.6635, "type": "Other", "normalized_text": "Kristinsson"}]}, "text": "RT @VincentRK: Great Keynote lecture on Screening for MGUS by @sykristinsson at the AMN Meeting. Dr. Kristinsson is leading a nationwide ra\u2026", "referenced_tweets": [{"type": "retweeted", "id": "1581072167315570689"}], "source": "Twitter Web App", "author_id": "3078258341", "conversation_id": "1581164494818250752", "created_at": "2022-10-15T06:06:06.000Z", "edit_history_tweet_ids": ["1581164494818250752"], "id": "1581164494818250752", "lang": "en"}, {"entities": {"mentions": [{"start": 9, "end": 21, "username": "SaemundurMD", "id": "1054784756704010241"}], "urls": [{"start": 76, "end": 99, "url": "https://t.co/7Uo279BiIp", "expanded_url": "https://twitter.com/sykristinsson/status/1579926453751517186/video/1", "display_url": "pic.twitter.com/7Uo279BiIp", "media_key": "7_1579926379872788480"}]}, "text": "And when @SaemundurMD celebrates...you know there is going to be a party!!! https://t.co/7Uo279BiIp", "referenced_tweets": [{"type": "replied_to", "id": "1579925997155409920"}], "source": "Twitter for Android", "author_id": "3078258341", "conversation_id": "1579925997155409920", "in_reply_to_user_id": "3078258341", "created_at": "2022-10-11T20:06:34.000Z", "edit_history_tweet_ids": ["1579926453751517186"], "id": "1579926453751517186", "lang": "en"}, {"entities": {"mentions": [{"start": 12, "end": 24, "username": "SaemundurMD", "id": "1054784756704010241"}, {"start": 141, "end": 154, "username": "ADispenzieri", "id": "2172483547"}], "urls": [{"start": 187, "end": 210, "url": "https://t.co/JQ4hu334Ix", "expanded_url": "https://twitter.com/sykristinsson/status/1579925997155409920/photo/1", "display_url": "pic.twitter.com/JQ4hu334Ix", "media_key": "3_1579925972173873180"}, {"start": 187, "end": 210, "url": "https://t.co/JQ4hu334Ix", "expanded_url": "https://twitter.com/sykristinsson/status/1579925997155409920/photo/1", "display_url": "pic.twitter.com/JQ4hu334Ix", "media_key": "3_1579925978498883584"}, {"start": 187, "end": 210, "url": "https://t.co/JQ4hu334Ix", "expanded_url": "https://twitter.com/sykristinsson/status/1579925997155409920/photo/1", "display_url": "pic.twitter.com/JQ4hu334Ix", "media_key": "3_1579925985851498500"}]}, "text": "So proud of @SaemundurMD my PhD student who defended his thesis yesterday.  His performance was outstanding! Congratulations!\n\nAnd thank you @ADispenzieri for being the perfect opponent! https://t.co/JQ4hu334Ix", "source": "Twitter for Android", "author_id": "3078258341", "conversation_id": "1579925997155409920", "created_at": "2022-10-11T20:04:45.000Z", "edit_history_tweet_ids": ["1579925997155409920"], "id": "1579925997155409920", "lang": "en"}, {"entities": {"mentions": [{"start": 3, "end": 18, "username": "TheBindingSite", "id": "321436678"}], "annotations": [{"start": 48, "end": 54, "probability": 0.8454, "type": "Other", "normalized_text": "iStopMM"}, {"start": 72, "end": 85, "probability": 0.7028, "type": "Person", "normalized_text": "Einarsson Long"}]}, "text": "RT @TheBindingSite: In collaboration with other iStopMM researchers, Dr Einarsson Long has published a paper on how kidney function is know\u2026", "referenced_tweets": [{"type": "retweeted", "id": "1575748530731360258"}], "source": "Twitter Web App", "author_id": "3078258341", "conversation_id": "1575781385784426496", "created_at": "2022-09-30T09:35:33.000Z", "edit_history_tweet_ids": ["1575781385784426496"], "id": "1575781385784426496", "lang": "en"}, {"entities": {"mentions": [{"start": 0, "end": 12, "username": "awechalekar", "id": "957790163014385665"}, {"start": 13, "end": 22, "username": "aishaikh", "id": "42107379"}], "annotations": [{"start": 99, "end": 105, "probability": 0.666, "type": "Other", "normalized_text": "LC-MGUS"}]}, "text": "@awechalekar @aishaikh Thanks!! I believe with our suggested reference values this will change the LC-MGUS criteria above. In individuals with renal dysfuncion, need to use our criteria instead.", "referenced_tweets": [{"type": "replied_to", "id": "1575079402442203136"}], "source": "Twitter for Android", "author_id": "3078258341", "conversation_id": "1575079402442203136", "in_reply_to_user_id": "957790163014385665", "created_at": "2022-09-28T11:09:44.000Z", "edit_history_tweet_ids": ["1575080311914135552"], "id": "1575080311914135552", "lang": "en"}, {"entities": {"mentions": [{"start": 69, "end": 80, "username": "thorirlong", "id": "3009607268"}, {"start": 238, "end": 253, "username": "BloodCancerJnl", "id": "1417061180997345288"}, {"start": 254, "end": 265, "username": "IMFmyeloma", "id": "34340707"}], "hashtags": [{"start": 208, "end": 213, "tag": "mmsm"}, {"start": 214, "end": 225, "tag": "nephrology"}, {"start": 226, "end": 237, "tag": "NephTwitte"}], "annotations": [{"start": 209, "end": 212, "probability": 0.5354, "type": "Other", "normalized_text": "mmsm"}, {"start": 215, "end": 224, "probability": 0.5783, "type": "Other", "normalized_text": "nephrology"}, {"start": 227, "end": 236, "probability": 0.6731, "type": "Other", "normalized_text": "NephTwitte"}], "urls": [{"start": 184, "end": 207, "url": "https://t.co/xWzjdbabzW", "expanded_url": "https://rdcu.be/cVw40", "display_url": "rdcu.be/cVw40", "status": 200, "unwound_url": "https://www.nature.com/articles/s41408-022-00732-3.epdf?sharing_token=be_jyr5_H0n0KX4Ae9Tl4tRgN0jAjWel9jnR3ZoTv0OhZ7TA_7WiBKrFOCJxMthJbyzHLTvYped-D9O_r3sEwUciwYize6yB4vNfAdOUgpUowNt8hvVF0HRLK5VyCU63JAo6rUjGdycaq4FC3pxeL8hc33kkWkxAJpLGZAd_nw4%3D&error=cookies_not_supported&code=879af185-f6a8-4c38-a1a9-331b83cc5f68"}, {"start": 266, "end": 289, "url": "https://t.co/bLKgvZVrdZ", "expanded_url": "https://twitter.com/TheBindingSite/status/1575017467407114242", "display_url": "twitter.com/TheBindingSite\u2026"}]}, "text": "Confused why and how kidney function imapcts light chain levels? Not @thorirlong . He knows and explains how in only 2 minutes! \n\nThis is why we needed to change the reference values: https://t.co/xWzjdbabzW #mmsm #nephrology #NephTwitte @BloodCancerJnl @IMFmyeloma https://t.co/bLKgvZVrdZ", "referenced_tweets": [{"type": "quoted", "id": "1575017467407114242"}], "source": "Twitter for Android", "author_id": "3078258341", "conversation_id": "1575069616467869696", "created_at": "2022-09-28T10:27:14.000Z", "edit_history_tweet_ids": ["1575069616467869696"], "id": "1575069616467869696", "lang": "en"}, {"entities": {"mentions": [{"start": 0, "end": 9, "username": "aishaikh", "id": "42107379"}, {"start": 10, "end": 18, "username": "iStopMM", "id": "844232399319941122"}, {"start": 19, "end": 28, "username": "MSK_Neph", "id": "1462362881731743746"}]}, "text": "@aishaikh @iStopMM @MSK_Neph Thanks a lot!", "referenced_tweets": [{"type": "replied_to", "id": "1574755505486053382"}], "source": "Twitter Web App", "author_id": "3078258341", "conversation_id": "1574539658989809670", "in_reply_to_user_id": "42107379", "created_at": "2022-09-27T14:04:19.000Z", "edit_history_tweet_ids": ["1574761858430631938"], "id": "1574761858430631938", "lang": "en"}, {"entities": {"mentions": [{"start": 0, "end": 9, "username": "aishaikh", "id": "42107379"}, {"start": 10, "end": 18, "username": "iStopMM", "id": "844232399319941122"}, {"start": 19, "end": 28, "username": "MSK_Neph", "id": "1462362881731743746"}]}, "text": "@aishaikh @iStopMM @MSK_Neph Fantastic slides! Would love to hear your take on our study.", "referenced_tweets": [{"type": "replied_to", "id": "1574539658989809670"}], "source": "Twitter Web App", "author_id": "3078258341", "conversation_id": "1574539658989809670", "in_reply_to_user_id": "42107379", "created_at": "2022-09-27T08:46:13.000Z", "edit_history_tweet_ids": ["1574681807911518209"], "id": "1574681807911518209", "lang": "en"}, {"entities": {"mentions": [{"start": 3, "end": 12, "username": "aishaikh", "id": "42107379"}], "annotations": [{"start": 69, "end": 71, "probability": 0.4386, "type": "Other", "normalized_text": "CKD"}]}, "text": "RT @aishaikh: New reference intervals for serum free light chains in CKD. Excited to discuss this study in an upcoming talk. It impacts LC-\u2026", "referenced_tweets": [{"type": "retweeted", "id": "1574539658989809670"}], "source": "Twitter Web App", "author_id": "3078258341", "conversation_id": "1574681522707251200", "created_at": "2022-09-27T08:45:05.000Z", "edit_history_tweet_ids": ["1574681522707251200"], "id": "1574681522707251200", "lang": "en"}, {"entities": {"mentions": [{"start": 3, "end": 15, "username": "HadidiSamer", "id": "774267564"}, {"start": 131, "end": 139, "username": "iStopMM", "id": "844232399319941122"}], "annotations": [{"start": 107, "end": 128, "probability": 0.7563, "type": "Other", "normalized_text": "chronic kidney disease"}]}, "text": "RT @HadidiSamer: Important paper suggesting a new normal range of serum free light chains in patients with chronic kidney disease  @iStopMM\u2026", "referenced_tweets": [{"type": "retweeted", "id": "1574579084423663616"}], "source": "Twitter Web App", "author_id": "3078258341", "conversation_id": "1574681012919050240", "created_at": "2022-09-27T08:43:04.000Z", "edit_history_tweet_ids": ["1574681012919050240"], "id": "1574681012919050240", "lang": "en"}, {"entities": {"mentions": [{"start": 3, "end": 17, "username": "MichaelJSlade", "id": "626650397"}], "annotations": [{"start": 56, "end": 62, "probability": 0.8841, "type": "Other", "normalized_text": "iStopMM"}]}, "text": "RT @MichaelJSlade: Interesting work from the phenomenal iStopMM group. This issue is that most EMRs (including Epic) don\u2019t support multiple\u2026", "referenced_tweets": [{"type": "retweeted", "id": "1574576681238646785"}], "source": "Twitter for Android", "author_id": "3078258341", "conversation_id": "1574667778719592449", "created_at": "2022-09-27T07:50:29.000Z", "edit_history_tweet_ids": ["1574667778719592449"], "id": "1574667778719592449", "lang": "en"}, {"entities": {"mentions": [{"start": 3, "end": 18, "username": "andrewinnes007", "id": "211982416"}], "annotations": [{"start": 93, "end": 96, "probability": 0.5244, "type": "Other", "normalized_text": "SFLC"}]}, "text": "RT @andrewinnes007: These data needs to be reflected in lab normal ranges. Borderline raised SFLC is one of the commonest referral reasons\u2026", "referenced_tweets": [{"type": "retweeted", "id": "1574644674773524481"}], "source": "Twitter for Android", "author_id": "3078258341", "conversation_id": "1574667752832667650", "created_at": "2022-09-27T07:50:22.000Z", "edit_history_tweet_ids": ["1574667752832667650"], "id": "1574667752832667650", "lang": "en"}, {"entities": {"mentions": [{"start": 3, "end": 19, "username": "RamonGarciaSanz", "id": "846500919021899777"}]}, "text": "RT @RamonGarciaSanz: \ud83d\udc4f\ud83d\udc4f\ud83d\udc4f", "referenced_tweets": [{"type": "retweeted", "id": "1574503605943443456"}], "source": "Twitter for Android", "author_id": "3078258341", "conversation_id": "1574506230059409408", "created_at": "2022-09-26T21:08:32.000Z", "edit_history_tweet_ids": ["1574506230059409408"], "id": "1574506230059409408", "lang": "art"}, {"entities": {"mentions": [{"start": 3, "end": 11, "username": "Psbntn9", "id": "716254481"}, {"start": 13, "end": 26, "username": "Pathologists", "id": "24725678"}]}, "text": "RT @Psbntn9: @Pathologists", "referenced_tweets": [{"type": "retweeted", "id": "1574493113854443536"}], "source": "Twitter for Android", "author_id": "3078258341", "conversation_id": "1574506200325976064", "created_at": "2022-09-26T21:08:25.000Z", "edit_history_tweet_ids": ["1574506200325976064"], "id": "1574506200325976064", "lang": "qam"}, {"entities": {"mentions": [{"start": 3, "end": 12, "username": "ecoladov", "id": "51187036"}], "annotations": [{"start": 72, "end": 74, "probability": 0.4162, "type": "Organization", "normalized_text": "FLC"}]}, "text": "RT @ecoladov: This should be practice-changing indeed. Overinterpreting FLC assays is not innocuous.", "referenced_tweets": [{"type": "retweeted", "id": "1574492256748204032"}], "source": "Twitter for Android", "author_id": "3078258341", "conversation_id": "1574506182697435136", "created_at": "2022-09-26T21:08:21.000Z", "edit_history_tweet_ids": ["1574506182697435136"], "id": "1574506182697435136", "lang": "en"}, {"entities": {"mentions": [{"start": 3, "end": 11, "username": "dikokaz", "id": "276053436"}], "annotations": [{"start": 121, "end": 123, "probability": 0.5093, "type": "Other", "normalized_text": "CKD"}]}, "text": "RT @dikokaz: This is great for clinical practice so we can use objective cut points rather than guestimate in those with CKD. \n\nOf Note, fo\u2026", "referenced_tweets": [{"type": "retweeted", "id": "1574466576761245697"}], "source": "Twitter for Android", "author_id": "3078258341", "conversation_id": "1574506108152172547", "created_at": "2022-09-26T21:08:03.000Z", "edit_history_tweet_ids": ["1574506108152172547"], "id": "1574506108152172547", "lang": "en"}, {"entities": {"mentions": [{"start": 0, "end": 12, "username": "JillingtonC", "id": "757934840"}]}, "text": "@JillingtonC Hahahah glad you liked it!", "referenced_tweets": [{"type": "replied_to", "id": "1574432562285608960"}], "source": "Twitter for Android", "author_id": "3078258341", "conversation_id": "1574432562285608960", "in_reply_to_user_id": "757934840", "created_at": "2022-09-26T17:08:15.000Z", "edit_history_tweet_ids": ["1574445757603913729"], "id": "1574445757603913729", "lang": "en"}, {"entities": {"mentions": [{"start": 3, "end": 11, "username": "mtmdphd", "id": "190337035"}], "hashtags": [{"start": 13, "end": 18, "tag": "mmsm"}]}, "text": "RT @mtmdphd: #mmsm FLC", "referenced_tweets": [{"type": "retweeted", "id": "1574425998589935618"}], "source": "Twitter Web App", "author_id": "3078258341", "conversation_id": "1574427108734111745", "created_at": "2022-09-26T15:54:08.000Z", "edit_history_tweet_ids": ["1574427108734111745"], "id": "1574427108734111745", "lang": "und"}, {"entities": {"mentions": [{"start": 3, "end": 15, "username": "KRakszawski", "id": "284694610"}], "hashtags": [{"start": 115, "end": 120, "tag": "mmsm"}], "annotations": [{"start": 95, "end": 98, "probability": 0.4389, "type": "Other", "normalized_text": "MGUS"}, {"start": 100, "end": 102, "probability": 0.4925, "type": "Other", "normalized_text": "CKD"}, {"start": 116, "end": 119, "probability": 0.3889, "type": "Other", "normalized_text": "mmsm"}]}, "text": "RT @KRakszawski: Definitely practice changing! I've already started to incorporate this in our MGUS/CKD referrals. #mmsm", "referenced_tweets": [{"type": "retweeted", "id": "1574426253481820161"}], "source": "Twitter Web App", "author_id": "3078258341", "conversation_id": "1574427094938943492", "created_at": "2022-09-26T15:54:05.000Z", "edit_history_tweet_ids": ["1574427094938943492"], "id": "1574427094938943492", "lang": "en"}, {"entities": {"mentions": [{"start": 0, "end": 12, "username": "KRakszawski", "id": "284694610"}]}, "text": "@KRakszawski Wow!!! That was fast :)", "referenced_tweets": [{"type": "replied_to", "id": "1574426253481820161"}], "source": "Twitter Web App", "author_id": "3078258341", "conversation_id": "1574426253481820161", "in_reply_to_user_id": "284694610", "created_at": "2022-09-26T15:54:00.000Z", "edit_history_tweet_ids": ["1574427073992687616"], "id": "1574427073992687616", "lang": "en"}, {"entities": {"mentions": [{"start": 29, "end": 40, "username": "IMFmyeloma", "id": "34340707"}, {"start": 41, "end": 56, "username": "TheBindingSite", "id": "321436678"}, {"start": 57, "end": 72, "username": "BloodCancerJnl", "id": "1417061180997345288"}, {"start": 73, "end": 84, "username": "thorirlong", "id": "3009607268"}, {"start": 85, "end": 93, "username": "iStopMM", "id": "844232399319941122"}, {"start": 95, "end": 109, "username": "DrOlaLandgren", "id": "2257190339"}, {"start": 110, "end": 126, "username": "MalinHultcrantz", "id": "212681144"}, {"start": 127, "end": 141, "username": "TBSsteharding", "id": "1975260703"}, {"start": 142, "end": 151, "username": "runolfpa", "id": "258483907"}, {"start": 152, "end": 164, "username": "SaemundurMD", "id": "1054784756704010241"}, {"start": 165, "end": 173, "username": "mtmdphd", "id": "190337035"}, {"start": 174, "end": 186, "username": "ThorvardurL", "id": "1199342830180651009"}, {"start": 187, "end": 203, "username": "SigrunThorstei1", "id": "1198917648630919168"}, {"start": 204, "end": 220, "username": "eliaseythorsson", "id": "133109181"}, {"start": 221, "end": 231, "username": "VincentRK", "id": "24261916"}], "hashtags": [{"start": 233, "end": 238, "tag": "mmsm"}, {"start": 239, "end": 250, "tag": "MedTwitter"}, {"start": 251, "end": 262, "tag": "Nephrology"}, {"start": 263, "end": 275, "tag": "amyloidosis"}], "annotations": [{"start": 240, "end": 249, "probability": 0.6047, "type": "Other", "normalized_text": "MedTwitter"}, {"start": 252, "end": 261, "probability": 0.5733, "type": "Other", "normalized_text": "Nephrology"}, {"start": 264, "end": 274, "probability": 0.5586, "type": "Other", "normalized_text": "amyloidosis"}]}, "text": "Please help spread the word: @IMFmyeloma @TheBindingSite @BloodCancerJnl @thorirlong @iStopMM  @DrOlaLandgren @MalinHultcrantz @TBSsteharding @runolfpa @SaemundurMD @mtmdphd @ThorvardurL @SigrunThorstei1 @eliaseythorsson @VincentRK  #mmsm #MedTwitter #Nephrology #amyloidosis", "referenced_tweets": [{"type": "replied_to", "id": "1574422541711642625"}], "source": "Twitter Web App", "author_id": "3078258341", "conversation_id": "1574422541711642625", "in_reply_to_user_id": "3078258341", "created_at": "2022-09-26T15:36:00.000Z", "edit_history_tweet_ids": ["1574422544513257473"], "id": "1574422544513257473", "lang": "en"}, {"entities": {"mentions": [{"start": 202, "end": 213, "username": "thorirlong", "id": "3009607268"}], "annotations": [{"start": 31, "end": 34, "probability": 0.5665, "type": "Other", "normalized_text": "MGUS"}], "urls": [{"start": 178, "end": 201, "url": "https://t.co/xWzjdbrMYw", "expanded_url": "https://rdcu.be/cVw40", "display_url": "rdcu.be/cVw40", "status": 200, "unwound_url": "https://www.nature.com/articles/s41408-022-00732-3.epdf?sharing_token=be_jyr5_H0n0KX4Ae9Tl4tRgN0jAjWel9jnR3ZoTv0OhZ7TA_7WiBKrFOCJxMthJbyzHLTvYped-D9O_r3sEwUciwYize6yB4vNfAdOUgpUowNt8hvVF0HRLK5VyCU63JAo6rUjGdycaq4FC3pxeL8hc33kkWkxAJpLGZAd_nw4%3D&error=cookies_not_supported&code=879af185-f6a8-4c38-a1a9-331b83cc5f68"}, {"start": 284, "end": 307, "url": "https://t.co/jGL2LO9cuw", "expanded_url": "https://twitter.com/sykristinsson/status/1574422541711642625/photo/1", "display_url": "pic.twitter.com/jGL2LO9cuw", "media_key": "3_1574415310794407936"}]}, "text": "New definition for light chain MGUS! \n\nPractice changing: New ref values for free light chains (FLC), kappa+ lambda in people with kidney dysfunction (GFR&lt;60) just published: https://t.co/xWzjdbrMYw @thorirlong \n\nAvoid unnecessary consultations, bone marrows, and\u2b07\ufe0fpatient anxiety https://t.co/jGL2LO9cuw", "source": "Twitter Web App", "author_id": "3078258341", "conversation_id": "1574422541711642625", "created_at": "2022-09-26T15:35:59.000Z", "edit_history_tweet_ids": ["1574422541711642625"], "id": "1574422541711642625", "lang": "en"}, {"text": "Thank you so much for inviting me! \n\nYou are doing a fantastic job at educating patients and their relatives! https://t.co/Vemwunoy46", "referenced_tweets": [{"type": "quoted", "id": "1573234918997598210"}], "source": "Twitter for Android", "author_id": "3078258341", "conversation_id": "1573242790552690692", "created_at": "2022-09-23T09:28:05.000Z", "edit_history_tweet_ids": ["1573242790552690692"], "id": "1573242790552690692", "lang": "en", "entities": {"urls": [{"start": 110, "end": 133, "url": "https://t.co/Vemwunoy46", "expanded_url": "https://twitter.com/GMyelomaAN/status/1573234918997598210", "display_url": "twitter.com/GMyelomaAN/sta\u2026"}]}}, {"entities": {"mentions": [{"start": 3, "end": 13, "username": "VincentRK", "id": "24261916"}], "annotations": [{"start": 104, "end": 107, "probability": 0.3552, "type": "Other", "normalized_text": "MGUS"}, {"start": 110, "end": 116, "probability": 0.6495, "type": "Other", "normalized_text": "myeloma"}, {"start": 122, "end": 132, "probability": 0.5583, "type": "Other", "normalized_text": "amyloidosis"}]}, "text": "RT @VincentRK: The serum free light chain assay is important for diagnosis &amp; response assessment in MGUS, myeloma, AL amyloidosis. But the\u2026", "referenced_tweets": [{"type": "retweeted", "id": "1572567061150433280"}], "source": "Twitter Web App", "author_id": "3078258341", "conversation_id": "1572572225018134529", "created_at": "2022-09-21T13:03:30.000Z", "edit_history_tweet_ids": ["1572572225018134529"], "id": "1572572225018134529", "lang": "en"}, {"entities": {"mentions": [{"start": 3, "end": 17, "username": "DrOlaLandgren", "id": "2257190339"}]}, "text": "RT @DrOlaLandgren: Important new paper on how to interpret serum free light chains (FLCs):\n\nDefining new reference intervals for serum FLCs\u2026", "referenced_tweets": [{"type": "retweeted", "id": "1570620366430818305"}], "source": "Twitter for Android", "author_id": "3078258341", "conversation_id": "1572123610487345152", "created_at": "2022-09-20T07:20:52.000Z", "edit_history_tweet_ids": ["1572123610487345152"], "id": "1572123610487345152", "lang": "en"}, {"entities": {"mentions": [{"start": 3, "end": 14, "username": "AlanYuNeph", "id": "20549404"}], "annotations": [{"start": 70, "end": 72, "probability": 0.5769, "type": "Other", "normalized_text": "CKD"}, {"start": 83, "end": 87, "probability": 0.4545, "type": "Other", "normalized_text": "kappa"}, {"start": 128, "end": 129, "probability": 0.6928, "type": "Other", "normalized_text": "BM"}]}, "text": "RT @AlanYuNeph: \ud83d\udc4fBeen waiting for this!\nCan't count how many times my CKD pts with kappa/lambda ratio of 2-3 have been sent for BM Bx, esp.\u2026", "referenced_tweets": [{"type": "retweeted", "id": "1571261954404007936"}], "source": "Twitter for Android", "author_id": "3078258341", "conversation_id": "1571830633751580672", "created_at": "2022-09-19T11:56:40.000Z", "edit_history_tweet_ids": ["1571830633751580672"], "id": "1571830633751580672", "lang": "en"}, {"entities": {"mentions": [{"start": 3, "end": 14, "username": "kidney_boy", "id": "18084746"}, {"start": 78, "end": 93, "username": "Amyloid_Planet", "id": "1138405094"}], "annotations": [{"start": 73, "end": 75, "probability": 0.5656, "type": "Other", "normalized_text": "CKD"}]}, "text": "RT @kidney_boy: What's the normal kappa lambda free light chain ratio in CKD? @Amyloid_Planet", "referenced_tweets": [{"type": "retweeted", "id": "1571206926314213376"}], "source": "Twitter for Android", "author_id": "3078258341", "conversation_id": "1571212430130159619", "created_at": "2022-09-17T19:00:09.000Z", "edit_history_tweet_ids": ["1571212430130159619"], "id": "1571212430130159619", "lang": "en"}, {"entities": {"mentions": [{"start": 3, "end": 12, "username": "Bloodman", "id": "16827782"}]}, "text": "RT @Bloodman: Key paper - we got a lot of econsults for slightly abnormal light chains in people with impaired renal function.", "referenced_tweets": [{"type": "retweeted", "id": "1570945974805352449"}], "source": "Twitter for Android", "author_id": "3078258341", "conversation_id": "1571212153318789120", "created_at": "2022-09-17T18:59:03.000Z", "edit_history_tweet_ids": ["1571212153318789120"], "id": "1571212153318789120", "lang": "en"}, {"entities": {"mentions": [{"start": 3, "end": 16, "username": "Abdallah81MD", "id": "1026947037080772610"}], "annotations": [{"start": 114, "end": 120, "probability": 0.5758, "type": "Other", "normalized_text": "disease"}]}, "text": "RT @Abdallah81MD: Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: Results of the i\u2026", "referenced_tweets": [{"type": "retweeted", "id": "1571165895078170631"}], "source": "Twitter for Android", "author_id": "3078258341", "conversation_id": "1571208415199764480", "created_at": "2022-09-17T18:44:12.000Z", "edit_history_tweet_ids": ["1571208415199764480"], "id": "1571208415199764480", "lang": "en"}, {"entities": {"mentions": [{"start": 3, "end": 14, "username": "thorirlong", "id": "3009607268"}], "annotations": [{"start": 77, "end": 80, "probability": 0.6191, "type": "Other", "normalized_text": "FLCs"}, {"start": 86, "end": 88, "probability": 0.622, "type": "Other", "normalized_text": "FLC"}]}, "text": "RT @thorirlong: Our paper were we redefine the reference intervals for serum FLCs and FLC ratio in individuals with chronic kidney disease\u2026", "referenced_tweets": [{"type": "retweeted", "id": "1570755512580583424"}], "source": "Twitter for Android", "author_id": "3078258341", "conversation_id": "1571037222694187010", "created_at": "2022-09-17T07:23:57.000Z", "edit_history_tweet_ids": ["1571037222694187010"], "id": "1571037222694187010", "lang": "en"}, {"entities": {"mentions": [{"start": 7, "end": 15, "username": "iStopMM", "id": "844232399319941122"}, {"start": 38, "end": 50, "username": "astrunhelga", "id": "2758432772"}, {"start": 84, "end": 97, "username": "Annakaren981", "id": "1268269154022436866"}, {"start": 98, "end": 110, "username": "SaemundurMD", "id": "1054784756704010241"}, {"start": 111, "end": 127, "username": "SigrunThorstei1", "id": "1198917648630919168"}, {"start": 213, "end": 224, "username": "IMFmyeloma", "id": "34340707"}], "annotations": [{"start": 148, "end": 154, "probability": 0.5916, "type": "Other", "normalized_text": "Myeloma"}], "urls": [{"start": 225, "end": 248, "url": "https://t.co/NrocETCrRV", "expanded_url": "https://twitter.com/SigrunThorstei1/status/1570470773609099264", "display_url": "twitter.com/SigrunThorstei\u2026"}]}, "text": "What a @iStopMM team! Congratulations @astrunhelga! Well deserved. \nAnd congrats to @Annakaren981 @SaemundurMD @SigrunThorstei1 for great projects. Myeloma research is moving fast forward with these rising stars!\n@IMFmyeloma https://t.co/NrocETCrRV", "referenced_tweets": [{"type": "quoted", "id": "1570470773609099264"}], "source": "Twitter Web App", "author_id": "3078258341", "conversation_id": "1570515590418403328", "created_at": "2022-09-15T20:51:10.000Z", "edit_history_tweet_ids": ["1570515590418403328"], "id": "1570515590418403328", "lang": "en"}, {"entities": {"mentions": [{"start": 3, "end": 13, "username": "vhugo8762", "id": "114124641"}, {"start": 64, "end": 78, "username": "sykristinsson", "id": "3078258341"}]}, "text": "RT @vhugo8762: Are we ready for the lift? Great presentation by @sykristinsson Congrats again, will learn lots from your amazing study! -#i\u2026", "referenced_tweets": [{"type": "retweeted", "id": "1563270667927097345"}], "source": "Twitter for Android", "author_id": "3078258341", "conversation_id": "1563291329093783555", "created_at": "2022-08-26T22:24:32.000Z", "edit_history_tweet_ids": ["1563291329093783555"], "id": "1563291329093783555", "lang": "en"}, {"entities": {"mentions": [{"start": 6, "end": 15, "username": "szusmani", "id": "83911786"}, {"start": 42, "end": 50, "username": "iStopMM", "id": "844232399319941122"}, {"start": 112, "end": 120, "username": "jthorir", "id": "247118539"}], "hashtags": [{"start": 103, "end": 111, "tag": "IMS2022"}], "annotations": [{"start": 104, "end": 110, "probability": 0.5913, "type": "Other", "normalized_text": "IMS2022"}], "urls": [{"start": 121, "end": 144, "url": "https://t.co/wDO9xgEqhG", "expanded_url": "https://twitter.com/sykristinsson/status/1562879673268256769/photo/1", "display_url": "pic.twitter.com/wDO9xgEqhG", "media_key": "3_1562879670340632579"}, {"start": 145, "end": 168, "url": "https://t.co/mGyzSIqKXk", "expanded_url": "https://twitter.com/sykristinsson/status/1562876616564322304", "display_url": "twitter.com/sykristinsson/\u2026"}]}, "text": "Or as @szusmani put it so elegantly: \"The @iStopMM study is going to be the gift that keeps on giving\" #IMS2022 @jthorir https://t.co/wDO9xgEqhG https://t.co/mGyzSIqKXk", "referenced_tweets": [{"type": "quoted", "id": "1562876616564322304"}], "source": "Twitter for Android", "author_id": "3078258341", "conversation_id": "1562879673268256769", "created_at": "2022-08-25T19:08:45.000Z", "edit_history_tweet_ids": ["1562879673268256769"], "id": "1562879673268256769", "lang": "en"}, {"entities": {"mentions": [{"start": 9, "end": 17, "username": "jthorir", "id": "247118539"}, {"start": 27, "end": 35, "username": "iStopMM", "id": "844232399319941122"}], "hashtags": [{"start": 213, "end": 221, "tag": "IMS2022"}], "annotations": [{"start": 108, "end": 110, "probability": 0.5159, "type": "Other", "normalized_text": "NGF"}, {"start": 115, "end": 118, "probability": 0.358, "type": "Place", "normalized_text": "MGUS"}, {"start": 214, "end": 220, "probability": 0.6006, "type": "Other", "normalized_text": "IMS2022"}], "urls": [{"start": 222, "end": 245, "url": "https://t.co/Moo33OMeuu", "expanded_url": "https://twitter.com/sykristinsson/status/1562876616564322304/photo/1", "display_url": "pic.twitter.com/Moo33OMeuu", "media_key": "3_1562876613938688000"}]}, "text": "Proud of @jthorir from the @iStopMM team who gave a great talk on the detection of aberrant plasma cells by NGF in MGUS. Negative result associated with transient M-proteins and possibly lower risk of progression #IMS2022 https://t.co/Moo33OMeuu", "source": "Twitter for Android", "author_id": "3078258341", "conversation_id": "1562876616564322304", "created_at": "2022-08-25T18:56:36.000Z", "edit_history_tweet_ids": ["1562876616564322304"], "id": "1562876616564322304", "lang": "en"}, {"entities": {"mentions": [{"start": 83, "end": 91, "username": "jthorir", "id": "247118539"}, {"start": 102, "end": 110, "username": "iStopMM", "id": "844232399319941122"}, {"start": 118, "end": 134, "username": "BrunoPaiva_UNAV", "id": "1335161063382376448"}, {"start": 136, "end": 146, "username": "RomanosSP", "id": "1113607578230165504"}, {"start": 153, "end": 166, "username": "Dagostino_MD", "id": "1459459064065404935"}], "hashtags": [{"start": 38, "end": 46, "tag": "IMS2022"}], "annotations": [{"start": 39, "end": 45, "probability": 0.806, "type": "Other", "normalized_text": "IMS2022"}], "urls": [{"start": 167, "end": 190, "url": "https://t.co/LxNaz3epD6", "expanded_url": "https://twitter.com/Myeloma_Society/status/1555629718132690945", "display_url": "twitter.com/Myeloma_Societ\u2026"}]}, "text": "Do not miss this fantastic session at #IMS2022 with great abstracts presented by:\n\n@jthorir (from the @iStopMM team), @BrunoPaiva_UNAV, @RomanosSP, and  @Dagostino_MD https://t.co/LxNaz3epD6", "referenced_tweets": [{"type": "quoted", "id": "1555629718132690945"}], "source": "Twitter Web App", "author_id": "3078258341", "conversation_id": "1561691259634319360", "created_at": "2022-08-22T12:26:25.000Z", "edit_history_tweet_ids": ["1561691259634319360"], "id": "1561691259634319360", "lang": "en"}, {"entities": {"mentions": [{"start": 3, "end": 19, "username": "eliaseythorsson", "id": "133109181"}, {"start": 41, "end": 49, "username": "iStopMM", "id": "844232399319941122"}], "annotations": [{"start": 67, "end": 74, "probability": 0.6924, "type": "Other", "normalized_text": "ASH 2022"}]}, "text": "RT @eliaseythorsson: We're working on it @iStopMM. More to come at ASH 2022", "referenced_tweets": [{"type": "retweeted", "id": "1558526217187377152"}], "source": "Twitter for Android", "author_id": "3078258341", "conversation_id": "1558532070367830016", "created_at": "2022-08-13T19:12:56.000Z", "edit_history_tweet_ids": ["1558532070367830016"], "id": "1558532070367830016", "lang": "en"}, {"entities": {"mentions": [{"start": 66, "end": 74, "username": "iStopMM", "id": "844232399319941122"}, {"start": 136, "end": 152, "username": "Myeloma_Society", "id": "841751045034369025"}, {"start": 153, "end": 164, "username": "IMFmyeloma", "id": "34340707"}], "hashtags": [{"start": 165, "end": 170, "tag": "mmsm"}], "annotations": [{"start": 11, "end": 18, "probability": 0.6704, "type": "Other", "normalized_text": "IMS 2022"}, {"start": 127, "end": 133, "probability": 0.6351, "type": "Other", "normalized_text": "myeloma"}], "urls": [{"start": 173, "end": 196, "url": "https://t.co/CnAOhgmCJ5", "expanded_url": "https://l.feathr.co/IMS-2022/Sigurdur-Y-Kristinsson", "display_url": "l.feathr.co/IMS-2022/Sigur\u2026", "images": [{"url": "https://pbs.twimg.com/news_img/1552287425820561408/Jtq1jYRH?format=jpg&name=orig", "width": 1200, "height": 630}, {"url": "https://pbs.twimg.com/news_img/1552287425820561408/Jtq1jYRH?format=jpg&name=150x150", "width": 150, "height": 150}], "status": 200, "title": "Join me for IMS 2022!", "description": "Join me at the 19th International Myeloma Society Annual Meeting this August in Los Angeles, California!", "unwound_url": "https://l.feathr.co/IMS-2022/Sigurdur-Y-Kristinsson"}]}, "text": "Join me at IMS 2022 where I will share some new findings from the @iStopMM study and discuss the role of early intervention in myeloma\n\n@Myeloma_Society @IMFmyeloma #mmsm \n\nhttps://t.co/CnAOhgmCJ5", "source": "Twitter Web App", "author_id": "3078258341", "conversation_id": "1552287402634448897", "created_at": "2022-07-27T13:38:51.000Z", "edit_history_tweet_ids": ["1552287402634448897"], "id": "1552287402634448897", "lang": "en"}, {"entities": {"mentions": [{"start": 0, "end": 15, "username": "AaronGoodman33", "id": "854692626015993857"}, {"start": 16, "end": 29, "username": "VPrasadMDMPH", "id": "1194962714"}], "annotations": [{"start": 67, "end": 79, "probability": 0.9721, "type": "Person", "normalized_text": "Louis Pasteur"}]}, "text": "@AaronGoodman33 @VPrasadMDMPH \"Luck favors the prepared mind\" :) //Louis Pasteur", "referenced_tweets": [{"type": "replied_to", "id": "1550560999404552192"}], "source": "Twitter Web App", "author_id": "3078258341", "conversation_id": "1550553502639804417", "in_reply_to_user_id": "854692626015993857", "created_at": "2022-07-22T22:15:45.000Z", "edit_history_tweet_ids": ["1550605546897768448"], "id": "1550605546897768448", "lang": "en"}, {"entities": {"mentions": [{"start": 3, "end": 14, "username": "NorthTxMSG", "id": "961409220"}], "annotations": [{"start": 39, "end": 40, "probability": 0.5663, "type": "Other", "normalized_text": "OS"}]}, "text": "RT @NorthTxMSG: \"If screening improves OS, we should, if it doesn't, we shouldn't\", \"please give me 2 more years. I'll give you the answer\"\u2026", "referenced_tweets": [{"type": "retweeted", "id": "1534441924760854528"}], "source": "Twitter Web App", "author_id": "3078258341", "conversation_id": "1534535251191549960", "created_at": "2022-06-08T13:58:08.000Z", "edit_history_tweet_ids": ["1534535251191549960"], "id": "1534535251191549960", "lang": "en"}, {"entities": {"mentions": [{"start": 3, "end": 13, "username": "VincentRK", "id": "24261916"}], "hashtags": [{"start": 101, "end": 108, "tag": "ASCO22"}], "annotations": [{"start": 57, "end": 63, "probability": 0.6235, "type": "Other", "normalized_text": "myeloma"}, {"start": 102, "end": 107, "probability": 0.4746, "type": "Organization", "normalized_text": "ASCO22"}]}, "text": "RT @VincentRK: My thoughts on the DETERMINATION trial in myeloma presented in the Plenary session of #ASCO22 and published simultaneously i\u2026", "referenced_tweets": [{"type": "retweeted", "id": "1534113835241639942"}], "source": "Twitter for Android", "author_id": "3078258341", "conversation_id": "1534117368678567936", "created_at": "2022-06-07T10:17:37.000Z", "edit_history_tweet_ids": ["1534117368678567936"], "id": "1534117368678567936", "lang": "en"}, {"text": "When you think your son is tweeting about football, but realize he was actually explaining life in a profound and elegant way! #proudfather https://t.co/0B6THziSSV", "referenced_tweets": [{"type": "quoted", "id": "1533112998612635651"}], "source": "Twitter for Android", "author_id": "3078258341", "entities": {"hashtags": [{"start": 127, "end": 139, "tag": "proudfather"}], "urls": [{"start": 140, "end": 163, "url": "https://t.co/0B6THziSSV", "expanded_url": "https://twitter.com/KirreSig/status/1533112998612635651", "display_url": "twitter.com/KirreSig/statu\u2026"}]}, "conversation_id": "1533410755881619457", "created_at": "2022-06-05T11:29:48.000Z", "edit_history_tweet_ids": ["1533410755881619457"], "id": "1533410755881619457", "lang": "en"}, {"entities": {"mentions": [{"start": 3, "end": 11, "username": "mtmdphd", "id": "190337035"}, {"start": 98, "end": 106, "username": "mtmdphd", "id": "190337035"}], "hashtags": [{"start": 84, "end": 91, "tag": "ASCO22"}, {"start": 92, "end": 97, "tag": "mmsm"}], "annotations": [{"start": 28, "end": 34, "probability": 0.7346, "type": "Other", "normalized_text": "Myeloma"}, {"start": 38, "end": 58, "probability": 0.8069, "type": "Other", "normalized_text": "Plasma Cell Dyscrasia"}, {"start": 61, "end": 63, "probability": 0.411, "type": "Other", "normalized_text": "PCD"}]}, "text": "RT @mtmdphd: Top 10 (or so) Myeloma / Plasma Cell Dyscrasia (PCD) Abstract Picks at #ASCO22 #mmsm @mtmdphd Table \u2013 *Draft* Update Jun 3, 20\u2026", "referenced_tweets": [{"type": "retweeted", "id": "1532846691270926344"}], "source": "Twitter for Android", "author_id": "3078258341", "conversation_id": "1532847627607359490", "created_at": "2022-06-03T22:12:08.000Z", "edit_history_tweet_ids": ["1532847627607359490"], "id": "1532847627607359490", "lang": "en"}, {"entities": {"mentions": [{"start": 3, "end": 11, "username": "mtmdphd", "id": "190337035"}, {"start": 98, "end": 106, "username": "mtmdphd", "id": "190337035"}], "hashtags": [{"start": 84, "end": 91, "tag": "ASCO22"}, {"start": 92, "end": 97, "tag": "mmsm"}], "annotations": [{"start": 28, "end": 34, "probability": 0.7354, "type": "Other", "normalized_text": "Myeloma"}, {"start": 38, "end": 58, "probability": 0.8068, "type": "Other", "normalized_text": "Plasma Cell Dyscrasia"}, {"start": 61, "end": 63, "probability": 0.4112, "type": "Other", "normalized_text": "PCD"}]}, "text": "RT @mtmdphd: Top 10 (or so) Myeloma / Plasma Cell Dyscrasia (PCD) Abstract Picks at #ASCO22 #mmsm @mtmdphd Table \u2013 *Draft* Update Jun 2, 20\u2026", "referenced_tweets": [{"type": "retweeted", "id": "1532463251459563547"}], "source": "Twitter Web App", "author_id": "3078258341", "conversation_id": "1532472258115035149", "created_at": "2022-06-02T21:20:32.000Z", "edit_history_tweet_ids": ["1532472258115035149"], "id": "1532472258115035149", "lang": "en"}, {"entities": {"mentions": [{"start": 3, "end": 11, "username": "mtmdphd", "id": "190337035"}], "annotations": [{"start": 73, "end": 79, "probability": 0.5869, "type": "Other", "normalized_text": "Iceland"}, {"start": 128, "end": 134, "probability": 0.4683, "type": "Other", "normalized_text": "iStopMM"}]}, "text": "RT @mtmdphd: Prevalence of Smoldering Multiple Myeloma: Results from the Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) St\u2026", "referenced_tweets": [{"type": "retweeted", "id": "1529189492950802432"}], "source": "Twitter Web App", "author_id": "3078258341", "conversation_id": "1529407113797197824", "created_at": "2022-05-25T10:20:45.000Z", "edit_history_tweet_ids": ["1529407113797197824"], "id": "1529407113797197824", "lang": "en"}], "includes": {"users": [{"id": "3078258341", "name": "Sigurdur Kristinsson", "username": "sykristinsson"}, {"id": "792165987273601024", "name": "Neha Korde", "username": "kordeneha1"}, {"id": "1269642863924609025", "name": "Manni Mohyuddin", "username": "ManniMD1"}, {"id": "190337035", "name": "Mike Thompson, MD, PhD, FASCO", "username": "mtmdphd"}, {"id": "209212922", "name": "Siddharth Kunte, MD", "username": "siddharthkunte"}, {"id": "2538011298", "name": "Luciano J Costa", "username": "End_myeloma"}, {"id": "1109824907393798144", "name": "Henry Chan", "username": "NZ_HenryChan"}, {"id": "2626263112", "name": "Mohamad Mohty", "username": "Mohty_EBMT"}, {"id": "83911786", "name": "Saad Z. Usmani MD MBA FACP (he/his/him)\ud83c\uddfa\ud83c\uddf8\ud83c\uddf5\ud83c\uddf0", "username": "szusmani"}, {"id": "24261916", "name": "Vincent Rajkumar", "username": "VincentRK"}, {"id": "419595308", "name": "Hira Mian", "username": "HiraSMian"}, {"id": "957790163014385665", "name": "awechalekar", "username": "awechalekar"}, {"id": "42107379", "name": "Aisha Shaikh @aishaikh@med-mastodon.com", "username": "aishaikh"}, {"id": "757934840", "name": "Jill Coll", "username": "JillingtonC"}, {"id": "284694610", "name": "Kevin Rakszawski, MD", "username": "KRakszawski"}, {"id": "854692626015993857", "name": "Aaron Goodman - \u201cPapa Heme\u201d", "username": "AaronGoodman33"}], "tweets": [{"entities": {"mentions": [{"start": 0, "end": 14, "username": "sykristinsson", "id": "3078258341"}], "annotations": [{"start": 20, "end": 26, "probability": 0.772, "type": "Other", "normalized_text": "Coronas"}]}, "text": "@sykristinsson Yes! Coronas. And I don\u2019t mean the virus", "referenced_tweets": [{"type": "replied_to", "id": "1600957243465535488"}], "source": "Twitter for iPhone", "author_id": "792165987273601024", "conversation_id": "1600940905732902913", "in_reply_to_user_id": "3078258341", "created_at": "2022-12-08T21:05:19.000Z", "edit_history_tweet_ids": ["1600959733535748096"], "id": "1600959733535748096", "lang": "en"}, {"entities": {"mentions": [{"start": 60, "end": 68, "username": "iStopMM", "id": "844232399319941122"}, {"start": 102, "end": 116, "username": "sykristinsson", "id": "3078258341"}], "hashtags": [{"start": 0, "end": 6, "tag": "ASH22"}, {"start": 117, "end": 122, "tag": "mmsm"}], "annotations": [{"start": 1, "end": 5, "probability": 0.5997, "type": "Other", "normalized_text": "ASH22"}, {"start": 118, "end": 121, "probability": 0.4085, "type": "Other", "normalized_text": "mmsm"}], "urls": [{"start": 123, "end": 146, "url": "https://t.co/lD630Py7md", "expanded_url": "https://twitter.com/sykristinsson/status/1589629504422805506", "display_url": "twitter.com/sykristinsson/\u2026"}]}, "text": "#ASH22 a fabulous collection of abstracts and data from the @iStopMM team with practice changing data @sykristinsson #mmsm https://t.co/lD630Py7md", "referenced_tweets": [{"type": "quoted", "id": "1589629504422805506"}], "source": "Twitter for iPhone", "author_id": "1014890726818238465", "conversation_id": "1600763735995736064", "created_at": "2022-12-08T08:06:30.000Z", "edit_history_tweet_ids": ["1600763735995736064"], "id": "1600763735995736064", "lang": "en"}, {"entities": {"mentions": [{"start": 0, "end": 14, "username": "sykristinsson", "id": "3078258341"}], "annotations": [{"start": 48, "end": 58, "probability": 0.9632, "type": "Place", "normalized_text": "New Orleans"}]}, "text": "@sykristinsson Still have fond memories of last New Orleans ASH", "referenced_tweets": [{"type": "replied_to", "id": "1600940905732902913"}], "source": "Twitter for iPhone", "author_id": "792165987273601024", "conversation_id": "1600940905732902913", "in_reply_to_user_id": "3078258341", "created_at": "2022-12-08T20:50:48.000Z", "edit_history_tweet_ids": ["1600956081253253120"], "id": "1600956081253253120", "lang": "en"}, {"entities": {"mentions": [{"start": 118, "end": 129, "username": "IMFmyeloma", "id": "34340707"}], "hashtags": [{"start": 15, "end": 21, "tag": "ASH22"}, {"start": 108, "end": 117, "tag": "IMFASH22"}, {"start": 130, "end": 135, "tag": "mmsm"}], "annotations": [{"start": 16, "end": 20, "probability": 0.716, "type": "Other", "normalized_text": "ASH22"}, {"start": 109, "end": 116, "probability": 0.6155, "type": "Other", "normalized_text": "IMFASH22"}, {"start": 131, "end": 134, "probability": 0.4424, "type": "Other", "normalized_text": "mmsm"}], "urls": [{"start": 136, "end": 159, "url": "https://t.co/lMqvVPRqf5", "expanded_url": "https://twitter.com/Daw6Jessie/status/1600630491115552768/photo/1", "display_url": "pic.twitter.com/lMqvVPRqf5", "media_key": "3_1600629883268468736"}]}, "text": "Gearing up for #ASH22, looking forward to many scientific presentations, and also this educational program: #IMFASH22 @IMFmyeloma #mmsm https://t.co/lMqvVPRqf5", "source": "Twitter Web App", "author_id": "1455299166511538176", "conversation_id": "1600630491115552768", "created_at": "2022-12-07T23:17:02.000Z", "edit_history_tweet_ids": ["1600630491115552768"], "id": "1600630491115552768", "lang": "en"}, {"entities": {"mentions": [{"start": 61, "end": 69, "username": "iStopMM", "id": "844232399319941122"}, {"start": 70, "end": 84, "username": "sykristinsson", "id": "3078258341"}], "hashtags": [{"start": 88, "end": 96, "tag": "Ash2022"}, {"start": 97, "end": 102, "tag": "mmsm"}], "annotations": [{"start": 89, "end": 95, "probability": 0.4537, "type": "Other", "normalized_text": "Ash2022"}, {"start": 98, "end": 101, "probability": 0.4315, "type": "Other", "normalized_text": "mmsm"}], "urls": [{"start": 103, "end": 126, "url": "https://t.co/6gXzUtfPfj", "expanded_url": "https://twitter.com/sykristinsson/status/1600123462827184128", "display_url": "twitter.com/sykristinsson/\u2026"}]}, "text": "Looking forward to more outstanding outputs from the amazing @iStopMM @sykristinsson at #Ash2022 #mmsm https://t.co/6gXzUtfPfj", "referenced_tweets": [{"type": "quoted", "id": "1600123462827184128"}], "source": "Twitter for iPad", "author_id": "1014890726818238465", "conversation_id": "1600372667277668352", "created_at": "2022-12-07T06:12:32.000Z", "edit_history_tweet_ids": ["1600372667277668352"], "id": "1600372667277668352", "lang": "en"}, {"entities": {"mentions": [{"start": 0, "end": 15, "username": "AaronGoodman33", "id": "854692626015993857"}, {"start": 16, "end": 24, "username": "iStopMM", "id": "844232399319941122"}, {"start": 25, "end": 39, "username": "sykristinsson", "id": "3078258341"}, {"start": 78, "end": 92, "username": "sykristinsson", "id": "3078258341"}], "annotations": [{"start": 62, "end": 64, "probability": 0.4606, "type": "Other", "normalized_text": "ASH"}]}, "text": "@AaronGoodman33 @iStopMM @sykristinsson I will send after the ASH meeting, as @sykristinsson was kind enough to share some confidential slides that I used. I will share after the meeting \ud83d\ude00", "referenced_tweets": [{"type": "replied_to", "id": "1600546340873781248"}], "source": "Twitter Web App", "author_id": "1269642863924609025", "conversation_id": "1600545405540126720", "in_reply_to_user_id": "854692626015993857", "created_at": "2022-12-07T17:43:30.000Z", "edit_history_tweet_ids": ["1600546555081027584"], "id": "1600546555081027584", "lang": "en"}, {"entities": {"mentions": [{"start": 125, "end": 133, "username": "iStopMM", "id": "844232399319941122"}, {"start": 134, "end": 148, "username": "sykristinsson", "id": "3078258341"}], "hashtags": [{"start": 230, "end": 236, "tag": "ASH22"}], "annotations": [{"start": 231, "end": 235, "probability": 0.6187, "type": "Other", "normalized_text": "ASH22"}], "urls": [{"start": 151, "end": 174, "url": "https://t.co/6Fok0TBUDi", "expanded_url": "https://ash.confex.com/ash/2022/webprogram/Paper169393.html", "display_url": "ash.confex.com/ash/2022/webpr\u2026", "status": 200, "title": "Paper: Autoimmune Diseases Are Not Associated with Monoclonal Gammopathy of Undetermined Significance: Results of the Prospective Population-Based Istopmm Study", "description": "Program: Oral and Poster Abstracts Session: 652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster III Hematology Disease Topics & Pathways: adult, Research, epidemiology, Plasma Cell Disorders, Clinical Research, Diseases, Lymphoid Malignancies, Human, Study Population Ingigerdur S Sverrisdottir, MD 1,2 *, Sigr\u00fan Thorsteinsd\u00f3ttir, MD, PhD 2,3, S\u00e6mundur R\u00f6gnvaldsson, MD 4 *, Thor Aspelund, PhD 2 *, Brynjar Vidarsson, MD 5, P\u00e1ll Torfi \u00d6nundarson, MD 5 *, Bjarni Agnarsson, MD", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Paper169393.html"}, {"start": 246, "end": 269, "url": "https://t.co/QUlXawKR7Z", "expanded_url": "https://twitter.com/ManniMD1/status/1600545405540126720/photo/1", "display_url": "pic.twitter.com/QUlXawKR7Z", "media_key": "3_1600545179307425792"}]}, "text": "The title of my talk today to rheumatologists, we are already changing practice and minds as a result of the amazing work by @iStopMM @sykristinsson \n\nhttps://t.co/6Fok0TBUDi\n\nAn example of practice changed even before the actual #ASH22 meeting! https://t.co/QUlXawKR7Z", "source": "Twitter Web App", "author_id": "1269642863924609025", "conversation_id": "1600545405540126720", "created_at": "2022-12-07T17:38:56.000Z", "edit_history_tweet_ids": ["1600545405540126720"], "id": "1600545405540126720", "lang": "en"}, {"entities": {"mentions": [{"start": 87, "end": 95, "username": "iStopMM", "id": "844232399319941122"}], "hashtags": [{"start": 71, "end": 77, "tag": "ASH22"}, {"start": 254, "end": 259, "tag": "mmsm"}], "annotations": [{"start": 72, "end": 76, "probability": 0.6339, "type": "Other", "normalized_text": "ASH22"}, {"start": 221, "end": 224, "probability": 0.4122, "type": "Organization", "normalized_text": "MGUS"}]}, "text": "4 orals, 6 posters, 1 educational and 2 Abstract achievement awards at #ASH22 from the @iStopMM study (w/9 different presenters)!\nWe are ridiculously excited to share our results after screening &gt;75,000 Icelanders for MGUS.\nAnd we are just beginning!\n#mmsm \ud83e\uddf5Abstracts:", "source": "Twitter Web App", "author_id": "3078258341", "conversation_id": "1589629504422805506", "created_at": "2022-11-07T14:43:02.000Z", "edit_history_tweet_ids": ["1589629504422805506"], "id": "1589629504422805506", "lang": "en"}, {"entities": {"mentions": [{"start": 29, "end": 40, "username": "UrviShahMD", "id": "905435513879973892"}], "annotations": [{"start": 107, "end": 113, "probability": 0.369, "type": "Other", "normalized_text": "Placebo"}, {"start": 118, "end": 121, "probability": 0.4052, "type": "Organization", "normalized_text": "MGUS"}, {"start": 123, "end": 125, "probability": 0.4939, "type": "Other", "normalized_text": "SMM"}], "urls": [{"start": 5, "end": 28, "url": "https://t.co/TH5rAuCksy", "expanded_url": "https://ash.confex.com/ash/2022/webprogram/Paper159794.html", "display_url": "ash.confex.com/ash/2022/webpr\u2026", "status": 200, "title": "Paper: A Randomized Placebo Controlled Study of a Plant-Based Dietary Versus Supplement Versus Placebo Intervention in Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Multiple Myeloma (SMM) - the Nutrition Prevention (NUTRIVENTION-3) Study", "description": "Program: Oral and Poster Abstracts Session: 902. Health Services and Quality\u2014Lymphoid Malignancies: Poster I Hematology Disease Topics & Pathways: clinical trials, adult, Research, Clinical Research, Plasma Cell Disorders, Diseases, metabolism, Lymphoid Malignancies, Biological Processes, microbiome, Study Population, Human Urvi A Shah, MD 1, Francesca Castro, MS 2 *, Aishwarya Anuraj, MBBS 3 *, Eliana Schach, BA 4,5 *, Andriy Derkach, PhD 6 *, Nisha S. Joseph, MD 7, Peter A. Adintori, MS, RD, CSO, CDN,", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Paper159794.html"}]}, "text": "2213 https://t.co/TH5rAuCksy\n@UrviShahMD Yes! A randomized study of a Plant-Based Dietary vs Supplement vs Placebo in MGUS/SMM. Although no results are in abstracts, this is supercool!", "referenced_tweets": [{"type": "replied_to", "id": "1600544431962480640"}], "source": "Twitter Web App", "author_id": "3078258341", "conversation_id": "1600544417827504144", "in_reply_to_user_id": "3078258341", "created_at": "2022-12-07T17:35:04.000Z", "edit_history_tweet_ids": ["1600544434160275457"], "id": "1600544434160275457", "lang": "en"}, {"entities": {"mentions": [{"start": 30, "end": 42, "username": "DrGerLobato", "id": "3689670976"}], "annotations": [{"start": 106, "end": 109, "probability": 0.5177, "type": "Other", "normalized_text": "MGUS"}, {"start": 115, "end": 117, "probability": 0.7062, "type": "Other", "normalized_text": "SMM"}], "urls": [{"start": 6, "end": 29, "url": "https://t.co/fgV6EeXHO1", "expanded_url": "https://ash.confex.com/ash/2022/webprogram/Paper165371.html", "display_url": "ash.confex.com/ash/2022/webpr\u2026", "status": 200, "title": "Paper: Evolving Pattern Improves the IMWG 2/20/20 Classification for Patients with Smoldering Multiple Myeloma", "description": "Program: Oral and Poster Abstracts Session: 652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster I Hematology Disease Topics & Pathways: Research, epidemiology, Clinical Research, Plasma Cell Disorders, Diseases, real-world evidence, Lymphoid Malignancies, survivorship Luis Gerardo Rodr\u00edguez-Lobato, MD, PhD *, Anna de Daniel i Bisbe, MD *, Natalia Tovar, MD, PhD *, Raquel Jim\u00e9nez-Segura, MD *, M. Teresa Cibeira, MD, PhD *, David F. Moreno, MD *, Aina Oliver-Caldes, MD *,", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Paper165371.html"}, {"start": 137, "end": 160, "url": "https://t.co/6s1n7JNZ4S", "expanded_url": "https://twitter.com/sykristinsson/status/1600544431962480640/photo/1", "display_url": "pic.twitter.com/6s1n7JNZ4S", "media_key": "3_1600543535308193794"}]}, "text": "#1892 https://t.co/fgV6EeXHO1\n@DrGerLobato A much-needed way of thinking when it comes to risk models for MGUS and SMM = Dynamic models! https://t.co/6s1n7JNZ4S", "referenced_tweets": [{"type": "replied_to", "id": "1600544427709169664"}], "source": "Twitter Web App", "author_id": "3078258341", "conversation_id": "1600544417827504144", "in_reply_to_user_id": "3078258341", "created_at": "2022-12-07T17:35:03.000Z", "edit_history_tweet_ids": ["1600544431962480640"], "id": "1600544431962480640", "lang": "en"}, {"entities": {"mentions": [{"start": 29, "end": 45, "username": "eliaseythorsson", "id": "133109181"}], "annotations": [{"start": 156, "end": 159, "probability": 0.5186, "type": "Place", "normalized_text": "MGUS"}], "urls": [{"start": 5, "end": 28, "url": "https://t.co/ZGqXHCm3Tv", "expanded_url": "https://ash.confex.com/ash/2022/webprogram/Paper170166.html", "display_url": "ash.confex.com/ash/2022/webpr\u2026", "status": 200, "title": "Paper: Predicting the Need for Upfront Bone Marrow Sampling in Individuals with MGUS: Derivation of a Multivariable Prediction Model Using the Prospective Population-Based Istopmm Cohort", "description": "Program: Oral and Poster Abstracts Type: Oral Session: 652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Precursor States: MGUS and Smoldering Myeloma Hematology Disease Topics & Pathways: adult, Research, Clinical Research, real-world evidence, Human, Study Population Elias Eythorsson, MD, PhD 1 *, S\u00e6mundur R\u00f6gnvaldsson, MD 1,2 *, Sigr\u00fan Thorsteinsd\u00f3ttir, MD, PhD 3,4, Elin Ruth Reed 3 *, Gudr\u00fan \u00c1sta Sigurdard\u00f3ttir 3 *, Brynjar Vidarsson, MD 1, P\u00e1ll Torfi Onundarson, MD 1,", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Paper170166.html"}]}, "text": "#107 https://t.co/ZGqXHCm3Tv\n@eliaseythorsson  Yes, I shamelessly picked one of my own abstracts :) Predicting the need for upfront bone marrow sampling in MGUS. We will present a risk model online during the presentation on Saturday!", "referenced_tweets": [{"type": "replied_to", "id": "1600544426300145664"}], "source": "Twitter Web App", "author_id": "3078258341", "conversation_id": "1600544417827504144", "in_reply_to_user_id": "3078258341", "created_at": "2022-12-07T17:35:02.000Z", "edit_history_tweet_ids": ["1600544427709169664"], "id": "1600544427709169664", "lang": "en"}, {"text": "#106 https://t.co/wC0NxMOlgL\nA gene score based upon twelve highly differentiating genes showed excellent accuracy in predicting 10-year MM progression from MGUS. Biology and clinical features will better define MGUS risk.", "referenced_tweets": [{"type": "replied_to", "id": "1600544424450211840"}], "source": "Twitter Web App", "author_id": "3078258341", "conversation_id": "1600544417827504144", "entities": {"annotations": [{"start": 157, "end": 160, "probability": 0.5628, "type": "Organization", "normalized_text": "MGUS"}, {"start": 212, "end": 215, "probability": 0.4646, "type": "Other", "normalized_text": "MGUS"}], "urls": [{"start": 5, "end": 28, "url": "https://t.co/wC0NxMOlgL", "expanded_url": "https://ash.confex.com/ash/2022/webprogram/Paper163654.html", "display_url": "ash.confex.com/ash/2022/webpr\u2026", "status": 200, "title": "Paper: A 12 Gene Signature Accurately Predicts Multiple Myeloma Progression from Monoclonal Gammopathy of Undetermined Significance", "description": "Program: Oral and Poster Abstracts Type: Oral Session: 652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Precursor States: MGUS and Smoldering Myeloma Hematology Disease Topics & Pathways: Research, Translational Research, epidemiology, Clinical Research Fumou Sun 1 *, Jun Ying 2 *, Yan Cheng 1 *, David Mery 1 *, Visanu Wanchai 1,3 *, Eric R. Siegel 2 *, Hongwei Xu 1 *, Dongzheng Gai 1 *, Jiahao Xu 4 *, Timothy Cody Ashby 3 *, Clyde Bailey 5 *, Samer Al Hadidi, MD, MSc 1,", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Paper163654.html"}]}, "in_reply_to_user_id": "3078258341", "created_at": "2022-12-07T17:35:02.000Z", "edit_history_tweet_ids": ["1600544426300145664"], "id": "1600544426300145664", "lang": "en"}, {"entities": {"mentions": [{"start": 29, "end": 45, "username": "FrancescoMaura4", "id": "1158556316576751617"}, {"start": 241, "end": 255, "username": "DrOlaLandgren", "id": "2257190339"}], "annotations": [{"start": 94, "end": 97, "probability": 0.6309, "type": "Other", "normalized_text": "NDMM"}, {"start": 235, "end": 238, "probability": 0.5077, "type": "Other", "normalized_text": "NDMM"}], "urls": [{"start": 5, "end": 28, "url": "https://t.co/zz69h8v4xU", "expanded_url": "https://ash.confex.com/ash/2022/webprogram/Paper160215.html", "display_url": "ash.confex.com/ash/2022/webpr\u2026", "status": 200, "title": "Paper: Individualized Treatment-Adjusted Risk Stratification in Newly Diagnosed Multiple Myeloma", "description": "Program: Oral and Poster Abstracts Type: Oral Session: 652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Prognostic Markers in Multiple Myeloma Hematology Disease Topics & Pathways: Research, artificial intelligence (AI), Translational Research, Clinical Research, Combination therapy, genomics, Plasma Cell Disorders, bioinformatics, patient-reported outcomes, Diseases, Therapies, Lymphoid Malignancies, computational biology, Biological Processes, Technology and Procedures,", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Paper160215.html"}]}, "text": "#646 https://t.co/zz69h8v4xU\n@FrancescoMaura4  A comprehensive model utilizing data from 1840 NDMM patients, that captures the interaction of genomic, clinical and therapy factors, enabling personally-tailored therapeutic decisions in NDMM. @DrOlaLandgren", "referenced_tweets": [{"type": "replied_to", "id": "1600544422852456448"}], "source": "Twitter Web App", "author_id": "3078258341", "conversation_id": "1600544417827504144", "in_reply_to_user_id": "3078258341", "created_at": "2022-12-07T17:35:02.000Z", "edit_history_tweet_ids": ["1600544424450211840"], "id": "1600544424450211840", "lang": "en"}, {"entities": {"mentions": [{"start": 29, "end": 39, "username": "myelomaMD", "id": "301568235"}, {"start": 189, "end": 202, "username": "BrianDurieMD", "id": "339306345"}], "annotations": [{"start": 78, "end": 80, "probability": 0.4828, "type": "Other", "normalized_text": "SMM"}, {"start": 124, "end": 126, "probability": 0.5338, "type": "Other", "normalized_text": "MRD"}], "urls": [{"start": 5, "end": 28, "url": "https://t.co/jrHlkNAN2G", "expanded_url": "https://ash.confex.com/ash/2022/webprogram/Paper168930.html", "display_url": "ash.confex.com/ash/2022/webpr\u2026", "status": 200, "title": "Paper: Fixed Duration Therapy with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone for High Risk Smoldering Multiple Myeloma-Results of the Ascent Trial", "description": "Program: Oral and Poster Abstracts Type: Oral Session: 653. Myeloma and Plasma Cell Dyscrasias: Prospective Therapeutic Trials: Risk-adapted Treatment Strategies in Myeloma and Related Conditions Hematology Disease Topics & Pathways: Research, clinical trials, Biological therapies, Antibody Therapy, Clinical Research, Plasma Cell Disorders, Combination therapy, Diseases, Therapies, Lymphoid Malignancies, Human, Minimal Residual Disease Shaji K Kumar, MD 1, Melissa Alsina, MD** 2, Betsy Laplant, MS 3 *,", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Paper168930.html"}]}, "text": "#757 https://t.co/jrHlkNAN2G\n@myelomaMD  The Ascent trial, treating high-risk SMM with dara-KRd and looking at response and MRD, and importantly toxicity in these asymptomatic individuals. @BrianDurieMD", "referenced_tweets": [{"type": "replied_to", "id": "1600544420968878080"}], "source": "Twitter Web App", "author_id": "3078258341", "conversation_id": "1600544417827504144", "in_reply_to_user_id": "3078258341", "created_at": "2022-12-07T17:35:01.000Z", "edit_history_tweet_ids": ["1600544422852456448"], "id": "1600544422852456448", "lang": "en"}, {"entities": {"mentions": [{"start": 29, "end": 38, "username": "mvmateos", "id": "2239926566"}, {"start": 198, "end": 214, "username": "BrunoPaiva_UNAV", "id": "1335161063382376448"}], "annotations": [{"start": 45, "end": 47, "probability": 0.3793, "type": "Other", "normalized_text": "GEM"}, {"start": 49, "end": 53, "probability": 0.3491, "type": "Person", "normalized_text": "Cesar"}, {"start": 115, "end": 117, "probability": 0.3979, "type": "Other", "normalized_text": "KRd"}], "urls": [{"start": 5, "end": 28, "url": "https://t.co/V845ob33DR", "expanded_url": "https://ash.confex.com/ash/2022/webprogram/Paper159606.html", "display_url": "ash.confex.com/ash/2022/webpr\u2026", "status": 200, "title": "Paper: Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Post-Hoc Analysis of Sustained Undetectable Measurable Residual Disease (MRD)", "description": "Program: Oral and Poster Abstracts Type: Oral Session: 731. Autologous Transplantation: Clinical and Epidemiological: Multiple Myeloma and CHIP Hematology Disease Topics & Pathways: Clinical Practice (Health Services and Quality), Plasma Cell Disorders, Diseases, Therapies, therapy sequence, Lymphoid Malignancies, Minimal Residual Disease Maria-Victoria Mateos, MD 1, Joaqu\u00edn Mart\u00ednez-L\u00f3pez, MD, PhD 2 *, Paula Rodr\u00edguez-Otero, MD, PhD 3 *, Jes\u00fas San-Miguel, MD, PhD 4, Veronica Gonzalez-Calle, MD, PhD 1 *,", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Paper159606.html"}]}, "text": "#118 https://t.co/V845ob33DR\n@mvmateos   The GEM-Cesar trial for high-risk SMM. An aggressive approach to SMM with KRd, high-dose melphalan, KRd and len-maintenance. 23% MRD neg 4 years after ASCT. @BrunoPaiva_UNAV", "referenced_tweets": [{"type": "replied_to", "id": "1600544419299704833"}], "source": "Twitter Web App", "author_id": "3078258341", "conversation_id": "1600544417827504144", "in_reply_to_user_id": "3078258341", "created_at": "2022-12-07T17:35:01.000Z", "edit_history_tweet_ids": ["1600544420968878080"], "id": "1600544420968878080", "lang": "en"}, {"entities": {"mentions": [{"start": 29, "end": 39, "username": "JBomsztyk", "id": "2686017822"}], "annotations": [{"start": 62, "end": 72, "probability": 0.673, "type": "Other", "normalized_text": "amyloidosis"}, {"start": 95, "end": 97, "probability": 0.3971, "type": "Other", "normalized_text": "FLC"}, {"start": 140, "end": 146, "probability": 0.5748, "type": "Other", "normalized_text": "amyloid"}, {"start": 202, "end": 204, "probability": 0.5421, "type": "Other", "normalized_text": "FLC"}, {"start": 244, "end": 246, "probability": 0.5221, "type": "Other", "normalized_text": "FLC"}], "urls": [{"start": 5, "end": 28, "url": "https://t.co/c1sF5fOUXn", "expanded_url": "https://ash.confex.com/ash/2022/webprogram/Paper160018.html", "display_url": "ash.confex.com/ash/2022/webpr\u2026", "status": 200, "title": "Paper: Use of Matrix-Assisted Laser Desorption/Ionisation Time-of-Flight Mass Spectrometry (MALDI-TOF MS) Free Light Chain Assessment for the Diagnosis and Monitoring of Systemic Immunoglobulin Light Chain (AL) Amyloidosis", "description": "Program: Oral and Poster Abstracts Type: Oral Session: 652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Disease Monitoring Hematology Disease Topics & Pathways: Plasma Cell Disorders, Diseases, Lymphoid Malignancies, emerging technologies, Technology and Procedures, Minimal Residual Disease Joshua Bomsztyk 1 *, Sriram Ravichandran, MBBS, MRCP, FRCPath 2 *, Hannah Victoria Giles, FRCPath, MRCP 3 *, Oscar Berlanga, PhD 4 *, Stephen Harding, PhD 5, Jahanzaib Khwaja 6 *, Shameem", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Paper160018.html"}]}, "text": "#972 https://t.co/c1sF5fOUXn\n@JBomsztyk Mass spec abstract in amyloidosis! Detection of clonal FLC by mass spec shows 100% concordance with amyloid fibril typing from tissue biopsies and can identify a FLC clone in pts presenting with a normal FLC ratio.", "referenced_tweets": [{"type": "replied_to", "id": "1600544417827504144"}], "source": "Twitter Web App", "author_id": "3078258341", "conversation_id": "1600544417827504144", "in_reply_to_user_id": "3078258341", "created_at": "2022-12-07T17:35:00.000Z", "edit_history_tweet_ids": ["1600544419299704833"], "id": "1600544419299704833", "lang": "en"}, {"entities": {"mentions": [{"start": 235, "end": 243, "username": "mtmdphd", "id": "190337035"}], "hashtags": [{"start": 98, "end": 104, "tag": "ASH22"}], "annotations": [{"start": 35, "end": 41, "probability": 0.5641, "type": "Other", "normalized_text": "myeloma"}, {"start": 73, "end": 76, "probability": 0.711, "type": "Other", "normalized_text": "MGUS"}, {"start": 99, "end": 103, "probability": 0.6266, "type": "Other", "normalized_text": "ASH22"}]}, "text": "Here is my top list of interesting myeloma abstracts, mostly focusing on MGUS and smoldering, for #ASH22. I have included a mixture of things, including treatment trials, mass spectrometry, risk models, genetics, amyloidosis and more. @mtmdphd", "source": "Twitter Web App", "author_id": "3078258341", "conversation_id": "1600544417827504144", "created_at": "2022-12-07T17:35:00.000Z", "edit_history_tweet_ids": ["1600544417827504144"], "id": "1600544417827504144", "lang": "en"}, {"entities": {"mentions": [{"start": 119, "end": 131, "username": "DrGerLobato", "id": "3689670976"}, {"start": 208, "end": 222, "username": "sykristinsson", "id": "3078258341"}], "hashtags": [{"start": 149, "end": 155, "tag": "ASH22"}, {"start": 180, "end": 185, "tag": "mmsm"}, {"start": 186, "end": 204, "tag": "PrecisionMedicine"}], "annotations": [{"start": 30, "end": 33, "probability": 0.634, "type": "Other", "normalized_text": "IMWG"}], "urls": [{"start": 156, "end": 179, "url": "https://t.co/hGGbsN5AGk", "expanded_url": "https://ash.confex.com/ash/2022/webprogram/Paper165371.html", "display_url": "ash.confex.com/ash/2022/webpr\u2026", "status": 200, "title": "Paper: Evolving Pattern Improves the IMWG 2/20/20 Classification for Patients with Smoldering Multiple Myeloma", "description": "Program: Oral and Poster Abstracts Session: 652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster I Hematology Disease Topics & Pathways: Research, epidemiology, Clinical Research, Plasma Cell Disorders, Diseases, real-world evidence, Lymphoid Malignancies, survivorship Luis Gerardo Rodr\u00edguez-Lobato, MD, PhD *, Anna de Daniel i Bisbe, MD *, Natalia Tovar, MD, PhD *, Raquel Jim\u00e9nez-Segura, MD *, M. Teresa Cibeira, MD, PhD *, David F. Moreno, MD *, Aina Oliver-Caldes, MD *,", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Paper165371.html"}, {"start": 223, "end": 246, "url": "https://t.co/pKJHLht3Zd", "expanded_url": "https://twitter.com/mtmdphd/status/1600123245784485888/photo/1", "display_url": "pic.twitter.com/pKJHLht3Zd", "media_key": "3_1600122524213411840"}]}, "text": "Evolving Pattern Improves the IMWG 2/20/20 Classification for Patients with Smoldering Multiple Myeloma [Dec 10, 2022] @DrGerLobato et al. Abst 1892 #ASH22 https://t.co/hGGbsN5AGk #mmsm #PrecisionMedicine HT @sykristinsson https://t.co/pKJHLht3Zd", "source": "Twitter Web App", "author_id": "190337035", "conversation_id": "1600123245784485888", "created_at": "2022-12-06T13:41:25.000Z", "edit_history_tweet_ids": ["1600123245784485888"], "id": "1600123245784485888", "lang": "en"}, {"entities": {"mentions": [{"start": 105, "end": 121, "username": "FrancescoMaura4", "id": "1158556316576751617"}, {"start": 129, "end": 143, "username": "DrOlaLandgren", "id": "2257190339"}, {"start": 212, "end": 226, "username": "sykristinsson", "id": "3078258341"}], "hashtags": [{"start": 153, "end": 159, "tag": "ASH22"}, {"start": 184, "end": 189, "tag": "mmsm"}, {"start": 190, "end": 208, "tag": "PrecisionMedicine"}], "urls": [{"start": 160, "end": 183, "url": "https://t.co/bJuKtxl52Z", "expanded_url": "https://ash.confex.com/ash/2022/webprogram/Paper160215.html", "display_url": "ash.confex.com/ash/2022/webpr\u2026", "status": 200, "title": "Paper: Individualized Treatment-Adjusted Risk Stratification in Newly Diagnosed Multiple Myeloma", "description": "Program: Oral and Poster Abstracts Type: Oral Session: 652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Prognostic Markers in Multiple Myeloma Hematology Disease Topics & Pathways: Research, artificial intelligence (AI), Translational Research, Clinical Research, Combination therapy, genomics, Plasma Cell Disorders, bioinformatics, patient-reported outcomes, Diseases, Therapies, Lymphoid Malignancies, computational biology, Biological Processes, Technology and Procedures,", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Paper160215.html"}, {"start": 227, "end": 250, "url": "https://t.co/FkjzkLnkVz", "expanded_url": "https://twitter.com/mtmdphd/status/1600120907858518018/photo/1", "display_url": "pic.twitter.com/FkjzkLnkVz", "media_key": "3_1600119562564935680"}]}, "text": "Individualized Treatment-Adjusted Risk Stratification in Newly Diagnosed Multiple Myeloma [Dec 11, 2022] @FrancescoMaura4 et al. @DrOlaLandgren Abst 646 #ASH22 https://t.co/bJuKtxl52Z #mmsm #PrecisionMedicine HT @sykristinsson https://t.co/FkjzkLnkVz", "source": "Twitter Web App", "author_id": "190337035", "conversation_id": "1600120907858518018", "created_at": "2022-12-06T13:32:07.000Z", "edit_history_tweet_ids": ["1600120907858518018"], "id": "1600120907858518018", "lang": "en"}, {"entities": {"mentions": [{"start": 195, "end": 211, "username": "eliaseythorsson", "id": "133109181"}, {"start": 219, "end": 233, "username": "sykristinsson", "id": "3078258341"}], "hashtags": [{"start": 244, "end": 250, "tag": "ASH22"}, {"start": 275, "end": 280, "tag": "mmsm"}], "annotations": [{"start": 44, "end": 51, "probability": 0.5142, "type": "Other", "normalized_text": "Sampling"}, {"start": 73, "end": 76, "probability": 0.4229, "type": "Other", "normalized_text": "MGUS"}, {"start": 165, "end": 171, "probability": 0.6901, "type": "Other", "normalized_text": "iStopMM"}], "urls": [{"start": 251, "end": 274, "url": "https://t.co/6jSHRTmUyO", "expanded_url": "https://ash.confex.com/ash/2022/webprogram/Paper170166.html", "display_url": "ash.confex.com/ash/2022/webpr\u2026", "status": 200, "title": "Paper: Predicting the Need for Upfront Bone Marrow Sampling in Individuals with MGUS: Derivation of a Multivariable Prediction Model Using the Prospective Population-Based Istopmm Cohort", "description": "Program: Oral and Poster Abstracts Type: Oral Session: 652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Precursor States: MGUS and Smoldering Myeloma Hematology Disease Topics & Pathways: adult, Research, Clinical Research, real-world evidence, Human, Study Population Elias Eythorsson, MD, PhD 1 *, S\u00e6mundur R\u00f6gnvaldsson, MD 1,2 *, Sigr\u00fan Thorsteinsd\u00f3ttir, MD, PhD 3,4, Elin Ruth Reed 3 *, Gudr\u00fan \u00c1sta Sigurdard\u00f3ttir 3 *, Brynjar Vidarsson, MD 1, P\u00e1ll Torfi Onundarson, MD 1,", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Paper170166.html"}, {"start": 281, "end": 304, "url": "https://t.co/POrQZyI2xm", "expanded_url": "https://twitter.com/mtmdphd/status/1599092878080606208/photo/1", "display_url": "pic.twitter.com/POrQZyI2xm", "media_key": "3_1599092525066866691"}]}, "text": "Predicting the Need for Upfront Bone Marrow Sampling in Individuals with MGUS: Derivation of a Multivariable Prediction Model Using the Prospective Population-Based iStopMM Cohort [Dec 10, 2022] @eliaseythorsson et al. @sykristinsson \nAbst 107 #ASH22 https://t.co/6jSHRTmUyO #mmsm https://t.co/POrQZyI2xm", "source": "Twitter Web App", "author_id": "190337035", "conversation_id": "1599092878080606208", "created_at": "2022-12-03T17:27:06.000Z", "edit_history_tweet_ids": ["1599092878080606208"], "id": "1599092878080606208", "lang": "en"}, {"entities": {"mentions": [{"start": 166, "end": 180, "username": "sykristinsson", "id": "3078258341"}, {"start": 181, "end": 197, "username": "eliaseythorsson", "id": "133109181"}, {"start": 198, "end": 210, "username": "SaemundurMD", "id": "1054784756704010241"}, {"start": 211, "end": 227, "username": "SigrunThorstei1", "id": "1198917648630919168"}], "hashtags": [{"start": 150, "end": 156, "tag": "ASH22"}, {"start": 157, "end": 165, "tag": "ASH22VR"}], "annotations": [{"start": 21, "end": 24, "probability": 0.7146, "type": "Other", "normalized_text": "MGUS"}, {"start": 73, "end": 79, "probability": 0.8989, "type": "Other", "normalized_text": "iStopMM"}, {"start": 151, "end": 155, "probability": 0.4944, "type": "Other", "normalized_text": "ASH22"}, {"start": 158, "end": 164, "probability": 0.5372, "type": "Other", "normalized_text": "ASH22VR"}], "urls": [{"start": 228, "end": 251, "url": "https://t.co/RmJJb5mELL", "expanded_url": "https://ash.confex.com/ash/2022/webprogram/Paper170166.html", "display_url": "ash.confex.com/ash/2022/webpr\u2026", "status": 200, "title": "Paper: Predicting the Need for Upfront Bone Marrow Sampling in Individuals with MGUS: Derivation of a Multivariable Prediction Model Using the Prospective Population-Based Istopmm Cohort", "description": "Program: Oral and Poster Abstracts Type: Oral Session: 652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Precursor States: MGUS and Smoldering Myeloma Hematology Disease Topics & Pathways: adult, Research, Clinical Research, real-world evidence, Human, Study Population Elias Eythorsson, MD, PhD 1 *, S\u00e6mundur R\u00f6gnvaldsson, MD 1,2 *, Sigr\u00fan Thorsteinsd\u00f3ttir, MD, PhD 3,4, Elin Ruth Reed 3 *, Gudr\u00fan \u00c1sta Sigurdard\u00f3ttir 3 *, Brynjar Vidarsson, MD 1, P\u00e1ll Torfi Onundarson, MD 1,", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Paper170166.html"}, {"start": 252, "end": 275, "url": "https://t.co/hkkE5FfQyQ", "expanded_url": "https://twitter.com/VincentRK/status/1599075821737500673/photo/1", "display_url": "pic.twitter.com/hkkE5FfQyQ", "media_key": "3_1599075816993947648"}]}, "text": "#5 Not everyone with MGUS diagnosis needs a marrow. Choosing wisely. The iStopMM trial provides a model that limits unnecessary bone marrow biopsies. #ASH22 #ASH22VR @sykristinsson @eliaseythorsson @SaemundurMD @SigrunThorstei1 https://t.co/RmJJb5mELL https://t.co/hkkE5FfQyQ", "referenced_tweets": [{"type": "replied_to", "id": "1599075814553026562"}], "source": "Twitter for iPhone", "author_id": "24261916", "conversation_id": "1599075814553026562", "in_reply_to_user_id": "24261916", "created_at": "2022-12-03T16:19:19.000Z", "edit_history_tweet_ids": ["1599075821737500673"], "id": "1599075821737500673", "lang": "en"}, {"entities": {"mentions": [{"start": 204, "end": 212, "username": "iStopMM", "id": "844232399319941122"}], "hashtags": [{"start": 213, "end": 218, "tag": "mmsm"}, {"start": 219, "end": 227, "tag": "myeloma"}, {"start": 228, "end": 234, "tag": "ASH22"}, {"start": 235, "end": 246, "tag": "MedTwitter"}, {"start": 247, "end": 253, "tag": "MedEd"}, {"start": 254, "end": 261, "tag": "USMIRC"}], "annotations": [{"start": 114, "end": 120, "probability": 0.5047, "type": "Other", "normalized_text": "disease"}, {"start": 123, "end": 126, "probability": 0.5329, "type": "Other", "normalized_text": "MGUS"}, {"start": 132, "end": 138, "probability": 0.6109, "type": "Other", "normalized_text": "LC-MGUS"}, {"start": 199, "end": 202, "probability": 0.4277, "type": "Other", "normalized_text": "MGUS"}, {"start": 214, "end": 217, "probability": 0.4461, "type": "Other", "normalized_text": "mmsm"}, {"start": 220, "end": 226, "probability": 0.5182, "type": "Other", "normalized_text": "myeloma"}, {"start": 229, "end": 233, "probability": 0.4239, "type": "Other", "normalized_text": "ASH22"}, {"start": 236, "end": 245, "probability": 0.5983, "type": "Other", "normalized_text": "MedTwitter"}, {"start": 255, "end": 260, "probability": 0.3803, "type": "Other", "normalized_text": "USMIRC"}], "urls": [{"start": 262, "end": 285, "url": "https://t.co/MFEKbKLcpJ", "expanded_url": "https://twitter.com/Abdallah81MD/status/1595845251604049920/photo/1", "display_url": "pic.twitter.com/MFEKbKLcpJ", "media_key": "3_1595845247795437583"}, {"start": 262, "end": 285, "url": "https://t.co/MFEKbKLcpJ", "expanded_url": "https://twitter.com/Abdallah81MD/status/1595845251604049920/photo/1", "display_url": "pic.twitter.com/MFEKbKLcpJ", "media_key": "3_1595845247807922179"}]}, "text": "This large, prospective screening study negates the previously reported biological correlation between autoimmune disease, MGUS and LC-MGUS and shows that autoimmune diseases are not associated with MGUS.@iStopMM #mmsm #myeloma #ASH22 #MedTwitter #MedEd #USMIRC https://t.co/MFEKbKLcpJ", "source": "Twitter for iPhone", "author_id": "1026947037080772610", "conversation_id": "1595845251604049920", "created_at": "2022-11-24T18:22:12.000Z", "edit_history_tweet_ids": ["1595845251604049920"], "id": "1595845251604049920", "lang": "en"}, {"entities": {"mentions": [{"start": 255, "end": 263, "username": "iStopMM", "id": "844232399319941122"}, {"start": 264, "end": 278, "username": "sykristinsson", "id": "3078258341"}], "hashtags": [{"start": 101, "end": 107, "tag": "ASH22"}], "annotations": [{"start": 102, "end": 106, "probability": 0.7326, "type": "Other", "normalized_text": "ASH22"}], "urls": [{"start": 279, "end": 302, "url": "https://t.co/HzADLnAJmc", "expanded_url": "https://twitter.com/ManniMD1/status/1590440085656580096", "display_url": "twitter.com/ManniMD1/statu\u2026"}]}, "text": "Although this study is only a poster (worthy of oral!), it is one of the most impactful abstracts at #ASH22, with impacts far beyond even the field of hematology.\n\nI intend to present this study to rheumatologists soon, and we all should share the word!\n\n@iStopMM @sykristinsson https://t.co/HzADLnAJmc", "referenced_tweets": [{"type": "quoted", "id": "1590440085656580096"}], "source": "Twitter Web App", "author_id": "1269642863924609025", "conversation_id": "1592885241953554432", "created_at": "2022-11-16T14:20:10.000Z", "edit_history_tweet_ids": ["1592885241953554432"], "id": "1592885241953554432", "lang": "en"}, {"entities": {"mentions": [{"start": 25, "end": 39, "username": "RDAnalyticsAB", "id": "1461992557999792129"}, {"start": 122, "end": 136, "username": "sykristinsson", "id": "3078258341"}, {"start": 159, "end": 167, "username": "iStopMM", "id": "844232399319941122"}], "hashtags": [{"start": 97, "end": 113, "tag": "multiplemyeloma"}], "annotations": [{"start": 98, "end": 112, "probability": 0.4665, "type": "Other", "normalized_text": "multiplemyeloma"}], "urls": [{"start": 177, "end": 200, "url": "https://t.co/6xRz7ngcXq", "expanded_url": "https://twitter.com/sykristinsson/status/1589629504422805506", "display_url": "twitter.com/sykristinsson/\u2026"}]}, "text": "Such a privilege for the @RDAnalyticsAB team to contribute to some of this inspirational work in #multiplemyeloma, led by @sykristinsson and the world leading @iStopMM study \u2935\ufe0f https://t.co/6xRz7ngcXq", "referenced_tweets": [{"type": "quoted", "id": "1589629504422805506"}], "source": "Twitter for iPhone", "author_id": "187922446", "conversation_id": "1592087263571501057", "created_at": "2022-11-14T09:29:17.000Z", "edit_history_tweet_ids": ["1592087263571501057"], "id": "1592087263571501057", "lang": "en"}, {"text": "5. I may now be able to omit bone marrow biopsies as part of initial diagnostic workup for a larger set of patients with MGUS, compared to what I currently do in practice (I currently omit for low-risk MGUS (IgG,M protein less than 1.5, normal FLC).\n\nhttps://t.co/HXfMqxsOtL", "referenced_tweets": [{"type": "replied_to", "id": "1590440077658066944"}], "source": "Twitter Web App", "author_id": "1269642863924609025", "conversation_id": "1590440063263182851", "entities": {"annotations": [{"start": 121, "end": 124, "probability": 0.505, "type": "Organization", "normalized_text": "MGUS"}, {"start": 202, "end": 205, "probability": 0.5423, "type": "Other", "normalized_text": "MGUS"}], "urls": [{"start": 251, "end": 274, "url": "https://t.co/HXfMqxsOtL", "expanded_url": "https://ash.confex.com/ash/2022/webprogram/Paper170166.html", "display_url": "ash.confex.com/ash/2022/webpr\u2026", "status": 200, "title": "Paper: Predicting the Need for Upfront Bone Marrow Sampling in Individuals with MGUS: Derivation of a Multivariable Prediction Model Using the Prospective Population-Based Istopmm Cohort", "description": "Program: Oral and Poster Abstracts Type: Oral Session: 652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Precursor States: MGUS and Smoldering Myeloma Hematology Disease Topics & Pathways: adult, Research, Clinical Research, real-world evidence, Human, Study Population Elias Eythorsson, MD, PhD 1 *, S\u00e6mundur R\u00f6gnvaldsson, MD 1,2 *, Sigr\u00fan Thorsteinsd\u00f3ttir, MD, PhD 3,4, Elin Ruth Reed 3 *, Gudr\u00fan \u00c1sta Sigurdard\u00f3ttir 3 *, Brynjar Vidarsson, MD 1, P\u00e1ll Torfi Onundarson, MD 1,", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Paper170166.html"}]}, "in_reply_to_user_id": "1269642863924609025", "created_at": "2022-11-09T20:23:58.000Z", "edit_history_tweet_ids": ["1590440079591624705"], "id": "1590440079591624705", "lang": "en"}, {"entities": {"mentions": [{"start": 40, "end": 56, "username": "Myeloma_Society", "id": "841751045034369025"}], "hashtags": [{"start": 208, "end": 216, "tag": "myeloma"}], "annotations": [{"start": 81, "end": 83, "probability": 0.9456, "type": "Organization", "normalized_text": "FDA"}, {"start": 209, "end": 215, "probability": 0.6268, "type": "Other", "normalized_text": "myeloma"}], "urls": [{"start": 247, "end": 270, "url": "https://t.co/QD2xEaX9Xr", "expanded_url": "http://ow.ly/mR2f50LpeWO", "display_url": "ow.ly/mR2f50LpeWO", "images": [{"url": "https://pbs.twimg.com/news_img/1589474710441840640/L4lSQCGG?format=jpg&name=orig", "width": 1200, "height": 1200}, {"url": "https://pbs.twimg.com/news_img/1589474710441840640/L4lSQCGG?format=jpg&name=150x150", "width": 150, "height": 150}], "status": 200, "title": "FDA-IMS Joint Workshop | November 08, 2022 - November 09, 2022", "description": "Join us on November 08-09", "unwound_url": "https://www.eventcreate.com/e/fda-imsjointsymposium"}, {"start": 271, "end": 294, "url": "https://t.co/V0d99OC5bm", "expanded_url": "https://twitter.com/Myeloma_Society/status/1588501796082929664/photo/1", "display_url": "pic.twitter.com/V0d99OC5bm", "media_key": "3_1588501794711379969"}]}, "text": "There is still time to register for the @Myeloma_Society joint workshop with the FDA on November 8-9. This two day meeting will provide a forum for open discussion about clinical drug development in multiple #myeloma. Learn more and register now! https://t.co/QD2xEaX9Xr https://t.co/V0d99OC5bm", "source": "Hootsuite Inc.", "author_id": "841751045034369025", "conversation_id": "1588501796082929664", "created_at": "2022-11-04T12:01:55.000Z", "edit_history_tweet_ids": ["1588501796082929664"], "id": "1588501796082929664", "lang": "en"}, {"entities": {"mentions": [{"start": 38, "end": 46, "username": "iStopMM", "id": "844232399319941122"}, {"start": 56, "end": 67, "username": "IMFmyeloma", "id": "34340707"}, {"start": 68, "end": 83, "username": "TheBindingSite", "id": "321436678"}, {"start": 85, "end": 97, "username": "uni_iceland", "id": "2769866904"}, {"start": 98, "end": 114, "username": "Haskoli_Islands", "id": "90458157"}, {"start": 115, "end": 129, "username": "RannisIceland", "id": "3095353150"}, {"start": 130, "end": 143, "username": "ERC_Research", "id": "467551928"}, {"start": 144, "end": 156, "username": "Landspitali", "id": "436581473"}, {"start": 158, "end": 172, "username": "TBSsteharding", "id": "1975260703"}, {"start": 173, "end": 188, "username": "ASH_hematology", "id": "84072624"}, {"start": 190, "end": 203, "username": "BrianDurieMD", "id": "339306345"}, {"start": 204, "end": 218, "username": "DrOlaLandgren", "id": "2257190339"}], "annotations": [{"start": 28, "end": 36, "probability": 0.6029, "type": "Other", "normalized_text": "Icelandic"}]}, "text": "Many thanks to to the whole Icelandic @iStopMM team and @IMFmyeloma @TheBindingSite  @uni_iceland @Haskoli_Islands @RannisIceland @ERC_Research @Landspitali  @TBSsteharding @ASH_hematology  @BrianDurieMD @DrOlaLandgren and many more!", "referenced_tweets": [{"type": "replied_to", "id": "1589629572265697282"}], "source": "Twitter Web App", "author_id": "3078258341", "conversation_id": "1589629504422805506", "in_reply_to_user_id": "3078258341", "created_at": "2022-11-07T14:47:41.000Z", "edit_history_tweet_ids": ["1589630676047126528"], "id": "1589630676047126528", "lang": "en"}, {"entities": {"mentions": [{"start": 23, "end": 31, "username": "iStopMM", "id": "844232399319941122"}], "hashtags": [{"start": 74, "end": 79, "tag": "mgus"}, {"start": 116, "end": 121, "tag": "mmsm"}], "annotations": [{"start": 75, "end": 78, "probability": 0.4984, "type": "Other", "normalized_text": "mgus"}, {"start": 117, "end": 120, "probability": 0.4906, "type": "Other", "normalized_text": "mmsm"}], "urls": [{"start": 122, "end": 145, "url": "https://t.co/eb3p2dMePz", "expanded_url": "https://twitter.com/sykristinsson/status/1589629504422805506", "display_url": "twitter.com/sykristinsson/\u2026"}]}, "text": "This is brilliant. The @iStopMM is redefining what we take for granted in #mgus! Congratulations to the entire team #mmsm https://t.co/eb3p2dMePz", "referenced_tweets": [{"type": "quoted", "id": "1589629504422805506"}], "source": "Twitter for Android", "author_id": "209212922", "conversation_id": "1589763561492221952", "created_at": "2022-11-07T23:35:44.000Z", "edit_history_tweet_ids": ["1589763561492221952"], "id": "1589763561492221952", "lang": "en"}, {"entities": {"mentions": [{"start": 0, "end": 14, "username": "sykristinsson", "id": "3078258341"}, {"start": 15, "end": 23, "username": "iStopMM", "id": "844232399319941122"}], "urls": [{"start": 24, "end": 47, "url": "https://t.co/RRFxmBTqdN", "expanded_url": "https://twitter.com/End_myeloma/status/1589786911354556417/photo/1", "display_url": "pic.twitter.com/RRFxmBTqdN", "media_key": "16_1589786904693817344"}]}, "text": "@sykristinsson @iStopMM https://t.co/RRFxmBTqdN", "referenced_tweets": [{"type": "replied_to", "id": "1589629504422805506"}], "source": "Twitter Web App", "author_id": "2538011298", "conversation_id": "1589629504422805506", "in_reply_to_user_id": "3078258341", "created_at": "2022-11-08T01:08:31.000Z", "edit_history_tweet_ids": ["1589786911354556417"], "id": "1589786911354556417", "lang": "qme"}, {"entities": {"mentions": [{"start": 0, "end": 14, "username": "sykristinsson", "id": "3078258341"}, {"start": 15, "end": 23, "username": "iStopMM", "id": "844232399319941122"}, {"start": 24, "end": 35, "username": "IMFmyeloma", "id": "34340707"}, {"start": 36, "end": 51, "username": "TheBindingSite", "id": "321436678"}, {"start": 52, "end": 64, "username": "uni_iceland", "id": "2769866904"}, {"start": 65, "end": 81, "username": "Haskoli_Islands", "id": "90458157"}, {"start": 82, "end": 96, "username": "RannisIceland", "id": "3095353150"}, {"start": 97, "end": 110, "username": "ERC_Research", "id": "467551928"}, {"start": 111, "end": 123, "username": "Landspitali", "id": "436581473"}, {"start": 124, "end": 138, "username": "TBSsteharding", "id": "1975260703"}, {"start": 139, "end": 154, "username": "ASH_hematology", "id": "84072624"}, {"start": 155, "end": 168, "username": "BrianDurieMD", "id": "339306345"}, {"start": 169, "end": 183, "username": "DrOlaLandgren", "id": "2257190339"}], "annotations": [{"start": 263, "end": 265, "probability": 0.3495, "type": "Other", "normalized_text": "ASH"}, {"start": 327, "end": 330, "probability": 0.6485, "type": "Other", "normalized_text": "MGUS"}, {"start": 332, "end": 334, "probability": 0.4493, "type": "Other", "normalized_text": "SMM"}]}, "text": "@sykristinsson @iStopMM @IMFmyeloma @TheBindingSite @uni_iceland @Haskoli_Islands @RannisIceland @ERC_Research @Landspitali @TBSsteharding @ASH_hematology @BrianDurieMD @DrOlaLandgren Congratulations! Amazing data. I look forward to seeing these presentations at ASH. Many of this will change how what we thought we knew about MGUS-SMM-MM.", "referenced_tweets": [{"type": "replied_to", "id": "1589630676047126528"}], "source": "Twitter for Android", "author_id": "1109824907393798144", "conversation_id": "1589629504422805506", "in_reply_to_user_id": "3078258341", "created_at": "2022-11-08T03:09:17.000Z", "edit_history_tweet_ids": ["1589817303541387264"], "id": "1589817303541387264", "lang": "en"}, {"entities": {"mentions": [{"start": 0, "end": 14, "username": "sykristinsson", "id": "3078258341"}, {"start": 15, "end": 23, "username": "iStopMM", "id": "844232399319941122"}]}, "text": "@sykristinsson @iStopMM Please keep going and advance this field. Congratulations for such huge achievements.", "referenced_tweets": [{"type": "replied_to", "id": "1589629504422805506"}], "source": "Twitter for iPad", "author_id": "2626263112", "conversation_id": "1589629504422805506", "in_reply_to_user_id": "3078258341", "created_at": "2022-11-08T08:01:16.000Z", "edit_history_tweet_ids": ["1589890786765975552"], "id": "1589890786765975552", "lang": "en"}, {"entities": {"mentions": [{"start": 0, "end": 14, "username": "sykristinsson", "id": "3078258341"}, {"start": 15, "end": 23, "username": "iStopMM", "id": "844232399319941122"}, {"start": 111, "end": 119, "username": "iStopMM", "id": "844232399319941122"}]}, "text": "@sykristinsson @iStopMM The gift that keeps on giving, a study that will provide so many hypotheses for others @iStopMM , strong work my friend!", "referenced_tweets": [{"type": "replied_to", "id": "1589629504422805506"}], "source": "Twitter for iPhone", "author_id": "83911786", "conversation_id": "1589629504422805506", "in_reply_to_user_id": "3078258341", "created_at": "2022-11-07T19:29:30.000Z", "edit_history_tweet_ids": ["1589701596531003393"], "id": "1589701596531003393", "lang": "en"}, {"entities": {"mentions": [{"start": 0, "end": 14, "username": "sykristinsson", "id": "3078258341"}, {"start": 15, "end": 23, "username": "iStopMM", "id": "844232399319941122"}], "annotations": [{"start": 124, "end": 131, "probability": 0.4637, "type": "Person", "normalized_text": "Sigurdur"}, {"start": 146, "end": 148, "probability": 0.7253, "type": "Organization", "normalized_text": "ASH"}]}, "text": "@sykristinsson @iStopMM You are ridiculously productive with a ridiculously productive trial. Congrats to you and your team Sigurdur. \nSee you at ASH.", "referenced_tweets": [{"type": "replied_to", "id": "1589629504422805506"}], "source": "Twitter for iPhone", "author_id": "24261916", "conversation_id": "1589629504422805506", "in_reply_to_user_id": "3078258341", "created_at": "2022-11-07T19:22:40.000Z", "edit_history_tweet_ids": ["1589699878753431552"], "id": "1589699878753431552", "lang": "en"}, {"text": "Visionary study with of course great results that will lead to changes in everyday clinical management in myeloma, excited to hear these results at #ASH22 https://t.co/S4CgyPYBMF", "referenced_tweets": [{"type": "quoted", "id": "1589629504422805506"}], "source": "Twitter for iPhone", "author_id": "419595308", "entities": {"hashtags": [{"start": 148, "end": 154, "tag": "ASH22"}], "annotations": [{"start": 106, "end": 112, "probability": 0.5117, "type": "Other", "normalized_text": "myeloma"}, {"start": 149, "end": 153, "probability": 0.5901, "type": "Other", "normalized_text": "ASH22"}], "urls": [{"start": 155, "end": 178, "url": "https://t.co/S4CgyPYBMF", "expanded_url": "https://twitter.com/sykristinsson/status/1589629504422805506", "display_url": "twitter.com/sykristinsson/\u2026"}]}, "conversation_id": "1589638006876827648", "created_at": "2022-11-07T15:16:49.000Z", "edit_history_tweet_ids": ["1589638006876827648"], "id": "1589638006876827648", "lang": "en"}, {"entities": {"mentions": [{"start": 93, "end": 104, "username": "thorirlong", "id": "3009607268"}], "annotations": [{"start": 72, "end": 78, "probability": 0.5166, "type": "Other", "normalized_text": "disease"}, {"start": 222, "end": 225, "probability": 0.4068, "type": "Organization", "normalized_text": "MGUS"}, {"start": 231, "end": 233, "probability": 0.5256, "type": "Organization", "normalized_text": "CKD"}], "urls": [{"start": 0, "end": 23, "url": "https://t.co/kNKC6qvvu0", "expanded_url": "https://ash.confex.com/ash/2022/webprogram/Paper170623.html", "display_url": "ash.confex.com/ash/2022/webpr\u2026", "status": 200, "title": "Paper: Monoclonal Gammopathy of Undetermined Significance and Risk of Chronic Kidney Disease: Results of the Population-Based Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) Study", "description": "Program: Oral and Poster Abstracts Session: 652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster III Hematology Disease Topics & Pathways: Research, epidemiology, Clinical Research, Plasma Cell Disorders, Diseases, Lymphoid Malignancies Thorir Einarsson Long, MD, PhD 1,2,3 *, Elias Eythorsson, MD, PhD 4 *, S\u00e6mundur R\u00f6gnvaldsson, MD 5,6 *, Olafur Indridason, MD, MHS 7 *, Runolfur Palsson, MD 6,8 *, Sigr\u00fan Thorsteinsd\u00f3ttir, MD, PhD 8,9, Ingigerdur S Sverrisdottir, MD 6,8,10", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Paper170623.html"}, {"start": 236, "end": 259, "url": "https://t.co/oY6kxaloiC", "expanded_url": "https://twitter.com/sykristinsson/status/1589629572265697282/photo/1", "display_url": "pic.twitter.com/oY6kxaloiC", "media_key": "3_1589628420073439232"}]}, "text": "https://t.co/kNKC6qvvu0\n\nLooking for M-proteins in everyone with kidney disease? \nPresenter: @thorirlong \nProspective population-based screening study of nearly 70,000 individuals\n\n\u2026 wait for it\u2026..\n\nNo association between MGUS and CKD! https://t.co/oY6kxaloiC", "referenced_tweets": [{"type": "replied_to", "id": "1589629566414655488"}], "source": "Twitter Web App", "author_id": "3078258341", "conversation_id": "1589629504422805506", "in_reply_to_user_id": "3078258341", "created_at": "2022-11-07T14:43:18.000Z", "edit_history_tweet_ids": ["1589629572265697282"], "id": "1589629572265697282", "lang": "en"}, {"entities": {"mentions": [{"start": 88, "end": 96, "username": "iStopMM", "id": "844232399319941122"}, {"start": 259, "end": 271, "username": "SaemundurMD", "id": "1054784756704010241"}], "annotations": [{"start": 187, "end": 189, "probability": 0.5616, "type": "Other", "normalized_text": "IgM"}], "urls": [{"start": 0, "end": 23, "url": "https://t.co/D7SwrDKhEu", "expanded_url": "https://ash.confex.com/ash/2022/webprogram/Paper168070.html", "display_url": "ash.confex.com/ash/2022/webpr\u2026", "status": 200, "title": "Paper: Monoclonal Gammopathy of Undetermined Significance (MGUS) with Multiple Paraproteins: Results from the Population-Based Istopmm Screening Study", "description": "Program: Oral and Poster Abstracts Session: 652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster III Hematology Disease Topics & Pathways: Research, epidemiology, Plasma Cell Disorders, Clinical Research, Diseases, Lymphoid Malignancies S\u00e6mundur R\u00f6gnvaldsson, MD 1,2 *, Jon \u00de\u00f3rir Oskarsson, MSc 3 *, Sigrun Thorsteinsdottir, MD, PhD 4,5, Elin Ruth Reed 4 *, Gudrun Asta Sigurdardottir 4 *, Brynjar Vidarsson, MD 2, Pall Torfi Onundarson, MD 2, Margret Sigurdardottir, MD 2 *,", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Paper168070.html"}, {"start": 272, "end": 295, "url": "https://t.co/CRjFIfClZO", "expanded_url": "https://twitter.com/sykristinsson/status/1589629566414655488/photo/1", "display_url": "pic.twitter.com/CRjFIfClZO", "media_key": "3_1589628011770511366"}]}, "text": "https://t.co/D7SwrDKhEu\nYou sometimes find &gt;1 M-spikes?\n\nWe screened 75422 people in @iStopMM  and found almost 10% have more than one M-proteins. Associated with older age, male, and IgM. Many disappear, none have progressed. Immune response? \nPresenter: @SaemundurMD https://t.co/CRjFIfClZO", "referenced_tweets": [{"type": "replied_to", "id": "1589629560056082432"}], "source": "Twitter Web App", "author_id": "3078258341", "conversation_id": "1589629504422805506", "in_reply_to_user_id": "3078258341", "created_at": "2022-11-07T14:43:17.000Z", "edit_history_tweet_ids": ["1589629566414655488"], "id": "1589629566414655488", "lang": "en"}, {"entities": {"mentions": [{"start": 251, "end": 263, "username": "astrunhelga", "id": "2758432772"}], "annotations": [{"start": 35, "end": 38, "probability": 0.3599, "type": "Other", "normalized_text": "CRAB"}, {"start": 106, "end": 109, "probability": 0.5122, "type": "Other", "normalized_text": "MGUS"}, {"start": 179, "end": 182, "probability": 0.4052, "type": "Other", "normalized_text": "MGUS"}], "urls": [{"start": 0, "end": 23, "url": "https://t.co/8jfMTQluaf", "expanded_url": "https://ash.confex.com/ash/2022/webprogram/Paper168822.html", "display_url": "ash.confex.com/ash/2022/webpr\u2026", "status": 200, "title": "Paper: Hypercalcemia in Individuals with Monoclonal Gammopathy of Undetermined Significance: Results from the Istopmm Study", "description": "Program: Oral and Poster Abstracts Session: 652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster III Hematology Disease Topics & Pathways: Research, adult, Clinical Practice (Health Services and Quality), elderly, Plasma Cell Disorders, Diseases, Lymphoid Malignancies, Study Population, Human \u00c1str\u00fan Helga J\u00f3nsd\u00f3ttir 1 *, S\u00e6mundur R\u00f6gnvaldsson, MD 1,2 *, Helga \u00c1g\u00fasta Sigurj\u00f3nsd\u00f3ttir 2,3 *, Sigr\u00fan Thorsteinsd\u00f3ttir, MD, PhD 3,4, Brynjar Vidarsson, MD 2, P\u00e1ll Torfi Onundarson,", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Paper168822.html"}, {"start": 264, "end": 287, "url": "https://t.co/tLQPbK4DBr", "expanded_url": "https://twitter.com/sykristinsson/status/1589629560056082432/photo/1", "display_url": "pic.twitter.com/tLQPbK4DBr", "media_key": "3_1589627613412265984"}]}, "text": "https://t.co/8jfMTQluaf\nThe \u201cC\u201c in CRAB does not walk alone!\n\nChecking s-calcium in 2546 individuals with MGUS: \n\n7.5% had hyperCa. Underlying causes similar as in &gt;70,000 non-MGUS. If associated with MM then other CRAB criteria present.\nPresenter @astrunhelga https://t.co/tLQPbK4DBr", "referenced_tweets": [{"type": "replied_to", "id": "1589629553001259008"}], "source": "Twitter Web App", "author_id": "3078258341", "conversation_id": "1589629504422805506", "in_reply_to_user_id": "3078258341", "created_at": "2022-11-07T14:43:15.000Z", "edit_history_tweet_ids": ["1589629560056082432"], "id": "1589629560056082432", "lang": "en"}, {"entities": {"mentions": [{"start": 122, "end": 130, "username": "iStopMM", "id": "844232399319941122"}, {"start": 215, "end": 231, "username": "SigrunThorstei1", "id": "1198917648630919168"}], "annotations": [{"start": 57, "end": 60, "probability": 0.5008, "type": "Other", "normalized_text": "CTPC"}, {"start": 102, "end": 104, "probability": 0.5918, "type": "Other", "normalized_text": "SMM"}, {"start": 114, "end": 117, "probability": 0.6341, "type": "Other", "normalized_text": "CTPC"}, {"start": 167, "end": 170, "probability": 0.5653, "type": "Other", "normalized_text": "MGUS"}, {"start": 172, "end": 174, "probability": 0.5205, "type": "Other", "normalized_text": "SMM"}, {"start": 176, "end": 177, "probability": 0.4613, "type": "Other", "normalized_text": "MM"}, {"start": 186, "end": 188, "probability": 0.5369, "type": "Other", "normalized_text": "SMM"}], "urls": [{"start": 0, "end": 23, "url": "https://t.co/RI350Lk9IL", "expanded_url": "https://ash.confex.com/ash/2022/webprogram/Paper168690.html", "display_url": "ash.confex.com/ash/2022/webpr\u2026", "status": 200, "title": "Paper: Circulating Tumor Plasma Cells in the Screened Istopmm Smoldering Multiple Myeloma Cohort", "description": "Program: Oral and Poster Abstracts Session: 651. Multiple Myelom a and Plasma Cell Dyscrasias: Basic and Translational: Poster III Hematology Disease Topics & Pathways: Research, Translational Research, Plasma Cell Disorders, Diseases, Lymphoid Malignancies Sigr\u00fan Thorsteinsd\u00f3ttir, MD, PhD 1,2, Jon \u00de\u00f3rir Oskarsson, MSc 3 *, S\u00e6mundur R\u00f6gnvaldsson, MD 4,5 *, Gauti G\u00edslason 1 *, Thor Aspelund, PhD 1 *, Gudr\u00fan \u00c1sta Sigurdard\u00f3ttir 1 *, \u00c1sdis R\u00f3sa Th\u00f3rdardottir 1 *, Brynjar Vidarsson, MD 5, P\u00e1ll Torfi Onundarson,", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Paper168690.html"}, {"start": 272, "end": 295, "url": "https://t.co/HDAUZMHgnP", "expanded_url": "https://twitter.com/sykristinsson/status/1589629553001259008/photo/1", "display_url": "pic.twitter.com/HDAUZMHgnP", "media_key": "3_1589626767215566851"}]}, "text": "https://t.co/RI350Lk9IL\n\nCirculating tumor plasma cells (CTPC) in an exciting topic!\n\nWe found 69% of SMM to have CTPC in @iStopMM. Detection and number increase from MGUS-SMM-MM and by SMM risk scores. \nPresenter: @SigrunThorstei1 \n\nMight be used instead of bone marrow? https://t.co/HDAUZMHgnP", "referenced_tweets": [{"type": "replied_to", "id": "1589629545870929920"}], "source": "Twitter Web App", "author_id": "3078258341", "conversation_id": "1589629504422805506", "in_reply_to_user_id": "3078258341", "created_at": "2022-11-07T14:43:13.000Z", "edit_history_tweet_ids": ["1589629553001259008"], "id": "1589629553001259008", "lang": "en"}, {"entities": {"mentions": [{"start": 110, "end": 123, "username": "ingigerdursv", "id": "740181058210107392"}, {"start": 151, "end": 159, "username": "iStopMM", "id": "844232399319941122"}], "annotations": [{"start": 73, "end": 76, "probability": 0.3936, "type": "Other", "normalized_text": "MGUS"}, {"start": 278, "end": 281, "probability": 0.4579, "type": "Other", "normalized_text": "MGUS"}], "urls": [{"start": 0, "end": 23, "url": "https://t.co/ydzq9PihCJ", "expanded_url": "https://ash.confex.com/ash/2022/webprogram/Paper169393.html", "display_url": "ash.confex.com/ash/2022/webpr\u2026", "status": 200, "title": "Paper: Autoimmune Diseases Are Not Associated with Monoclonal Gammopathy of Undetermined Significance: Results of the Prospective Population-Based Istopmm Study", "description": "Program: Oral and Poster Abstracts Session: 652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster III Hematology Disease Topics & Pathways: adult, Research, epidemiology, Plasma Cell Disorders, Clinical Research, Diseases, Lymphoid Malignancies, Human, Study Population Ingigerdur S Sverrisdottir, MD 1,2 *, Sigr\u00fan Thorsteinsd\u00f3ttir, MD, PhD 2,3, S\u00e6mundur R\u00f6gnvaldsson, MD 4 *, Thor Aspelund, PhD 2 *, Brynjar Vidarsson, MD 5, P\u00e1ll Torfi \u00d6nundarson, MD 5 *, Bjarni Agnarsson, MD", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Paper169393.html"}, {"start": 284, "end": 307, "url": "https://t.co/Fq3CvtLe8n", "expanded_url": "https://twitter.com/sykristinsson/status/1589629545870929920/photo/1", "display_url": "pic.twitter.com/Fq3CvtLe8n", "media_key": "3_1589625928606515206"}]}, "text": "https://t.co/ydzq9PihCJ\nAutoimmunity is well established risk factor for MGUS an MM. Think again! \nPresenter: @ingigerdursv: In a prospective screened @iStopMM , &gt;75000 individuals+ complete data on all diagnosis in the country: \n\nAutoimmune disease is not a risk factor for MGUS! https://t.co/Fq3CvtLe8n", "referenced_tweets": [{"type": "replied_to", "id": "1589629540409954305"}], "source": "Twitter Web App", "author_id": "3078258341", "conversation_id": "1589629504422805506", "in_reply_to_user_id": "3078258341", "created_at": "2022-11-07T14:43:12.000Z", "edit_history_tweet_ids": ["1589629545870929920"], "id": "1589629545870929920", "lang": "en"}, {"entities": {"mentions": [{"start": 80, "end": 88, "username": "iStopMM", "id": "844232399319941122"}, {"start": 171, "end": 179, "username": "jthorir", "id": "247118539"}], "annotations": [{"start": 24, "end": 26, "probability": 0.5592, "type": "Other", "normalized_text": "MRD"}, {"start": 92, "end": 94, "probability": 0.3759, "type": "Other", "normalized_text": "NGF"}], "urls": [{"start": 0, "end": 23, "url": "https://t.co/vWsOPXEfZa", "expanded_url": "https://ash.confex.com/ash/2022/webprogram/Paper168741.html", "display_url": "ash.confex.com/ash/2022/webpr\u2026", "status": 200, "title": "Paper: Determining Hemodilution in Diagnostic Bone Marrow Samples in Multiple Myeloma and Its Precursors By Next-Generation Flow Cytometry: Data from the Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) Study", "description": "Program: Oral and Poster Abstracts Session: 652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster II Hematology Disease Topics & Pathways: assays, Technology and Procedures, Minimal Residual Disease Jon \u00de\u00f3rir Oskarsson, MSc 1 *, S\u00e6mundur R\u00f6gnvaldsson, MD 2,3 *, Sigr\u00fan Thorsteinsd\u00f3ttir, MD, PhD 1,4, Hrafnhildur Una \u00de\u00f3r\u00f0ard\u00f3ttir 1 *, Gudlaug Katrin Hakonardottir 1 *, Steinar Bragi Gunnarsson 1 *, Gudr\u00fan \u00c1sta Sigurdard\u00f3ttir 1 *, \u00c1sdis R\u00f3sa Th\u00f3rdardottir 1 *, Gauti G\u00edslason 1", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Paper168741.html"}, {"start": 273, "end": 296, "url": "https://t.co/v5Ru54vLcM", "expanded_url": "https://twitter.com/sykristinsson/status/1589629540409954305/photo/1", "display_url": "pic.twitter.com/v5Ru54vLcM", "media_key": "3_1589625408626036739"}]}, "text": "https://t.co/vWsOPXEfZa\nMRD in MM can be false negative b/c of hemodilution. In @iStopMM by NGF we show a large difference in the # of PCs in 1st vs 2nd pull. \nPresenter: @jthorir\n\nSuggest hemodilution score model to evaluate quality and whether useful for diagnostic use. https://t.co/v5Ru54vLcM", "referenced_tweets": [{"type": "replied_to", "id": "1589629535292882945"}], "source": "Twitter Web App", "author_id": "3078258341", "conversation_id": "1589629504422805506", "in_reply_to_user_id": "3078258341", "created_at": "2022-11-07T14:43:10.000Z", "edit_history_tweet_ids": ["1589629540409954305"], "id": "1589629540409954305", "lang": "en"}, {"entities": {"mentions": [{"start": 102, "end": 118, "username": "SigrunThorstei1", "id": "1198917648630919168"}], "annotations": [{"start": 62, "end": 84, "probability": 0.4404, "type": "Person", "normalized_text": "Sigrun Thorsteinsdottir"}, {"start": 174, "end": 181, "probability": 0.5037, "type": "Other", "normalized_text": "\u2019s Guide"}], "urls": [{"start": 0, "end": 23, "url": "https://t.co/5SRZGKzaid", "expanded_url": "https://ash.confex.com/ash/2022/webprogram/Paper155386.html", "display_url": "ash.confex.com/ash/2022/webpr\u2026", "status": 200, "title": "Paper: The Consultant\u2019s Guide to Smoldering Multiple Myeloma", "description": "Program: Education Program Session: Treatment Approaches for the Multiple Myeloma Patient in 2022 Hematology Disease Topics & Pathways: Clinical Trials, Workforce, Plasma Cell Disorders, Diseases, Real World Evidence, Lymphoid Malignancies Sigrun Thorsteinsdottir, MD, PhD Department of Hematology, Rigshospitalet, K\u00f8benhavn, Copenhagen, Denmark Disclosures: No relevant conflicts of interest to", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Paper155386.html"}]}, "text": "https://t.co/5SRZGKzaid\nThe rising star of smoldering myeloma Sigrun Thorsteinsdottir, MD, PhD a.k.a. @SigrunThorstei1  gives an Educational Program talk on: \n\nThe Consultant\u2019s Guide to Smoldering Multiple Myeloma\n\nShe knows what she is talking about!", "referenced_tweets": [{"type": "replied_to", "id": "1589629531933282307"}], "source": "Twitter Web App", "author_id": "3078258341", "conversation_id": "1589629504422805506", "in_reply_to_user_id": "3078258341", "created_at": "2022-11-07T14:43:09.000Z", "edit_history_tweet_ids": ["1589629535292882945"], "id": "1589629535292882945", "lang": "en"}, {"entities": {"mentions": [{"start": 45, "end": 60, "username": "PalmasonRobert", "id": "1291096121733939202"}], "annotations": [{"start": 179, "end": 184, "probability": 0.6024, "type": "Other", "normalized_text": "cancer"}, {"start": 187, "end": 203, "probability": 0.7007, "type": "Other", "normalized_text": "pulmonary disease"}], "urls": [{"start": 0, "end": 23, "url": "https://t.co/LnThC0Q7yO", "expanded_url": "https://ash.confex.com/ash/2022/webprogram/Paper164758.html", "display_url": "ash.confex.com/ash/2022/webpr\u2026", "status": 200, "title": "Paper: Transient M-Proteins: Epidemiology, Causes, and the Impact of Mass Spectrometry: The Istopmm Study", "description": "Program: Oral and Poster Abstracts Type: Oral Session: 652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Disease Monitoring Hematology Disease Topics & Pathways: Plasma Cell Disorders, Diseases, Lymphoid Malignancies Robert Palmason 1,2,3 *, Oscar Berlanga, PhD 4 *, Jon Kristinn Sigurdsson 1 *, S\u00e6mundur R\u00f6gnvaldsson, MD 5,6 *, Sigrun Thorsteinsdottir, MD, PhD 1,7, Sara Ekberg, PhD 8 *, Michael Crowther, PhD 8 *, Marina Levy 1 *, Elin Ruth Reed 1 *, Jon \u00de\u00f3rir Oskarsson, MSc 9", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Paper164758.html"}, {"start": 281, "end": 304, "url": "https://t.co/VM1LyC0Weg", "expanded_url": "https://twitter.com/sykristinsson/status/1589629531933282307/photo/1", "display_url": "pic.twitter.com/VM1LyC0Weg", "media_key": "3_1589624444024197122"}]}, "text": "https://t.co/LnThC0Q7yO\nOral presentation by @PalmasonRobert : Can M-protein disappear? \nYes. Almost 10% by using standard approach. Underlying factors: infections, autoimmunity, cancer, pulmonary disease and drugs.\n\nBut by using mass spec (\u2b06\ufe0fsensitive) only 2.6% are really gone! https://t.co/VM1LyC0Weg", "referenced_tweets": [{"type": "replied_to", "id": "1589629524886446082"}], "source": "Twitter Web App", "author_id": "3078258341", "conversation_id": "1589629504422805506", "in_reply_to_user_id": "3078258341", "created_at": "2022-11-07T14:43:08.000Z", "edit_history_tweet_ids": ["1589629531933282307"], "id": "1589629531933282307", "lang": "en"}, {"entities": {"mentions": [{"start": 45, "end": 57, "username": "ThorvardurL", "id": "1199342830180651009"}, {"start": 111, "end": 119, "username": "iStopMM", "id": "844232399319941122"}], "annotations": [{"start": 74, "end": 77, "probability": 0.4052, "type": "Other", "normalized_text": "MGUS"}, {"start": 184, "end": 186, "probability": 0.6012, "type": "Other", "normalized_text": "IgA"}, {"start": 233, "end": 236, "probability": 0.466, "type": "Other", "normalized_text": "MGUS"}], "urls": [{"start": 0, "end": 23, "url": "https://t.co/fS149kE6mn", "expanded_url": "https://ash.confex.com/ash/2022/webprogram/Paper163169.html", "display_url": "ash.confex.com/ash/2022/webpr\u2026", "status": 200, "title": "Paper: Prevalence of MGUS Is High in the Istopmm Study but the Prevalence of IgA MGUS Does Not Increase with Age in the Way Other Immunoglobulin Subtypes Do", "description": "Program: Oral and Poster Abstracts Type: Oral Session: 652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Precursor States: MGUS and Smoldering Myeloma Hematology Disease Topics & Pathways: Research, clinical trials, epidemiology, Clinical Research, real-world evidence Thorvardur Jon Love, MD, PhD 1,2 *, S\u00e6mundur R\u00f6gnvaldsson, MD 3 *, Sigrun Thorsteinsdottir, MD, PhD 1,4, Thor Aspelund, PhD 1 *, Elin Ruth Reed 1 *, Brynjar Vidarsson, MD 2, Pall Torfi Onundarson, MD 2, Bjarni", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Paper163169.html"}, {"start": 273, "end": 296, "url": "https://t.co/ct1G8O4i0M", "expanded_url": "https://twitter.com/sykristinsson/status/1589629524886446082/photo/1", "display_url": "pic.twitter.com/ct1G8O4i0M", "media_key": "3_1589623815709102083"}]}, "text": "https://t.co/fS149kE6mn\nOral presentation by @ThorvardurL : How common is MGUS after screening 75422 people in @iStopMM? \n\nPrevalence is 3.9% in 40+ and 5% in 50+. All isotypes except IgA increasing with age. Most (43%) are low-risk MGUS. \nShould we screen? We for OS data https://t.co/ct1G8O4i0M", "referenced_tweets": [{"type": "replied_to", "id": "1589629516858953729"}], "source": "Twitter Web App", "author_id": "3078258341", "conversation_id": "1589629504422805506", "in_reply_to_user_id": "3078258341", "created_at": "2022-11-07T14:43:07.000Z", "edit_history_tweet_ids": ["1589629524886446082"], "id": "1589629524886446082", "lang": "en"}, {"entities": {"mentions": [{"start": 42, "end": 58, "username": "eliaseythorsson", "id": "133109181"}, {"start": 186, "end": 194, "username": "iStopMM", "id": "844232399319941122"}], "annotations": [{"start": 162, "end": 165, "probability": 0.5585, "type": "Other", "normalized_text": "BMPC"}, {"start": 237, "end": 240, "probability": 0.5048, "type": "Other", "normalized_text": "MGUS"}, {"start": 250, "end": 251, "probability": 0.5638, "type": "Other", "normalized_text": "BM"}], "urls": [{"start": 0, "end": 23, "url": "https://t.co/ZGqXHCmBJ3", "expanded_url": "https://ash.confex.com/ash/2022/webprogram/Paper170166.html", "display_url": "ash.confex.com/ash/2022/webpr\u2026", "status": 200, "title": "Paper: Predicting the Need for Upfront Bone Marrow Sampling in Individuals with MGUS: Derivation of a Multivariable Prediction Model Using the Prospective Population-Based Istopmm Cohort", "description": "Program: Oral and Poster Abstracts Type: Oral Session: 652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Precursor States: MGUS and Smoldering Myeloma Hematology Disease Topics & Pathways: adult, Research, Clinical Research, real-world evidence, Human, Study Population Elias Eythorsson, MD, PhD 1 *, S\u00e6mundur R\u00f6gnvaldsson, MD 1,2 *, Sigr\u00fan Thorsteinsd\u00f3ttir, MD, PhD 3,4, Elin Ruth Reed 3 *, Gudr\u00fan \u00c1sta Sigurdard\u00f3ttir 3 *, Brynjar Vidarsson, MD 1, P\u00e1ll Torfi Onundarson, MD 1,", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Paper170166.html"}, {"start": 279, "end": 302, "url": "https://t.co/5pjgkDzNDO", "expanded_url": "https://twitter.com/sykristinsson/status/1589629516858953729/photo/1", "display_url": "pic.twitter.com/5pjgkDzNDO", "media_key": "3_1589622746450903040"}]}, "text": "https://t.co/ZGqXHCmBJ3\nOral presentation @eliaseythorsson : Bone marrow in individual with M-protein? \nWe made a multivariable model to predict the risk of \u226510% BMPC in the prospective @iStopMM. Provides evidence to select persons with MGUS in whom BM sampling may be deferred. https://t.co/5pjgkDzNDO", "referenced_tweets": [{"type": "replied_to", "id": "1589629509418242048"}], "source": "Twitter Web App", "author_id": "3078258341", "conversation_id": "1589629504422805506", "in_reply_to_user_id": "3078258341", "created_at": "2022-11-07T14:43:05.000Z", "edit_history_tweet_ids": ["1589629516858953729"], "id": "1589629516858953729", "lang": "en"}, {"entities": {"mentions": [{"start": 42, "end": 57, "username": "PalmasonRobert", "id": "1291096121733939202"}, {"start": 122, "end": 130, "username": "iStopMM", "id": "844232399319941122"}], "annotations": [{"start": 159, "end": 163, "probability": 0.9421, "type": "Other", "normalized_text": "Covid"}, {"start": 176, "end": 179, "probability": 0.3526, "type": "Other", "normalized_text": "MGUS"}, {"start": 246, "end": 249, "probability": 0.4675, "type": "Other", "normalized_text": "MGUS"}, {"start": 269, "end": 273, "probability": 0.9078, "type": "Other", "normalized_text": "covid"}], "urls": [{"start": 0, "end": 23, "url": "https://t.co/SVUC9PkSjC", "expanded_url": "https://ash.confex.com/ash/2022/webprogram/Paper157138.html", "display_url": "ash.confex.com/ash/2022/webpr\u2026", "status": 200, "title": "Paper: Sars-Cov-2 Vaccinations Do Not Lead to Progression of Monoclonal Gammopathy of Undetermined Significance: Results from the Population-Based Istopmm Screening Study", "description": "Program: Oral and Poster Abstracts Type: Oral Session: 652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Precursor States: MGUS and Smoldering Myeloma Hematology Disease Topics & Pathways: Plasma Cell Disorders, Diseases, Lymphoid Malignancies Robert Palmason 1,2,3 *, Elias Eythorsson, MD, PhD 1 *, S\u00e6mundur R\u00f6gnvaldsson, MD 1,4 *, Sigrun Thorsteinsdottir, MD, PhD 3,5, Sara Ekberg, PhD 6 *, Michael Crowther, PhD 6 *, Elin Ruth Reed 3 *, Jon \u00de\u00f3rir Oskarsson, MSc 7 *, Gudrun", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Paper157138.html"}, {"start": 288, "end": 311, "url": "https://t.co/Iw8eT5en58", "expanded_url": "https://twitter.com/sykristinsson/status/1589629509418242048/photo/1", "display_url": "pic.twitter.com/Iw8eT5en58", "media_key": "3_1589621421390663680"}]}, "text": "https://t.co/SVUC9PkSjC\nOral presentation @PalmasonRobert: Do vaccinations trigger antibody-producing plasma cell clones? @iStopMM prospectively followed 1814 Covid vaccinated MGUS individuals. &gt;6000 tests pre&amp;post vacc: \n\nNo evidence for MGUS progression after covid vaccination. https://t.co/Iw8eT5en58", "referenced_tweets": [{"type": "replied_to", "id": "1589629504422805506"}], "source": "Twitter Web App", "author_id": "3078258341", "conversation_id": "1589629504422805506", "in_reply_to_user_id": "3078258341", "created_at": "2022-11-07T14:43:03.000Z", "edit_history_tweet_ids": ["1589629509418242048"], "id": "1589629509418242048", "lang": "en"}, {"entities": {"mentions": [{"start": 69, "end": 83, "username": "sykristinsson", "id": "3078258341"}, {"start": 107, "end": 118, "username": "IMFmyeloma", "id": "34340707"}], "hashtags": [{"start": 85, "end": 93, "tag": "myeloma"}, {"start": 94, "end": 106, "tag": "knowmyeloma"}], "annotations": [{"start": 27, "end": 33, "probability": 0.5162, "type": "Other", "normalized_text": "Iceland"}], "urls": [{"start": 119, "end": 142, "url": "https://t.co/Iw39ugInlT", "expanded_url": "https://twitter.com/GMyelomaAN/status/1587388080817831936/photo/1", "display_url": "pic.twitter.com/Iw39ugInlT", "media_key": "3_1587388073205186561"}]}, "text": "We are starting our hybrid Iceland Patient &amp; Family Seminar with @sykristinsson \n#myeloma #knowmyeloma @IMFmyeloma https://t.co/Iw39ugInlT", "source": "Twitter for iPhone", "author_id": "3083937603", "conversation_id": "1587388080817831936", "created_at": "2022-11-01T10:16:25.000Z", "edit_history_tweet_ids": ["1587388080817831936"], "id": "1587388080817831936", "lang": "en"}, {"text": "The iStopMM study has been running since 2016 and continues to produce vital data.\n\nJon Porir Oskarsson - PhD candidate at the University of Iceland highlights the work he is conducting in the study and the data collected so far.\n\nWatch it now: https://t.co/Df4oGbHbel https://t.co/7ymWzcb3LJ", "source": "HubSpot", "author_id": "321436678", "conversation_id": "1584439548511064064", "entities": {"annotations": [{"start": 4, "end": 10, "probability": 0.4884, "type": "Organization", "normalized_text": "iStopMM"}, {"start": 84, "end": 102, "probability": 0.6754, "type": "Person", "normalized_text": "Jon Porir Oskarsson"}, {"start": 127, "end": 147, "probability": 0.9725, "type": "Organization", "normalized_text": "University of Iceland"}], "urls": [{"start": 245, "end": 268, "url": "https://t.co/Df4oGbHbel", "expanded_url": "https://hubs.li/Q01qdY_X0", "display_url": "hubs.li/Q01qdY_X0", "images": [{"url": "https://pbs.twimg.com/news_img/1584439552277553152/KTGfwPiI?format=jpg&name=orig", "width": 1280, "height": 720}, {"url": "https://pbs.twimg.com/news_img/1584439552277553152/KTGfwPiI?format=jpg&name=150x150", "width": 150, "height": 150}], "status": 200, "title": "iStopMM Scientific Discussion - Jon Porir Oskarsson", "unwound_url": "https://www.youtube.com/watch?utm_campaign=Social+Media&utm_content=221328397&utm_medium=social&utm_source=twitter&hss_channel=tw-321436678&v=1QH8GmZxv_s&feature=youtu.be"}, {"start": 269, "end": 292, "url": "https://t.co/7ymWzcb3LJ", "expanded_url": "https://twitter.com/TheBindingSite/status/1584439548511064064/photo/1", "display_url": "pic.twitter.com/7ymWzcb3LJ", "media_key": "3_1584439546338484224"}]}, "created_at": "2022-10-24T07:00:00.000Z", "edit_history_tweet_ids": ["1584439548511064064"], "id": "1584439548511064064", "lang": "en"}, {"entities": {"mentions": [{"start": 130, "end": 144, "username": "sykristinsson", "id": "3078258341"}, {"start": 150, "end": 158, "username": "iStopMM", "id": "844232399319941122"}], "annotations": [{"start": 38, "end": 47, "probability": 0.5467, "type": "Other", "normalized_text": "Monoclonal"}], "urls": [{"start": 272, "end": 295, "url": "https://t.co/wcEESO5TgJ", "expanded_url": "https://twitter.com/SaemundurMD/status/1582879446490841088/photo/1", "display_url": "pic.twitter.com/wcEESO5TgJ", "media_key": "3_1582879423585452032"}, {"start": 272, "end": 295, "url": "https://t.co/wcEESO5TgJ", "expanded_url": "https://twitter.com/SaemundurMD/status/1582879446490841088/photo/1", "display_url": "pic.twitter.com/wcEESO5TgJ", "media_key": "3_1582879423568781313"}, {"start": 272, "end": 295, "url": "https://t.co/wcEESO5TgJ", "expanded_url": "https://twitter.com/SaemundurMD/status/1582879446490841088/photo/1", "display_url": "pic.twitter.com/wcEESO5TgJ", "media_key": "3_1582879423577182208"}]}, "text": "Last week I defended my PhD thesis: \n\u201cMonoclonal gammopathy of what significance?\u201d \n\nI\u2019m so proud of this work and so grateful to @sykristinsson, the @iStopMM team, and so many more!\n\nBonus pic of me in 2016 camping while recruiting labs for istop. It\u2019s been a wild ride\u2026 https://t.co/wcEESO5TgJ", "source": "Twitter for Mac", "author_id": "1054784756704010241", "conversation_id": "1582879446490841088", "created_at": "2022-10-19T23:40:43.000Z", "edit_history_tweet_ids": ["1582879446490841088"], "id": "1582879446490841088", "lang": "en"}, {"entities": {"mentions": [{"start": 16, "end": 30, "username": "sykristinsson", "id": "3078258341"}], "annotations": [{"start": 0, "end": 13, "probability": 0.82, "type": "Person", "normalized_text": "Sigurdur Yngvi"}, {"start": 109, "end": 115, "probability": 0.9645, "type": "Place", "normalized_text": "Iceland"}], "urls": [{"start": 140, "end": 163, "url": "https://t.co/B54kHeNqN8", "expanded_url": "https://twitter.com/VincentRK/status/1581072167315570689", "display_url": "twitter.com/VincentRK/stat\u2026"}]}, "text": "Sigurdur Yngvi, @sykristinsson, is an International star in clinical haematology. We in academic Medicine in Iceland are very proud of him. https://t.co/B54kHeNqN8", "referenced_tweets": [{"type": "quoted", "id": "1581072167315570689"}], "source": "Twitter for iPhone", "author_id": "1126600712086069250", "conversation_id": "1581267263625125892", "created_at": "2022-10-15T12:54:28.000Z", "edit_history_tweet_ids": ["1581267263625125892"], "id": "1581267263625125892", "lang": "en"}, {"entities": {"mentions": [{"start": 47, "end": 61, "username": "sykristinsson", "id": "3078258341"}, {"start": 160, "end": 171, "username": "IMFmyeloma", "id": "34340707"}, {"start": 172, "end": 180, "username": "iStopMM", "id": "844232399319941122"}], "hashtags": [{"start": 181, "end": 192, "tag": "medtwitter"}], "annotations": [{"start": 39, "end": 42, "probability": 0.4877, "type": "Organization", "normalized_text": "MGUS"}, {"start": 69, "end": 71, "probability": 0.4313, "type": "Other", "normalized_text": "AMN"}, {"start": 86, "end": 96, "probability": 0.637, "type": "Other", "normalized_text": "Kristinsson"}, {"start": 140, "end": 146, "probability": 0.4415, "type": "Other", "normalized_text": "iSTOPMM"}, {"start": 151, "end": 157, "probability": 0.9525, "type": "Place", "normalized_text": "Iceland"}], "urls": [{"start": 281, "end": 304, "url": "https://t.co/NAXrKb5iwt", "expanded_url": "https://twitter.com/VincentRK/status/1581072167315570689/photo/1", "display_url": "pic.twitter.com/NAXrKb5iwt", "media_key": "3_1581072148390563840"}]}, "text": "Great Keynote lecture on Screening for MGUS by @sykristinsson at the AMN Meeting. Dr. Kristinsson is leading a nationwide randomized trial, iSTOPMM in Iceland. @IMFmyeloma @iStopMM #medtwitter \n\nPeople can talk about screening. Takes great vision and leadership to pull off an RCT https://t.co/NAXrKb5iwt", "source": "Twitter for iPhone", "author_id": "24261916", "conversation_id": "1581072167315570689", "created_at": "2022-10-14T23:59:14.000Z", "edit_history_tweet_ids": ["1581072167315570689"], "id": "1581072167315570689", "lang": "en"}, {"entities": {"mentions": [{"start": 12, "end": 24, "username": "SaemundurMD", "id": "1054784756704010241"}, {"start": 141, "end": 154, "username": "ADispenzieri", "id": "2172483547"}], "urls": [{"start": 187, "end": 210, "url": "https://t.co/JQ4hu334Ix", "expanded_url": "https://twitter.com/sykristinsson/status/1579925997155409920/photo/1", "display_url": "pic.twitter.com/JQ4hu334Ix", "media_key": "3_1579925972173873180"}, {"start": 187, "end": 210, "url": "https://t.co/JQ4hu334Ix", "expanded_url": "https://twitter.com/sykristinsson/status/1579925997155409920/photo/1", "display_url": "pic.twitter.com/JQ4hu334Ix", "media_key": "3_1579925978498883584"}, {"start": 187, "end": 210, "url": "https://t.co/JQ4hu334Ix", "expanded_url": "https://twitter.com/sykristinsson/status/1579925997155409920/photo/1", "display_url": "pic.twitter.com/JQ4hu334Ix", "media_key": "3_1579925985851498500"}]}, "text": "So proud of @SaemundurMD my PhD student who defended his thesis yesterday.  His performance was outstanding! Congratulations!\n\nAnd thank you @ADispenzieri for being the perfect opponent! https://t.co/JQ4hu334Ix", "source": "Twitter for Android", "author_id": "3078258341", "conversation_id": "1579925997155409920", "created_at": "2022-10-11T20:04:45.000Z", "edit_history_tweet_ids": ["1579925997155409920"], "id": "1579925997155409920", "lang": "en"}, {"text": "In collaboration with other iStopMM researchers, Dr Einarsson Long has published a paper on how kidney function is known to greatly affect serum free light chain concentrations.\n\nTo read the paper, click here: https://t.co/PpFdIGyE3Q https://t.co/3x8a7nAk7h", "source": "HubSpot", "author_id": "321436678", "conversation_id": "1575748530731360258", "entities": {"annotations": [{"start": 28, "end": 34, "probability": 0.7636, "type": "Other", "normalized_text": "iStopMM"}, {"start": 52, "end": 65, "probability": 0.5581, "type": "Other", "normalized_text": "Einarsson Long"}], "urls": [{"start": 210, "end": 233, "url": "https://t.co/PpFdIGyE3Q", "expanded_url": "https://hubs.li/Q01nyCRR0", "display_url": "hubs.li/Q01nyCRR0", "status": 200, "unwound_url": "https://www.nature.com/articles/s41408-022-00732-3.pdf?utm_campaign=Social%20Media&utm_content=222790825&utm_medium=social&utm_source=twitter&hss_channel=tw-321436678&error=cookies_not_supported&code=2cb7eba4-2545-436b-b338-9cc7da0042e5"}, {"start": 234, "end": 257, "url": "https://t.co/3x8a7nAk7h", "expanded_url": "https://twitter.com/TheBindingSite/status/1575748530731360258/photo/1", "display_url": "pic.twitter.com/3x8a7nAk7h", "media_key": "3_1575748528533635072"}]}, "created_at": "2022-09-30T07:25:00.000Z", "edit_history_tweet_ids": ["1575748530731360258"], "id": "1575748530731360258", "lang": "en"}, {"entities": {"mentions": [{"start": 24, "end": 38, "username": "sykristinsson", "id": "3078258341"}, {"start": 113, "end": 122, "username": "aishaikh", "id": "42107379"}], "annotations": [{"start": 65, "end": 67, "probability": 0.4474, "type": "Other", "normalized_text": "FLC"}, {"start": 194, "end": 197, "probability": 0.4062, "type": "Organization", "normalized_text": "MGCS"}], "urls": [{"start": 225, "end": 248, "url": "https://t.co/a9HXoaZ72g", "expanded_url": "https://twitter.com/awechalekar/status/1575079402442203136/photo/1", "display_url": "pic.twitter.com/a9HXoaZ72g", "media_key": "3_1575079398478417921"}, {"start": 249, "end": 272, "url": "https://t.co/3CGxdcsSTR", "expanded_url": "https://twitter.com/aishaikh/status/1574539658989809670", "display_url": "twitter.com/aishaikh/statu\u2026"}]}, "text": "Ground breaking work by @sykristinsson and colleagues redefining FLC ranges in renal disease - but this slide by @aishaikh is critical - useful only when ALL criteria met otherwise AL and other MGCS conditions will be missed https://t.co/a9HXoaZ72g https://t.co/3CGxdcsSTR", "referenced_tweets": [{"type": "quoted", "id": "1574539658989809670"}], "source": "Twitter for iPhone", "author_id": "957790163014385665", "conversation_id": "1575079402442203136", "created_at": "2022-09-28T11:06:07.000Z", "edit_history_tweet_ids": ["1575079402442203136"], "id": "1575079402442203136", "lang": "en"}, {"text": "In this video, Thorir Einarsson Long - Postdoctoral Researcher in the iStopMM study discusses how serum free light chains can be affected by kidney functionality. \n\nWatch it now: https://t.co/WxAqknstYv\n\n#MultipleMyeloma #iStopMM https://t.co/6QWiwOGGen", "source": "HubSpot", "author_id": "321436678", "entities": {"hashtags": [{"start": 204, "end": 220, "tag": "MultipleMyeloma"}, {"start": 221, "end": 229, "tag": "iStopMM"}], "annotations": [{"start": 15, "end": 30, "probability": 0.702, "type": "Person", "normalized_text": "Thorir Einarsson"}, {"start": 70, "end": 76, "probability": 0.7858, "type": "Other", "normalized_text": "iStopMM"}, {"start": 222, "end": 228, "probability": 0.6338, "type": "Other", "normalized_text": "iStopMM"}], "urls": [{"start": 179, "end": 202, "url": "https://t.co/WxAqknstYv", "expanded_url": "https://hubs.li/Q01njSMb0", "display_url": "hubs.li/Q01njSMb0", "images": [{"url": "https://pbs.twimg.com/news_img/1575017470225686534/8hHT3AQN?format=jpg&name=orig", "width": 1280, "height": 720}, {"url": "https://pbs.twimg.com/news_img/1575017470225686534/8hHT3AQN?format=jpg&name=150x150", "width": 150, "height": 150}], "status": 200, "title": "iStopMM Scientific Discussion - Thorir Einarsson Long", "unwound_url": "https://www.youtube.com/watch?utm_campaign=Social+Media&utm_content=221327783&utm_medium=social&utm_source=twitter&hss_channel=tw-321436678&v=LDqc3zCqXdQ&feature=youtu.be"}, {"start": 230, "end": 253, "url": "https://t.co/6QWiwOGGen", "expanded_url": "https://twitter.com/TheBindingSite/status/1575017467407114242/photo/1", "display_url": "pic.twitter.com/6QWiwOGGen", "media_key": "3_1575017464819236865"}]}, "conversation_id": "1575017467407114242", "created_at": "2022-09-28T07:00:01.000Z", "edit_history_tweet_ids": ["1575017467407114242"], "id": "1575017467407114242", "lang": "en"}, {"entities": {"mentions": [{"start": 0, "end": 14, "username": "sykristinsson", "id": "3078258341"}, {"start": 15, "end": 23, "username": "iStopMM", "id": "844232399319941122"}, {"start": 24, "end": 33, "username": "MSK_Neph", "id": "1462362881731743746"}], "annotations": [{"start": 276, "end": 278, "probability": 0.3896, "type": "Other", "normalized_text": "CKD"}]}, "text": "@sykristinsson @iStopMM @MSK_Neph Congratulations on a very important study, relevant to hematology &amp; nephrology practice!\nThe strength of the study is: large # of participants w/more preserved GFR 51 ml/min vs the previous study (29 ml/min) from which FLC &amp; ratio in CKD was derived (cont.)", "referenced_tweets": [{"type": "replied_to", "id": "1574681807911518209"}], "source": "Twitter for iPhone", "author_id": "42107379", "conversation_id": "1574539658989809670", "in_reply_to_user_id": "3078258341", "created_at": "2022-09-27T13:39:04.000Z", "edit_history_tweet_ids": ["1574755505486053382"], "id": "1574755505486053382", "lang": "en"}, {"text": "New reference intervals for serum free light chains in CKD. Excited to discuss this study in an upcoming talk. It impacts LC-MGUS definition which can be a precursor to LC-MM,AL amyloidosis. New vs old ref. range\ud83d\udc47\ud83c\udffd\nhttps://t.co/NkC56WqUZp\n#OncoNephrology https://t.co/0gvf2YLY2B", "source": "Twitter for iPhone", "author_id": "42107379", "entities": {"hashtags": [{"start": 239, "end": 254, "tag": "OncoNephrology"}], "annotations": [{"start": 55, "end": 57, "probability": 0.5629, "type": "Other", "normalized_text": "CKD"}, {"start": 122, "end": 128, "probability": 0.6033, "type": "Other", "normalized_text": "LC-MGUS"}, {"start": 169, "end": 170, "probability": 0.5415, "type": "Other", "normalized_text": "LC"}, {"start": 178, "end": 188, "probability": 0.5778, "type": "Other", "normalized_text": "amyloidosis"}], "urls": [{"start": 215, "end": 238, "url": "https://t.co/NkC56WqUZp", "expanded_url": "https://pubmed.ncbi.nlm.nih.gov/36100605/", "display_url": "pubmed.ncbi.nlm.nih.gov/36100605/", "status": 200, "title": "Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: Results of the iStopMM study - PubMed", "description": "Serum free light chain (FLC) concentration is greatly affected by kidney function. Using a large prospective population-based cohort, we aimed to establish a reference interval for FLCs in persons with chronic kidney disease (CKD). A total of 75422 participants of the iStopMM study were screened wit \u2026", "unwound_url": "https://pubmed.ncbi.nlm.nih.gov/36100605/"}, {"start": 255, "end": 278, "url": "https://t.co/0gvf2YLY2B", "expanded_url": "https://twitter.com/aishaikh/status/1574539658989809670/photo/1", "display_url": "pic.twitter.com/0gvf2YLY2B", "media_key": "3_1574539654128435200"}, {"start": 255, "end": 278, "url": "https://t.co/0gvf2YLY2B", "expanded_url": "https://twitter.com/aishaikh/status/1574539658989809670/photo/1", "display_url": "pic.twitter.com/0gvf2YLY2B", "media_key": "3_1574539654107484167"}]}, "conversation_id": "1574539658989809670", "created_at": "2022-09-26T23:21:22.000Z", "edit_history_tweet_ids": ["1574539658989809670"], "id": "1574539658989809670", "lang": "en"}, {"entities": {"mentions": [{"start": 114, "end": 122, "username": "iStopMM", "id": "844232399319941122"}], "hashtags": [{"start": 123, "end": 128, "tag": "mmsm"}], "annotations": [{"start": 90, "end": 111, "probability": 0.6688, "type": "Other", "normalized_text": "chronic kidney disease"}, {"start": 124, "end": 127, "probability": 0.5142, "type": "Other", "normalized_text": "mmsm"}], "urls": [{"start": 131, "end": 154, "url": "https://t.co/aowv9yA3Iz", "expanded_url": "https://www.nature.com/articles/s41408-022-00732-3", "display_url": "nature.com/articles/s4140\u2026", "images": [{"url": "https://pbs.twimg.com/news_img/1574143094328623105/0RfCjRTj?format=png&name=orig", "width": 955, "height": 1078}, {"url": "https://pbs.twimg.com/news_img/1574143094328623105/0RfCjRTj?format=png&name=150x150", "width": 150, "height": 150}], "status": 200, "title": "Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: Results of the iStopMM study", "description": "Blood Cancer Journal - Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: Results of the iStopMM study", "unwound_url": "https://www.nature.com/articles/s41408-022-00732-3"}, {"start": 155, "end": 178, "url": "https://t.co/eFwrFg8qyj", "expanded_url": "https://twitter.com/HadidiSamer/status/1574579084423663616/photo/1", "display_url": "pic.twitter.com/eFwrFg8qyj", "media_key": "3_1574579080128774162"}]}, "text": "Important paper suggesting a new normal range of serum free light chains in patients with chronic kidney disease  @iStopMM #mmsm \n\nhttps://t.co/aowv9yA3Iz https://t.co/eFwrFg8qyj", "source": "Twitter for iPhone", "author_id": "774267564", "conversation_id": "1574579084423663616", "created_at": "2022-09-27T01:58:02.000Z", "edit_history_tweet_ids": ["1574579084423663616"], "id": "1574579084423663616", "lang": "en"}, {"text": "Interesting work from the phenomenal iStopMM group. This issue is that most EMRs (including Epic) don\u2019t support multiple reference intervals for one lab value. There are alternative approaches, one coming soon from our group! https://t.co/kxxmHAUlud", "referenced_tweets": [{"type": "quoted", "id": "1574422541711642625"}], "source": "Twitter for iPhone", "author_id": "626650397", "conversation_id": "1574576681238646785", "entities": {"annotations": [{"start": 37, "end": 43, "probability": 0.8663, "type": "Other", "normalized_text": "iStopMM"}], "urls": [{"start": 226, "end": 249, "url": "https://t.co/kxxmHAUlud", "expanded_url": "https://twitter.com/sykristinsson/status/1574422541711642625", "display_url": "twitter.com/sykristinsson/\u2026"}]}, "created_at": "2022-09-27T01:48:29.000Z", "edit_history_tweet_ids": ["1574576681238646785"], "id": "1574576681238646785", "lang": "en"}, {"text": "These data needs to be reflected in lab normal ranges. Borderline raised SFLC is one of the commonest referral reasons from #GeneralPractice/#GP to #TeamHaem. https://t.co/n0vl9eoOh6", "referenced_tweets": [{"type": "quoted", "id": "1574422541711642625"}], "source": "Twitter for iPhone", "author_id": "211982416", "entities": {"hashtags": [{"start": 124, "end": 140, "tag": "GeneralPractice"}, {"start": 141, "end": 144, "tag": "GP"}, {"start": 148, "end": 157, "tag": "TeamHaem"}], "annotations": [{"start": 73, "end": 76, "probability": 0.4327, "type": "Organization", "normalized_text": "SFLC"}, {"start": 149, "end": 156, "probability": 0.4078, "type": "Other", "normalized_text": "TeamHaem"}], "urls": [{"start": 159, "end": 182, "url": "https://t.co/n0vl9eoOh6", "expanded_url": "https://twitter.com/sykristinsson/status/1574422541711642625", "display_url": "twitter.com/sykristinsson/\u2026"}]}, "conversation_id": "1574644674773524481", "created_at": "2022-09-27T06:18:40.000Z", "edit_history_tweet_ids": ["1574644674773524481"], "id": "1574644674773524481", "lang": "en"}, {"text": "\ud83d\udc4f\ud83d\udc4f\ud83d\udc4f https://t.co/kUEBqkLuCA", "referenced_tweets": [{"type": "quoted", "id": "1574422541711642625"}], "source": "Twitter for iPhone", "author_id": "846500919021899777", "conversation_id": "1574503605943443456", "created_at": "2022-09-26T20:58:07.000Z", "edit_history_tweet_ids": ["1574503605943443456"], "id": "1574503605943443456", "lang": "art", "entities": {"urls": [{"start": 4, "end": 27, "url": "https://t.co/kUEBqkLuCA", "expanded_url": "https://twitter.com/sykristinsson/status/1574422541711642625", "display_url": "twitter.com/sykristinsson/\u2026"}]}}, {"entities": {"mentions": [{"start": 0, "end": 13, "username": "Pathologists", "id": "24725678"}], "urls": [{"start": 14, "end": 37, "url": "https://t.co/GLhDyyCqKK", "expanded_url": "https://twitter.com/sykristinsson/status/1574422541711642625", "display_url": "twitter.com/sykristinsson/\u2026"}]}, "text": "@Pathologists https://t.co/GLhDyyCqKK", "referenced_tweets": [{"type": "quoted", "id": "1574422541711642625"}], "source": "Twitter for iPhone", "author_id": "716254481", "conversation_id": "1574493113854443536", "in_reply_to_user_id": "24725678", "created_at": "2022-09-26T20:16:25.000Z", "edit_history_tweet_ids": ["1574493113854443536"], "id": "1574493113854443536", "lang": "qam"}, {"text": "This should be practice-changing indeed. Overinterpreting FLC assays is not innocuous. https://t.co/r1BaaIW4km", "referenced_tweets": [{"type": "quoted", "id": "1574422541711642625"}], "source": "Twitter for Android", "author_id": "51187036", "conversation_id": "1574492256748204032", "entities": {"annotations": [{"start": 58, "end": 60, "probability": 0.4817, "type": "Other", "normalized_text": "FLC"}], "urls": [{"start": 87, "end": 110, "url": "https://t.co/r1BaaIW4km", "expanded_url": "https://twitter.com/sykristinsson/status/1574422541711642625", "display_url": "twitter.com/sykristinsson/\u2026"}]}, "created_at": "2022-09-26T20:13:01.000Z", "edit_history_tweet_ids": ["1574492256748204032"], "id": "1574492256748204032", "lang": "en"}, {"text": "This is great for clinical practice so we can use objective cut points rather than guestimate in those with CKD. \n\nOf Note, for those who don't do MM everyday, NOTE the units are mg/L in the chart and NOT mg/dL which is often used in the US! https://t.co/68aLK7oXzQ", "referenced_tweets": [{"type": "quoted", "id": "1574422541711642625"}], "source": "Twitter Web App", "author_id": "276053436", "conversation_id": "1574466576761245697", "entities": {"annotations": [{"start": 108, "end": 110, "probability": 0.599, "type": "Other", "normalized_text": "CKD"}, {"start": 147, "end": 148, "probability": 0.4785, "type": "Other", "normalized_text": "MM"}, {"start": 238, "end": 239, "probability": 0.9515, "type": "Place", "normalized_text": "US"}], "urls": [{"start": 242, "end": 265, "url": "https://t.co/68aLK7oXzQ", "expanded_url": "https://twitter.com/sykristinsson/status/1574422541711642625", "display_url": "twitter.com/sykristinsson/\u2026"}]}, "created_at": "2022-09-26T18:30:58.000Z", "edit_history_tweet_ids": ["1574466576761245697"], "id": "1574466576761245697", "lang": "en"}, {"text": "The joy this brings me makes me really wonder if I need to get out more... https://t.co/kSNwbAbqMf", "referenced_tweets": [{"type": "quoted", "id": "1574422541711642625"}], "source": "Twitter for Android", "author_id": "757934840", "conversation_id": "1574432562285608960", "created_at": "2022-09-26T16:15:49.000Z", "edit_history_tweet_ids": ["1574432562285608960"], "id": "1574432562285608960", "lang": "en", "entities": {"urls": [{"start": 75, "end": 98, "url": "https://t.co/kSNwbAbqMf", "expanded_url": "https://twitter.com/sykristinsson/status/1574422541711642625", "display_url": "twitter.com/sykristinsson/\u2026"}]}}, {"text": "#mmsm FLC https://t.co/V8dK4XXFCe", "referenced_tweets": [{"type": "quoted", "id": "1574422541711642625"}], "source": "Twitter Web App", "author_id": "190337035", "entities": {"hashtags": [{"start": 0, "end": 5, "tag": "mmsm"}], "urls": [{"start": 10, "end": 33, "url": "https://t.co/V8dK4XXFCe", "expanded_url": "https://twitter.com/sykristinsson/status/1574422541711642625", "display_url": "twitter.com/sykristinsson/\u2026"}]}, "conversation_id": "1574425998589935618", "created_at": "2022-09-26T15:49:44.000Z", "edit_history_tweet_ids": ["1574425998589935618"], "id": "1574425998589935618", "lang": "und"}, {"text": "Definitely practice changing! I've already started to incorporate this in our MGUS/CKD referrals. #mmsm https://t.co/JfuMi7rPUd", "referenced_tweets": [{"type": "quoted", "id": "1574422541711642625"}], "source": "Twitter Web App", "author_id": "284694610", "entities": {"hashtags": [{"start": 98, "end": 103, "tag": "mmsm"}], "annotations": [{"start": 78, "end": 81, "probability": 0.481, "type": "Other", "normalized_text": "MGUS"}, {"start": 83, "end": 85, "probability": 0.5175, "type": "Other", "normalized_text": "CKD"}, {"start": 99, "end": 102, "probability": 0.436, "type": "Other", "normalized_text": "mmsm"}], "urls": [{"start": 104, "end": 127, "url": "https://t.co/JfuMi7rPUd", "expanded_url": "https://twitter.com/sykristinsson/status/1574422541711642625", "display_url": "twitter.com/sykristinsson/\u2026"}]}, "conversation_id": "1574426253481820161", "created_at": "2022-09-26T15:50:44.000Z", "edit_history_tweet_ids": ["1574426253481820161"], "id": "1574426253481820161", "lang": "en"}, {"entities": {"mentions": [{"start": 202, "end": 213, "username": "thorirlong", "id": "3009607268"}], "annotations": [{"start": 31, "end": 34, "probability": 0.5665, "type": "Other", "normalized_text": "MGUS"}], "urls": [{"start": 178, "end": 201, "url": "https://t.co/xWzjdbrMYw", "expanded_url": "https://rdcu.be/cVw40", "display_url": "rdcu.be/cVw40", "status": 200, "unwound_url": "https://www.nature.com/articles/s41408-022-00732-3.epdf?sharing_token=be_jyr5_H0n0KX4Ae9Tl4tRgN0jAjWel9jnR3ZoTv0OhZ7TA_7WiBKrFOCJxMthJbyzHLTvYped-D9O_r3sEwUciwYize6yB4vNfAdOUgpUowNt8hvVF0HRLK5VyCU63JAo6rUjGdycaq4FC3pxeL8hc33kkWkxAJpLGZAd_nw4%3D&error=cookies_not_supported&code=879af185-f6a8-4c38-a1a9-331b83cc5f68"}, {"start": 284, "end": 307, "url": "https://t.co/jGL2LO9cuw", "expanded_url": "https://twitter.com/sykristinsson/status/1574422541711642625/photo/1", "display_url": "pic.twitter.com/jGL2LO9cuw", "media_key": "3_1574415310794407936"}]}, "text": "New definition for light chain MGUS! \n\nPractice changing: New ref values for free light chains (FLC), kappa+ lambda in people with kidney dysfunction (GFR&lt;60) just published: https://t.co/xWzjdbrMYw @thorirlong \n\nAvoid unnecessary consultations, bone marrows, and\u2b07\ufe0fpatient anxiety https://t.co/jGL2LO9cuw", "source": "Twitter Web App", "author_id": "3078258341", "conversation_id": "1574422541711642625", "created_at": "2022-09-26T15:35:59.000Z", "edit_history_tweet_ids": ["1574422541711642625"], "id": "1574422541711642625", "lang": "en"}, {"entities": {"mentions": [{"start": 31, "end": 45, "username": "sykristinsson", "id": "3078258341"}, {"start": 138, "end": 152, "username": "MyelomatoseDK", "id": "1083742357445636096"}], "hashtags": [{"start": 67, "end": 75, "tag": "istopMM"}, {"start": 192, "end": 218, "tag": "BloodCancerAwarenessMonth"}, {"start": 219, "end": 231, "tag": "kNOwmyeloma"}], "annotations": [{"start": 68, "end": 74, "probability": 0.6096, "type": "Other", "normalized_text": "istopMM"}], "urls": [{"start": 232, "end": 255, "url": "https://t.co/S8ePYOV3Dh", "expanded_url": "https://twitter.com/GMyelomaAN/status/1573234918997598210/photo/1", "display_url": "pic.twitter.com/S8ePYOV3Dh", "media_key": "3_1573234909509976070"}, {"start": 232, "end": 255, "url": "https://t.co/S8ePYOV3Dh", "expanded_url": "https://twitter.com/GMyelomaAN/status/1573234918997598210/photo/1", "display_url": "pic.twitter.com/S8ePYOV3Dh", "media_key": "3_1573234909501685761"}]}, "text": "Such a great presentation from @sykristinsson telling the story of #istopMM study at our Danish Patient &amp; Family Seminar organized by @MyelomatoseDK with more than 200 participants during #BloodCancerAwarenessMonth\n#kNOwmyeloma https://t.co/S8ePYOV3Dh", "source": "Twitter for iPhone", "author_id": "3083937603", "conversation_id": "1573234918997598210", "created_at": "2022-09-23T08:56:48.000Z", "edit_history_tweet_ids": ["1573234918997598210"], "id": "1573234918997598210", "lang": "en"}, {"entities": {"mentions": [{"start": 174, "end": 185, "username": "thorirlong", "id": "3009607268"}, {"start": 186, "end": 200, "username": "sykristinsson", "id": "3078258341"}, {"start": 245, "end": 260, "username": "BloodCancerJnl", "id": "1417061180997345288"}], "annotations": [{"start": 89, "end": 92, "probability": 0.4051, "type": "Place", "normalized_text": "MGUS"}, {"start": 95, "end": 101, "probability": 0.5671, "type": "Other", "normalized_text": "myeloma"}, {"start": 107, "end": 117, "probability": 0.631, "type": "Other", "normalized_text": "amyloidosis"}], "urls": [{"start": 261, "end": 284, "url": "https://t.co/t7fz8Ggnzb", "expanded_url": "https://www.nature.com/articles/s41408-022-00732-3", "display_url": "nature.com/articles/s4140\u2026", "images": [{"url": "https://pbs.twimg.com/news_img/1574143094328623105/0RfCjRTj?format=png&name=orig", "width": 955, "height": 1078}, {"url": "https://pbs.twimg.com/news_img/1574143094328623105/0RfCjRTj?format=png&name=150x150", "width": 150, "height": 150}], "status": 200, "title": "Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: Results of the iStopMM study", "description": "Blood Cancer Journal - Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: Results of the iStopMM study", "unwound_url": "https://www.nature.com/articles/s41408-022-00732-3"}, {"start": 285, "end": 308, "url": "https://t.co/fIx0XdkIw8", "expanded_url": "https://twitter.com/VincentRK/status/1572567061150433280/photo/1", "display_url": "pic.twitter.com/fIx0XdkIw8", "media_key": "3_1572567057790652418"}]}, "text": "The serum free light chain assay is important for diagnosis &amp; response assessment in MGUS, myeloma, AL amyloidosis. But the normal range is affected by renal function. \n\n@thorirlong @sykristinsson establish reference ranges in renal failure @BloodCancerJnl https://t.co/t7fz8Ggnzb https://t.co/fIx0XdkIw8", "source": "Twitter for iPhone", "author_id": "24261916", "conversation_id": "1572567061150433280", "created_at": "2022-09-21T12:42:58.000Z", "edit_history_tweet_ids": ["1572567061150433280"], "id": "1572567061150433280", "lang": "en"}, {"entities": {"mentions": [{"start": 209, "end": 220, "username": "IMFmyeloma", "id": "34340707"}, {"start": 221, "end": 229, "username": "theMMRF", "id": "50227506"}, {"start": 247, "end": 263, "username": "SylvesterCancer", "id": "137901227"}, {"start": 264, "end": 278, "username": "sykristinsson", "id": "3078258341"}], "hashtags": [{"start": 203, "end": 208, "tag": "mmsm"}], "annotations": [{"start": 116, "end": 119, "probability": 0.4248, "type": "Other", "normalized_text": "FLCs"}], "urls": [{"start": 177, "end": 200, "url": "https://t.co/HtBcS8DYz9", "expanded_url": "https://pubmed.ncbi.nlm.nih.gov/36100605/", "display_url": "pubmed.ncbi.nlm.nih.gov/36100605/", "status": 200, "title": "Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: Results of the iStopMM study - PubMed", "description": "Serum free light chain (FLC) concentration is greatly affected by kidney function. Using a large prospective population-based cohort, we aimed to establish a reference interval for FLCs in persons with chronic kidney disease (CKD). A total of 75422 participants of the iStopMM study were screened wit \u2026", "unwound_url": "https://pubmed.ncbi.nlm.nih.gov/36100605/"}]}, "text": "Important new paper on how to interpret serum free light chains (FLCs):\n\nDefining new reference intervals for serum FLCs in individuals with chronic kidney disease: Results of\u2026 https://t.co/HtBcS8DYz9 \n\n#mmsm @IMFmyeloma @theMMRF @healthtreeforMM @SylvesterCancer @sykristinsson", "source": "Twitter Web App", "author_id": "2257190339", "conversation_id": "1570620366430818305", "created_at": "2022-09-16T03:47:30.000Z", "edit_history_tweet_ids": ["1570620366430818305"], "id": "1570620366430818305", "lang": "en"}, {"text": "\ud83d\udc4fBeen waiting for this!\nCan't count how many times my CKD pts with kappa/lambda ratio of 2-3 have been sent for BM Bx, esp. for Tx eval. https://t.co/hHy1JgF9i1", "referenced_tweets": [{"type": "quoted", "id": "1570957996099788800"}], "source": "Twitter Web App", "author_id": "20549404", "conversation_id": "1571261954404007936", "entities": {"annotations": [{"start": 54, "end": 56, "probability": 0.4902, "type": "Other", "normalized_text": "CKD"}, {"start": 112, "end": 113, "probability": 0.6651, "type": "Other", "normalized_text": "BM"}], "urls": [{"start": 137, "end": 160, "url": "https://t.co/hHy1JgF9i1", "expanded_url": "https://twitter.com/onconephsociety/status/1570957996099788800", "display_url": "twitter.com/onconephsociet\u2026"}]}, "created_at": "2022-09-17T22:16:57.000Z", "edit_history_tweet_ids": ["1571261954404007936"], "id": "1571261954404007936", "lang": "en"}, {"entities": {"mentions": [{"start": 62, "end": 77, "username": "Amyloid_Planet", "id": "1138405094"}], "annotations": [{"start": 18, "end": 22, "probability": 0.464, "type": "Other", "normalized_text": "kappa"}, {"start": 57, "end": 59, "probability": 0.5161, "type": "Other", "normalized_text": "CKD"}], "urls": [{"start": 78, "end": 101, "url": "https://t.co/GdJ62jN6M7", "expanded_url": "https://twitter.com/thorirlong/status/1570755512580583424", "display_url": "twitter.com/thorirlong/sta\u2026"}]}, "text": "What's the normal kappa lambda free light chain ratio in CKD? @Amyloid_Planet https://t.co/GdJ62jN6M7", "referenced_tweets": [{"type": "quoted", "id": "1570755512580583424"}], "source": "Twitter Web App", "author_id": "18084746", "conversation_id": "1571206926314213376", "created_at": "2022-09-17T18:38:17.000Z", "edit_history_tweet_ids": ["1571206926314213376"], "id": "1571206926314213376", "lang": "en"}, {"text": "Key paper - we got a lot of econsults for slightly abnormal light chains in people with impaired renal function. https://t.co/X6HaFqW3el", "referenced_tweets": [{"type": "quoted", "id": "1570755512580583424"}], "source": "Twitter for iPhone", "author_id": "16827782", "conversation_id": "1570945974805352449", "created_at": "2022-09-17T01:21:21.000Z", "edit_history_tweet_ids": ["1570945974805352449"], "id": "1570945974805352449", "lang": "en", "entities": {"urls": [{"start": 113, "end": 136, "url": "https://t.co/X6HaFqW3el", "expanded_url": "https://twitter.com/thorirlong/status/1570755512580583424", "display_url": "twitter.com/thorirlong/sta\u2026"}]}}, {"text": "Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: Results of the iStopMM study. An important paper in real world https://t.co/bdzCLz1l2j #mmsm #myeloma #MedTwitter #MedEd https://t.co/fweKXlQzwl", "source": "Twitter for iPhone", "author_id": "1026947037080772610", "entities": {"hashtags": [{"start": 192, "end": 197, "tag": "mmsm"}, {"start": 198, "end": 206, "tag": "myeloma"}, {"start": 207, "end": 218, "tag": "MedTwitter"}, {"start": 219, "end": 225, "tag": "MedEd"}], "annotations": [{"start": 96, "end": 102, "probability": 0.5585, "type": "Other", "normalized_text": "disease"}, {"start": 120, "end": 126, "probability": 0.8655, "type": "Other", "normalized_text": "iStopMM"}, {"start": 193, "end": 196, "probability": 0.5713, "type": "Other", "normalized_text": "mmsm"}, {"start": 199, "end": 205, "probability": 0.6218, "type": "Other", "normalized_text": "myeloma"}, {"start": 208, "end": 217, "probability": 0.8051, "type": "Other", "normalized_text": "MedTwitter"}], "urls": [{"start": 168, "end": 191, "url": "https://t.co/bdzCLz1l2j", "expanded_url": "https://www.nature.com/articles/s41408-022-00732-3", "display_url": "nature.com/articles/s4140\u2026", "images": [{"url": "https://pbs.twimg.com/news_img/1574143094328623105/0RfCjRTj?format=png&name=orig", "width": 955, "height": 1078}, {"url": "https://pbs.twimg.com/news_img/1574143094328623105/0RfCjRTj?format=png&name=150x150", "width": 150, "height": 150}], "status": 200, "title": "Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: Results of the iStopMM study", "description": "Blood Cancer Journal - Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: Results of the iStopMM study", "unwound_url": "https://www.nature.com/articles/s41408-022-00732-3"}, {"start": 226, "end": 249, "url": "https://t.co/fweKXlQzwl", "expanded_url": "https://twitter.com/Abdallah81MD/status/1571165895078170631/photo/1", "display_url": "pic.twitter.com/fweKXlQzwl", "media_key": "3_1571165891219300355"}]}, "conversation_id": "1571165895078170631", "created_at": "2022-09-17T15:55:14.000Z", "edit_history_tweet_ids": ["1571165895078170631"], "id": "1571165895078170631", "lang": "en"}, {"text": "Our paper were we redefine the reference intervals for serum FLCs and FLC ratio in individuals with chronic kidney disease using the #iStopMM data has been published!  Full paper here:\nhttps://t.co/igtZ2xZUUV\n#mmsm #Nephrology \nSummary of the new reference intervals: https://t.co/IjGAMPzk5a", "source": "Twitter Web App", "author_id": "3009607268", "entities": {"hashtags": [{"start": 133, "end": 141, "tag": "iStopMM"}, {"start": 209, "end": 214, "tag": "mmsm"}, {"start": 215, "end": 226, "tag": "Nephrology"}], "annotations": [{"start": 61, "end": 64, "probability": 0.5472, "type": "Other", "normalized_text": "FLCs"}, {"start": 70, "end": 72, "probability": 0.5697, "type": "Other", "normalized_text": "FLC"}, {"start": 115, "end": 121, "probability": 0.5115, "type": "Other", "normalized_text": "disease"}, {"start": 134, "end": 140, "probability": 0.8143, "type": "Other", "normalized_text": "iStopMM"}, {"start": 216, "end": 225, "probability": 0.4976, "type": "Other", "normalized_text": "Nephrology"}], "urls": [{"start": 185, "end": 208, "url": "https://t.co/igtZ2xZUUV", "expanded_url": "https://www.nature.com/articles/s41408-022-00732-3", "display_url": "nature.com/articles/s4140\u2026", "images": [{"url": "https://pbs.twimg.com/news_img/1574143094328623105/0RfCjRTj?format=png&name=orig", "width": 955, "height": 1078}, {"url": "https://pbs.twimg.com/news_img/1574143094328623105/0RfCjRTj?format=png&name=150x150", "width": 150, "height": 150}], "status": 200, "title": "Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: Results of the iStopMM study", "description": "Blood Cancer Journal - Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: Results of the iStopMM study", "unwound_url": "https://www.nature.com/articles/s41408-022-00732-3"}, {"start": 268, "end": 291, "url": "https://t.co/IjGAMPzk5a", "expanded_url": "https://twitter.com/thorirlong/status/1570755512580583424/photo/1", "display_url": "pic.twitter.com/IjGAMPzk5a", "media_key": "3_1570752862019362819"}]}, "conversation_id": "1570755512580583424", "created_at": "2022-09-16T12:44:32.000Z", "edit_history_tweet_ids": ["1570755512580583424"], "id": "1570755512580583424", "lang": "en"}, {"entities": {"mentions": [{"start": 72, "end": 84, "username": "astrunhelga", "id": "2758432772"}, {"start": 108, "end": 121, "username": "Annakaren981", "id": "1268269154022436866"}, {"start": 122, "end": 134, "username": "SaemundurMD", "id": "1054784756704010241"}, {"start": 135, "end": 149, "username": "sykristinsson", "id": "3078258341"}], "hashtags": [{"start": 29, "end": 34, "tag": "nmsg"}, {"start": 54, "end": 62, "tag": "iStopMM"}], "annotations": [{"start": 30, "end": 33, "probability": 0.3982, "type": "Other", "normalized_text": "nmsg"}, {"start": 55, "end": 61, "probability": 0.6975, "type": "Other", "normalized_text": "iStopMM"}], "urls": [{"start": 150, "end": 173, "url": "https://t.co/tRSOCuF0QV", "expanded_url": "https://twitter.com/SigrunThorstei1/status/1570470773609099264/photo/1", "display_url": "pic.twitter.com/tRSOCuF0QV", "media_key": "3_1570470770270261248"}]}, "text": "Proud of our students at the #nmsg meeting presenting #iStopMM data and @astrunhelga winning best abstract! @Annakaren981 @SaemundurMD @sykristinsson https://t.co/tRSOCuF0QV", "source": "Twitter for Android", "author_id": "1198917648630919168", "conversation_id": "1570470773609099264", "created_at": "2022-09-15T17:53:05.000Z", "edit_history_tweet_ids": ["1570470773609099264"], "id": "1570470773609099264", "lang": "en"}, {"entities": {"mentions": [{"start": 49, "end": 63, "username": "sykristinsson", "id": "3078258341"}], "hashtags": [{"start": 122, "end": 128, "tag": "ims22"}], "urls": [{"start": 129, "end": 152, "url": "https://t.co/VcZxxDXvje", "expanded_url": "https://twitter.com/vhugo8762/status/1563270667927097345/photo/1", "display_url": "pic.twitter.com/VcZxxDXvje", "media_key": "3_1563270607864639488"}]}, "text": "Are we ready for the lift? Great presentation by @sykristinsson Congrats again, will learn lots from your amazing study! -#ims22 https://t.co/VcZxxDXvje", "source": "Twitter Web App", "author_id": "114124641", "conversation_id": "1563270667927097345", "created_at": "2022-08-26T21:02:26.000Z", "edit_history_tweet_ids": ["1563270667927097345"], "id": "1563270667927097345", "lang": "en"}, {"entities": {"mentions": [{"start": 9, "end": 17, "username": "jthorir", "id": "247118539"}, {"start": 27, "end": 35, "username": "iStopMM", "id": "844232399319941122"}], "hashtags": [{"start": 213, "end": 221, "tag": "IMS2022"}], "annotations": [{"start": 108, "end": 110, "probability": 0.5159, "type": "Other", "normalized_text": "NGF"}, {"start": 115, "end": 118, "probability": 0.358, "type": "Place", "normalized_text": "MGUS"}, {"start": 214, "end": 220, "probability": 0.6006, "type": "Other", "normalized_text": "IMS2022"}], "urls": [{"start": 222, "end": 245, "url": "https://t.co/Moo33OMeuu", "expanded_url": "https://twitter.com/sykristinsson/status/1562876616564322304/photo/1", "display_url": "pic.twitter.com/Moo33OMeuu", "media_key": "3_1562876613938688000"}]}, "text": "Proud of @jthorir from the @iStopMM team who gave a great talk on the detection of aberrant plasma cells by NGF in MGUS. Negative result associated with transient M-proteins and possibly lower risk of progression #IMS2022 https://t.co/Moo33OMeuu", "source": "Twitter for Android", "author_id": "3078258341", "conversation_id": "1562876616564322304", "created_at": "2022-08-25T18:56:36.000Z", "edit_history_tweet_ids": ["1562876616564322304"], "id": "1562876616564322304", "lang": "en"}, {"text": "Disease Monitoring \u2013 Featured Abstracts Announced \u2013 Romanos Sklavenitis-Pistofidis, Bruno Paiva, Mattia D\u2019Agostino, and J\u00f3n \u00de\u00f3rir \u00d3skarsson present at #IMS2022. Learn more https://t.co/PtnHwj7uvt #myeloma https://t.co/5n92NoSwes", "source": "Twitter for Advertisers", "author_id": "841751045034369025", "entities": {"hashtags": [{"start": 151, "end": 159, "tag": "IMS2022"}, {"start": 196, "end": 204, "tag": "myeloma"}], "urls": [{"start": 172, "end": 195, "url": "https://t.co/PtnHwj7uvt", "expanded_url": "https://bit.ly/3z6yDMp", "display_url": "bit.ly/3z6yDMp", "status": 200, "title": "2022 International Myeloma Workshop", "unwound_url": "https://events.jspargo.com/imw22/public/enter.aspx?utm_source=twitter&utm_medium=social&utm_campaign=program"}, {"start": 205, "end": 228, "url": "https://t.co/5n92NoSwes", "expanded_url": "https://twitter.com/Myeloma_Society/status/1555629718132690945/photo/1", "display_url": "pic.twitter.com/5n92NoSwes", "media_key": "3_1548338856633589761"}]}, "conversation_id": "1555629718132690945", "created_at": "2022-08-05T19:00:01.000Z", "edit_history_tweet_ids": ["1555629718132690945"], "id": "1555629718132690945", "lang": "und"}, {"entities": {"mentions": [{"start": 20, "end": 28, "username": "iStopMM", "id": "844232399319941122"}], "annotations": [{"start": 46, "end": 53, "probability": 0.8649, "type": "Other", "normalized_text": "ASH 2022"}], "urls": [{"start": 55, "end": 78, "url": "https://t.co/5yPwCtJyuG", "expanded_url": "https://twitter.com/VincentRK/status/1558456195131793410", "display_url": "twitter.com/VincentRK/stat\u2026"}]}, "text": "We're working on it @iStopMM. More to come at ASH 2022 https://t.co/5yPwCtJyuG", "referenced_tweets": [{"type": "quoted", "id": "1558456195131793410"}], "source": "Twitter for iPhone", "author_id": "133109181", "conversation_id": "1558526217187377152", "created_at": "2022-08-13T18:49:40.000Z", "edit_history_tweet_ids": ["1558526217187377152"], "id": "1558526217187377152", "lang": "en"}, {"entities": {"mentions": [{"start": 0, "end": 13, "username": "VPrasadMDMPH", "id": "1194962714"}]}, "text": "@VPrasadMDMPH yes and I managed to maintain a social life while at it", "referenced_tweets": [{"type": "replied_to", "id": "1550560700317122560"}], "source": "Twitter Web App", "author_id": "854692626015993857", "conversation_id": "1550553502639804417", "in_reply_to_user_id": "1194962714", "created_at": "2022-07-22T19:18:44.000Z", "edit_history_tweet_ids": ["1550560999404552192"], "id": "1550560999404552192", "lang": "en"}, {"entities": {"mentions": [{"start": 124, "end": 138, "username": "sykristinsson", "id": "3078258341"}, {"start": 142, "end": 150, "username": "iStopMM", "id": "844232399319941122"}, {"start": 152, "end": 166, "username": "SagarLonialMD", "id": "2289851689"}], "hashtags": [{"start": 252, "end": 257, "tag": "mmsm"}, {"start": 258, "end": 267, "tag": "IMWG2022"}, {"start": 268, "end": 272, "tag": "smm"}], "annotations": [{"start": 23, "end": 24, "probability": 0.4795, "type": "Other", "normalized_text": "OS"}, {"start": 253, "end": 256, "probability": 0.4898, "type": "Other", "normalized_text": "mmsm"}, {"start": 259, "end": 266, "probability": 0.5874, "type": "Other", "normalized_text": "IMWG2022"}], "urls": [{"start": 273, "end": 296, "url": "https://t.co/4p1SrQaEVG", "expanded_url": "https://twitter.com/NorthTxMSG/status/1534441924760854528/photo/1", "display_url": "pic.twitter.com/4p1SrQaEVG", "media_key": "3_1534441919652184064"}, {"start": 273, "end": 296, "url": "https://t.co/4p1SrQaEVG", "expanded_url": "https://twitter.com/NorthTxMSG/status/1534441924760854528/photo/1", "display_url": "pic.twitter.com/4p1SrQaEVG", "media_key": "3_1534441922391048192"}]}, "text": "\"If screening improves OS, we should, if it doesn't, we shouldn't\", \"please give me 2 more years. I'll give you the answer\" @sykristinsson of @iStopMM \n@SagarLonialMD cautioning generalization from predominantly Caucasian pt base to non-Caucasian pts. #mmsm #IMWG2022 #smm https://t.co/4p1SrQaEVG", "source": "Twitter for Android", "author_id": "961409220", "conversation_id": "1534441924760854528", "created_at": "2022-06-08T07:47:18.000Z", "edit_history_tweet_ids": ["1534441924760854528"], "id": "1534441924760854528", "lang": "en"}, {"entities": {"mentions": [{"start": 126, "end": 131, "username": "NEJM", "id": "25950355"}], "hashtags": [{"start": 86, "end": 93, "tag": "ASCO22"}, {"start": 132, "end": 141, "tag": "ASCO22VR"}], "annotations": [{"start": 42, "end": 48, "probability": 0.6199, "type": "Other", "normalized_text": "myeloma"}, {"start": 87, "end": 92, "probability": 0.5018, "type": "Other", "normalized_text": "ASCO22"}, {"start": 133, "end": 140, "probability": 0.4278, "type": "Other", "normalized_text": "ASCO22VR"}]}, "text": "My thoughts on the DETERMINATION trial in myeloma presented in the Plenary session of #ASCO22 and published simultaneously in @NEJM #ASCO22VR\n\n 1) This is not a trial of transplant vs no transplant. \n\n2) It's ~ the 5th RCT of early vs delayed transplant", "source": "Twitter for iPhone", "author_id": "24261916", "conversation_id": "1534113835241639942", "created_at": "2022-06-07T10:03:35.000Z", "edit_history_tweet_ids": ["1534113835241639942"], "id": "1534113835241639942", "lang": "en"}, {"entities": {"mentions": [{"start": 0, "end": 13, "username": "DavidVujanic", "id": "91454381"}]}, "text": "@DavidVujanic That\u2019s what happens when you grow up and the things you love keep evolving and changing. The reasons we fell in love with football may no longer be there so the connection can fade over time. Either you learn to love the new things or you find something else that grabs your heart", "referenced_tweets": [{"type": "replied_to", "id": "1533062321559437312"}], "source": "Twitter Web App", "author_id": "407740811", "conversation_id": "1533062321559437312", "in_reply_to_user_id": "91454381", "created_at": "2022-06-04T15:46:37.000Z", "edit_history_tweet_ids": ["1533112998612635651"], "id": "1533112998612635651", "lang": "en"}, {"entities": {"mentions": [{"start": 85, "end": 93, "username": "mtmdphd", "id": "190337035"}, {"start": 132, "end": 144, "username": "grpetersen1", "id": "523778748"}, {"start": 145, "end": 155, "username": "bdermanmd", "id": "872983600416862208"}, {"start": 156, "end": 168, "username": "End_myeloma", "id": "2538011298"}, {"start": 169, "end": 179, "username": "SLentzsch", "id": "2923507674"}, {"start": 180, "end": 194, "username": "sykristinsson", "id": "3078258341"}, {"start": 195, "end": 205, "username": "VincentRK", "id": "24261916"}, {"start": 206, "end": 215, "username": "szusmani", "id": "83911786"}, {"start": 216, "end": 231, "username": "Amyloid_Planet", "id": "1138405094"}, {"start": 232, "end": 246, "username": "DrOlaLandgren", "id": "2257190339"}, {"start": 247, "end": 258, "username": "ninashah33", "id": "1559241414"}, {"start": 259, "end": 271, "username": "nsc_natalie", "id": "462524995"}], "hashtags": [{"start": 71, "end": 78, "tag": "ASCO22"}, {"start": 79, "end": 84, "tag": "mmsm"}], "annotations": [{"start": 15, "end": 21, "probability": 0.7553, "type": "Other", "normalized_text": "Myeloma"}, {"start": 25, "end": 45, "probability": 0.8078, "type": "Other", "normalized_text": "Plasma Cell Dyscrasia"}, {"start": 48, "end": 50, "probability": 0.3963, "type": "Other", "normalized_text": "PCD"}, {"start": 72, "end": 77, "probability": 0.4456, "type": "Other", "normalized_text": "ASCO22"}], "urls": [{"start": 272, "end": 295, "url": "https://t.co/qV4YyX8Zy8", "expanded_url": "https://twitter.com/mtmdphd/status/1532846691270926344/photo/1", "display_url": "pic.twitter.com/qV4YyX8Zy8", "media_key": "3_1532845961957060616"}]}, "text": "Top 10 (or so) Myeloma / Plasma Cell Dyscrasia (PCD) Abstract Picks at #ASCO22 #mmsm @mtmdphd Table \u2013 *Draft* Update Jun 3, 2022 cc @grpetersen1 @bdermanmd @End_myeloma @SLentzsch @sykristinsson @VincentRK @szusmani @Amyloid_Planet @DrOlaLandgren @ninashah33 @nsc_natalie https://t.co/qV4YyX8Zy8", "source": "Twitter Web App", "author_id": "190337035", "conversation_id": "1532846691270926344", "created_at": "2022-06-03T22:08:24.000Z", "edit_history_tweet_ids": ["1532846691270926344"], "id": "1532846691270926344", "lang": "en"}, {"entities": {"mentions": [{"start": 85, "end": 93, "username": "mtmdphd", "id": "190337035"}, {"start": 135, "end": 147, "username": "grpetersen1", "id": "523778748"}, {"start": 148, "end": 159, "username": "AuclairDan", "id": "817184467915853828"}, {"start": 160, "end": 170, "username": "bdermanmd", "id": "872983600416862208"}, {"start": 171, "end": 183, "username": "End_myeloma", "id": "2538011298"}, {"start": 184, "end": 190, "username": "Phari", "id": "14985396"}, {"start": 191, "end": 201, "username": "SLentzsch", "id": "2923507674"}, {"start": 202, "end": 216, "username": "sykristinsson", "id": "3078258341"}, {"start": 217, "end": 227, "username": "VincentRK", "id": "24261916"}, {"start": 228, "end": 237, "username": "szusmani", "id": "83911786"}, {"start": 238, "end": 253, "username": "Amyloid_Planet", "id": "1138405094"}, {"start": 254, "end": 268, "username": "DrOlaLandgren", "id": "2257190339"}, {"start": 269, "end": 280, "username": "ninashah33", "id": "1559241414"}], "hashtags": [{"start": 71, "end": 78, "tag": "ASCO22"}, {"start": 79, "end": 84, "tag": "mmsm"}], "annotations": [{"start": 15, "end": 21, "probability": 0.7557, "type": "Other", "normalized_text": "Myeloma"}, {"start": 25, "end": 45, "probability": 0.8089, "type": "Other", "normalized_text": "Plasma Cell Dyscrasia"}, {"start": 48, "end": 50, "probability": 0.3992, "type": "Other", "normalized_text": "PCD"}, {"start": 72, "end": 77, "probability": 0.4549, "type": "Other", "normalized_text": "ASCO22"}], "urls": [{"start": 281, "end": 304, "url": "https://t.co/TbKNzIzF5C", "expanded_url": "https://twitter.com/mtmdphd/status/1532463251459563547/photo/1", "display_url": "pic.twitter.com/TbKNzIzF5C", "media_key": "3_1532462479229476866"}]}, "text": "Top 10 (or so) Myeloma / Plasma Cell Dyscrasia (PCD) Abstract Picks at #ASCO22 #mmsm @mtmdphd Table \u2013 *Draft* Update Jun 2, 2022 v3 cc @grpetersen1 @AuclairDan @bdermanmd @End_myeloma @Phari @SLentzsch @sykristinsson @VincentRK @szusmani @Amyloid_Planet @DrOlaLandgren @ninashah33 https://t.co/TbKNzIzF5C", "source": "Twitter Web App", "author_id": "190337035", "conversation_id": "1532463251459563547", "created_at": "2022-06-02T20:44:45.000Z", "edit_history_tweet_ids": ["1532463251459563547"], "id": "1532463251459563547", "lang": "en"}, {"entities": {"mentions": [{"start": 145, "end": 161, "username": "SigrunThorstei1", "id": "1198917648630919168"}, {"start": 169, "end": 183, "username": "sykristinsson", "id": "3078258341"}, {"start": 184, "end": 192, "username": "iStopMM", "id": "844232399319941122"}], "hashtags": [{"start": 206, "end": 212, "tag": "ASH21"}, {"start": 237, "end": 242, "tag": "mmsm"}, {"start": 243, "end": 251, "tag": "iStopMM"}], "annotations": [{"start": 60, "end": 66, "probability": 0.6555, "type": "Other", "normalized_text": "Iceland"}, {"start": 115, "end": 121, "probability": 0.6179, "type": "Other", "normalized_text": "iStopMM"}, {"start": 244, "end": 250, "probability": 0.5671, "type": "Other", "normalized_text": "iStopMM"}], "urls": [{"start": 213, "end": 236, "url": "https://t.co/Biz5qFphjA", "expanded_url": "http://ow.ly/r9ll50H0Mnn", "display_url": "ow.ly/r9ll50H0Mnn", "status": 200, "unwound_url": "https://ash.confex.com/ash/2021/webprogram/Paper148617.html"}, {"start": 252, "end": 275, "url": "https://t.co/UdXu1PdGcM", "expanded_url": "https://twitter.com/mtmdphd/status/1529189492950802432/photo/1", "display_url": "pic.twitter.com/UdXu1PdGcM", "media_key": "3_1529189434637357057"}]}, "text": "Prevalence of Smoldering Multiple Myeloma: Results from the Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) Study [Dec 11, 2021] @SigrunThorstei1 et al. @sykristinsson @iStopMM Abstract 151 #ASH21 https://t.co/Biz5qFphjA #mmsm #iStopMM https://t.co/UdXu1PdGcM", "source": "Twitter Web App", "author_id": "190337035", "conversation_id": "1529189492950802432", "created_at": "2022-05-24T19:56:00.000Z", "edit_history_tweet_ids": ["1529189492950802432"], "id": "1529189492950802432", "lang": "en"}]}, "errors": [{"value": "1334650653403197440", "detail": "Could not find user with in_reply_to_user_id: [1334650653403197440].", "title": "Not Found Error", "resource_type": "user", "parameter": "in_reply_to_user_id", "resource_id": "1334650653403197440", "type": "https://api.twitter.com/2/problems/resource-not-found"}, {"value": "1582918513022205952", "detail": "Could not find tweet with referenced_tweets.id: [1582918513022205952].", "title": "Not Found Error", "resource_type": "tweet", "parameter": "referenced_tweets.id", "resource_id": "1582918513022205952", "type": "https://api.twitter.com/2/problems/resource-not-found"}], "meta": {"result_count": 100, "newest_id": "1600975868389490688", "oldest_id": "1529407113797197824", "next_token": "7140dibdnow9c7btw421edvntychbozu7fdtvvuclj7lg"}, "neighbors": ["844232399319941122", "190337035", "2257190339", "3078258341", "34340707", "1054784756704010241", "321436678"]}